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General Introduction
 
 
 
 
  
CHAPTER 1 
This introduction provides a concise overview of germ cell development followed by a discussion 
of its relation to human germ cell tumors (GCT). The etiology, pathogenesis and molecular 
characteristics of the various types of GCTs are extensively reviewed in chapters 2 and 9. These 
chapters also evaluate the onco-fetal relation of GCTs to (early embryonic) germ cell development. 
The results presented in this thesis describe the (genome-wide) regulation of gene and protein 
expression, i.e. “functional genomics”. This subject is therefore also briefly introduced. In the last 
section of this chapter, the aims and outlines of this thesis are presented. 
Normal germ cell development 
During embryogenesis germ cell progenitor cells migrate from the yolk sac to the genital ridge 
while undergoing massive (epigenetic) changes. Primordial germ cells (PGCs) migrate from the 
yolk sac via the hindgut. They finally arrive at the progenitor site of the gonad, the so called genital 
ridge, where they are referred to as gonocytes. The genital ridge normally develops into either a 
functional testis or an ovary. During migration and most notable after arrival at the genital ridge, 
PGCs evolve from a totipotent phenotype into sex specific mature germ cells (spermatozoa and 
oocytes). The developmental program guiding the maturation of PGCs/gonocytes into fully 
developed germ cells is characterized by changes in RNA and protein expression. Maturing germ 
cells also undergo an epigenetic “reset” (see also: “functional genomics in a nutshell” and chapter 
9). Most importantly in the context of this thesis, these cells show characteristic patterns of histone 
modifications and DNA CpG methylation (see below for an explanation of these terms). Epigenetic 
reprogramming of germ cells is partly sex specific. It is of particular interest that genomic 
imprinting differs between males and females while X chromosome reactivation occurs in females 
only. These features are established during (fetal) germ cell maturation. The characteristic 
molecular properties of developing germ cells can be assessed experimentally to investigate their 
developmental status as mirrored in their malignant derivatives (GCTs). It must be kept in mind that 
most experiments evaluating the various aspects of physiological germ cell development have 
been performed in mice. While differences between species have to be taken into account, 
important similarities have been shown as well. For detailed references and an extensive review of 
normal germ cell development, please see chapter 2 (core literature: [1-7]). 
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Germ cell tumors 
GCTs are a unique, heterogeneous group of tumors originating from germ cells at different 
developmental stages and can be classified into five subtypes (I-V). These subtypes are part of the 
current World Health Organization (WHO) classification (Figure 1). Type I-V GCTs are related to 
different stages of (embryonic) germ cell development and exhibit distinct characteristics which are 
frequently directly related to their immature (fetal) non-malignant ancestors. Many of these 
characteristics can be used as clinical tumor markers in GCT diagnostics and patient follow-up as 
reviewed in chapter 2. GCTs do not arise from epithelial cells (i.e. carcinomas), mesenchymal cells 
(i.e. sarcomas) or hematopoietic cells (i.e. leukemias or lymphomas). Therefore, they represent a 
completely separate class of malignant entities [8-11]. 
 
Figure 1. Germ cell tumor subtypes and their relation to normal germ cell development. Migration and maturation of 
(fetal) germ cells are shown in the grey box. Developmental schemes are indicated in blue (male), red (female) or in 
white when unrelated to sex. These color schemes are extended to the boxes identifying the various GCT subtypes. This 
visualization is based on the model proposed by Oosterhuis and Looijenga [8] as used in the current WHO classification 
[10]. This figure is adapted from chapter 9, Figure 1A. For more details, please see the main text, section “Germ cell 
tumors”. 
Type I GCTs, also called infantile or pediatric GCTs, are rare and generally benign. They generally 
appear before the age of six and occur in 0.12/100,000 individuals. Type I GCTs are composed of 
teratoma (TE) and/or yolk sac tumor (YS) components and typically require only surgical resection 
to cure the patient. Interestingly, many primary type I GCTs occur outside of the gonads, along the 
migration route of the germ cells. They differ from the type II TE and YS in their age of 
presentation, lack of the precursor lesion Carcinoma In Situ (CIS), absence of the stem cell 
component embryonal carcinoma and lack of trophoblastic differentiation (choriocarcinoma)  [8-
10, 12, 13]. 
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Type II GCTs include a heterogeneous set of histological subtypes with clearly defined totipotent 
stem cell components, together accounting for 60% of all cancers in Caucasian males between the 
ages of 20 and 40. Because of their malignant behavior, type II GCTs are also called Germ Cell 
Cancer (GCC). GCCs are most frequently seen in adolescents and young adults and primarily occur 
in the testis. They represent ¨1% of all solid cancers in Caucasian males, but account for 60% of all 
cancers in these males between the ages of 20 and 40 [8, 9]. Incidence has almost doubled in the 
Netherlands over the last decade (9.43/100,000 ESR 2012, Dutch Caner Registration (IKNL), 
www.cijfersoverkanker.nl). This corresponds with international observations [14]. The increase is 
most frequently associated with environmental changes [15]. Indeed, GCC risk has been associated 
with a complex set of interacting environmental and genetic, i.e. genvironmental, risk factors which 
are reviewed in chapter 2 (core literature: [15-19]). Current treatment regiments cure over 95% of 
the patients. However, GCCs still represent an important cause of (treatment related) mortality in 
these young men [20, 21].  All GCCs arise from a common precursor lesion (CIS in the testis, 
gonadoblastoma in the ovary and dysgenetic gonad) [8, 9, 22, 23]. CIS is improperly named 
carcinoma because of the non-epithelial origin of the tumor (see above). The WHO therefore 
baptized this precursor lesion “intratubular germ cell neoplasia unclassified” (IGCNU) [10]. 
However, throughout this thesis the term CIS will be used for reasons of consistency with most of 
the existing literature. CIS cells in many ways represent maturation arrested PGCs/gonocytes and 
can transform into two invasive entities: seminoma (SE) and embryonal carcinoma (EC). EC has 
totipotent potential and can differentiate into all embryonic (teratoma, TE) and extra-embryonic 
(YS and choriocarcinoma) tissue lineages. EC and its differentiated derivatives are collectively called 
non-seminomas (NS). SE incidence peaks at 35 years of age while NS incidence shows a peak 
about ten years earlier. GCCs occur only rarely at extra-gonadal sites, in contrast to the type I GCTs 
[8, 9]. In the testis and anterior mediastinum SEs are called seminomas, in contrast to similar GCCs 
in the ovary (dysgerminoma) and brain (germinoma). Despite differences in their anatomical 
localization, these tumors all show very similar molecular profiles [24]. Strong similarities have been 
shown between early embryonic (germ cell) development and the pluri-/totipotent phenotype of 
CIS, SE and EC as reviewed in chapter 2. 
Type III, IV and V GCTs are generally benign and arise from more mature germ cells. Type III GCTs 
are called spermatocytic seminomas. They occur after the age of 50 and are exclusively located in 
the testis. Surgical resection suffices in the majority of the cases. Type IV GCTs, or dermoid cysts 
are derivatives of committed female germ cells. Type V GCTs (hydatiform moles) are formed by 
the fertilization of an empty ovum by two mature male germ cells [8-10]. 
The spectrum of GCTs (type I-V) represents a unique class of malignant entities in young patients 
with strong and traceable onco-fetal roots that clinical applications can take advantage of. Even 
though GCTs are relatively rare compared to other neoplasms and their sensitivity to chemo-
/radiotherapy is generally extremely good, they still impose a considerable disease burden on 
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mostly young males. This is relevant both in the short term (disease, treatment) and the long term 
(fertility, long term side effects of treatment). Moreover, the availability of representative cell lines 
(see chapter 2) and animal models [15] provides research opportunities to evaluate GCC as a 
model for early embryonic (stem) cells and (germ cell) development. This thesis illustrates that 
fundamental research into the unique (embryonic) characteristics of these tumors translates to 
clinical applications, helping to identify individuals who are at risk for GCT and enhancing the 
quality of care for testicular GCT patients (diagnosis, treatment and follow-up). 
Functional genomics in a nutshell 
The genome is comprised of DNA which is the core information storage facility in a cell’s nucleus 
and is subsequently transcribed into RNA and in many cases translated into proteins. In humans 
the genome comprises of ¨3 billion base pairs: adenine (A) pairs with thymine (T) and guanine (G) 
pairs with cytosine (C). The pairs are organized in a double helix structure and divided over 21 
autosomes and 2 sex specific chromosomes (XX: female, XY male). For DNA to exhibit any 
function, the base-pair sequence needs to be transcribed into RNA. A major subclass of RNA is the 
messenger RNA (mRNA), which is translated into a polypeptides. These are then modified into a 3-
dimensional functional protein. Historically, the term (gene) expression refers to mRNA levels and 
“gene” refers to protein coding DNA regions. However, the term expression is also frequently used 
to describe the levels of proteins or other types of RNA in a cell. Proteins are major actors in a cell, 
for example as building blocks of the cell’s physical structures or as transducers in signaling 
pathways that allow the cell to adjust to internal and external stimuli. The human genome encodes 
around 20,000 protein coding genes. The large majority of the DNA is therefore non-protein 
coding, but far from useless as science has only just started to discover [25-29]. Indeed, the “one 
gene to one protein” process presented above is a major simplification of reality. Within the 
context of this thesis two additional notions are important to keep in mind: (1) some RNAs are not 
translated into protein (non-coding RNAs, see below) but still regulate important cell functions and 
(2) a single gene coding region can produce different alternative transcripts and proteins (iso-
forms) [30, 31] (Figure 2). 
The functional genome controls which part the genome is used. A cell has many complex 
interacting tools at its disposure to regulate (gene) expression. This is necessary to ensure that a 
cell only generates the molecular machinery needed for its specific function. In many diseases, 
including (germ cell) cancer, this process is disturbed [32, 33]. Regulation starts even before 
transcription. In a non-dividing cell, the DNA is tightly wound up around coils (histones). The term 
histone modification refers to chemical additions to these coils that alter the accessibility of the 
DNA for transcription [34-36]. The DNA itself can also be modified to make it less accessible, most 
notably by CpG methylation. This constitutes the chemical addition of a methyl group to a CG 
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dinucleotide in the DNA [35, 37]. Modification of the DNA’s availability for transcription is called 
epigenetics. The epigenomic blueprint organizes the DNA archive according to the needs of a 
specific cell type in certain environmental conditions [38]. Epigenetics should not be confused with 
“genetics.” Genetics is defined as to the genetic code or base-pair sequence of the DNA which is 
not changed by epigenetic modifications. On top of epigenetic regulation, transcription depends 
on the activation of a gene’s transcription regulatory regions. These typically consist of a region 
directly before/upstream of the gene (promoter) and can include more distant sites as well 
(enhancers). Promoters and enhancers provide binding sites for proteins (transcription factors) 
which can, for example, stimulate the expression of a group of genes with a similar function [30, 
31, 39]. If a gene is transcribed, post-transcriptional regulation takes over, targeting the mRNA. In 
this thesis, emphasis is placed on a specific type of post-transcriptional regulation by micro-RNAs 
(miRs). miRs are 22 nucleotide long strings of RNA that bind to the tail (3’UTR) of a mRNA and 
usually inhibit translation / promote degradation of that mRNA [29, 40]. The term post-
translational modification is used to indicate chemical modification of proteins, e.g. to activate 
them or prime them for degradation (Figure 2). 
Cross sections of a cell at specific functional or regulatory levels are referred to as “omics” or 
“ome.” They are used to describe the simultaneous quantification of all members of a certain 
functional class in a cell. Examples of these classes are: mRNA, miRs, DNA, etc. [41, 42]. The 
textbook example of an “-ome” is the genome: the complete DNA base-pair sequence of a cell. 
Epigenomics is the investigation of epigenetic modifications as present across the whole genome. 
This includes investigation of the methylome, the methylation status of all CG dinucleotides in the 
genome. The term transcriptome is used to refer to all RNAs. The proteome refers to all proteins in 
a cell. Many more “omes” have been identified [42]. These are not directly relevant to this thesis 
and are therefore not discussed here. With the exception of the genome in normal diploid cells 
from the same individual, “omes” are generally different for each cell type and environmental 
condition. The terms “omics” and “ome” are also used when only a representative sample of all 
members in a class is investigated instead of al members. For example, the methylation array used 
in this thesis inquires the methylation status of ¨480,000 CG sites on the genome. This number 
does not even come close to the total number of CG dinucleotides in the total genome, but 
provides a useful indication of the total methylome. Such a representative sample is also referred 
to as a “genome-wide profile.” Omic datasets are basically big buckets of numbers representing 
cross sections of the state of a cell at certain functional or regulatory levels. Such datasets contain 
technical artifacts and difficulties inherent to the complex methods used to produce them, 
requiring normalization / pre-processing and validation. Normalization and pre-processing refer to 
all steps necessary to remove technical artifacts, noise and other non-biological effects from the 
data (relevant for this thesis: [43, 44]). Validation refers to the targeted experiments required to 
confirm the omics findings (Figure 2).   
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Figure 2. Schematic represtnation of the functional genome and its quantification into "omics" datasets. This highly 
simplified schematic illustration depicts the transcription of the DNA (genome) into RNA under the control of epitenetic 
mechanisms and other actors like transcription factors. Epigenetic mechanisms include DNA CpG methylation and 
various histone modifications. Translation of the RNA (transcriptome) is further influenced by post-transcriptional 
regulation, including micro-RNAs. The resulting set of proteins is called the proteome. In the proteome cogwheel, the 3-
dimensional structurea of the OCT3/4 protein is shown as an example. Proteins can be modified by the addition of 
various biochemical groups, i.e. post-translational modification. The dashed grey arrows illustrate the genome-wide 
experimental evaluation of the factors represented by the cogwheels. This results in large omics dataset. The aim of 
integrated functional genomics is to evaluate and if possible integrate these datasets. These datasets are quite literally 
the pieces of the puzzle that need to be put together to decipher the functional genome. For more details, see the main 
text. 
Functional genomics aims to integrate multiple (omics) datasets to better understand the 
functional interactions that determine a cells identity and behavior, requiring a multidisciplinary 
approach and a cultural change towards sharing and disclosing data & tools. Functional genomics 
is closely related to the field of systems biology which aims to model biological systems based on 
observations. Analogous, an important ambition of integrated genomics is to combine various 
(omics) datasets and create a complete map of the functional genome to better understand the 
functional interactions that determine a cells identity and behavior [45] (Figure 2). A great number 
                                                 
a http://www.ncbi.nlm.nih.gov/Structure/  
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of global initiatives strive to disclose complex (integrated) omics datasets. Examples of these 
initiatives include mainstream genome browsers/databases (Ensemblb, UCSCc, NCBId) which include 
numerous data tracks concerning functional genomics. Specialized databases are also freely 
available online. Examples are: genomics (NHGRI GWAS catalog e , dbSNP f ), epigenomics 
(ENCODEg, Blueprint projecth, WADIMEXi, geneimprint.comj, Cancer Genome Atlask), miR target 
prediction (microRNA.orgl, TargetScanm) and disease/pathway relations (OMIMn, KEGGo). GEOp 
and ArrayExpressq are online repositories where researchers can submit their data, which is often 
mandatory for publication. On the bioinformatics side, platforms like Bioconductorr and CRANs are 
available, facilitating the exchange, development and the standardization of bioinformatic tools. 
Making data and tools available is not enough however. A multidisciplinary approach including, 
among others, mathematicians, biologists and clinicians is crucial to successfully retrieve 
biologically and clinically relevant results from integrated functional genomic analysis [46]. 
Ultimately such results contribute to better understanding of (patho)biology and optimization of 
health care. 
  
                                                 
b http://www.ensembl.org/index.html  
c https://genome.ucsc.edu/  
d http://www.ncbi.nlm.nih.gov/  
e http://www.genome.gov/gwastudies/  
f http://www.ncbi.nlm.nih.gov/projects/SNP/  
g http://genome.ucsc.edu/ENCODE/  
h http://www.blueprint-epigenome.eu/  
i https://atlas.genetics.kcl.ac.uk/atlas.php  
j http://geneimprint.com/  
k http://www.broadinstitute.org/cancer/cga/  
l http://www.microrna.org/microrna/home.do  
m http://www.targetscan.org/  
n http://www.ncbi.nlm.nih.gov/omim  
o http://www.genome.jp/kegg/  
p http://www.ncbi.nlm.nih.gov/geo/  
q http://www.ebi.ac.uk/arrayexpress/  
r http://www.bioconductor.org/  
s http://cran.r-project.org/  
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Aims & outline of the thesis 
The work discussed in the thesis aims to elucidate the role of the functional genome in GCT 
(pathogenesis) by applying newly developed and existing computation methods to (genome-wide) 
datasets. Epigenetic and (post-)transcriptional regulation in GCTs is studied to gain deeper 
understanding about disease pathogenesis, also aiming at clinical application of the findings. The 
exploratory approach of the studies also contributes to the emergence of new hypothesis that can 
be experimentally and clinically validated in the future. 
Chapter 2 / part I of this thesis starts with an in depth review of the etiology, developmental 
biology and onco-fetal roots of GCC.  
Part II discusses the application of oncofetal proteins and miRs in GCC diagnostics and follow-up 
as well as a tool to identify functional miR-mRNA interactions in genome-wide datasets. Chapter 3 
verifies the specificity of a distinct OCT3/4 isoform as a marker for GCCs by comparing mRNA and 
protein levels of three OCT3/4 isoforms in GCCs, non-GCC malignancies and representative cell 
lines. This chapter highlights the importance of alternative splicing in gene function and clinical 
marker specificity. Chapter 4 describes miMsg, a bioinformatic tool to effectively reduce a high 
number of predicted miR-mRNA interactions to a small, high confidence set directly applicable to 
research. In this chapter, miMsg is also applied to a number of in-house GCT and public non-GCT 
datasets to illustrate its validity. This kind of tools is relevant to identify new disease specific targets 
and molecular networks that can be further studied in targeted experiments. Chapter 5 describes 
the application of serum embryonic miR levels as a new biomarker for GCCs, which is sensitive for 
the stem cell components SE and EC. The identification of these miRs as GCC markers could be 
applied to optimize diagnosis and follow-up of GCC patients. Chapter 6 compares the serum levels 
of ¨750 miRs in GCC cases and controls, validating known miR markers and identifying novel GCC 
specific targets / potential biomarkers. 
Part III focusses on the epigenetic constitution of GCTs and their cells or origin. Chapter 7 outlines 
DMRforPairs, a tool developed to detect differentially methylated genomic regions between 
unique samples using array based methylation data. This tool is applied in chapters 8 and 9 which 
elaborate on the epigenetic constitution of GCTs and their representative cell lines. Chapter 8 
sketches the functional genomic footprints of SE versus EC cell lines by integrating genome-wide 
data describing histone modifications, methylation status and RNA expression. Chapter 9 provides 
insight into the developmental timing and underlying biology of the various subtypes of GCTs and 
their (embryonic) cells of origin by identifying specific and global methylation differences between 
GCT subtypes.  
17
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Overall, the findings presented in this thesis outline interacting levels of the functional genomic 
landscape in GCTs and demonstrate (potential) clinical applications. Chapter 10 integrates the 
results. This last chapter provides a concise set of concluding remarks and future prospects 
regarding three main topics. Firstly, the unique onco-fetal hallmarks of GCC and the related clinical 
applications are discussed. Secondly, the insights gained into the developmental biology of GCT 
through the analysis of characteristic epigenetic properties of GCTs are revisited. Lastly, challenges 
faced when exploring (integrated) functional genomics underlying disease are examined from a 
more general point of view. 
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CHAPTER 2 
Abstract 
Germ cell tumors (GCTs) represent a diverse group of tumors presumably originating from (early 
fetal) developing germ cells. Most frequent are the testicular germ cell cancers (TGCC). Overall, 
TGCC is the most frequent malignancy in Caucasian males (20-40yr) and remains an important 
cause of (treatment related) mortality in these young men. The strong association between the 
phenotype of TGCC stem cell components and their totipotent ancestor (fetal primordial germ cell 
or gonocyte) makes these tumors highly relevant from an onco-fetal point of view. This review 
subsequently discusses the evidence for the early embryonic origin of TGCCs, followed by an 
overview of the crucial association between TGCC pathogenesis, genetics, environmental exposure 
and the (fetal) testicular micro-environment (genvironment). This culminates in an evaluation of 
three genvironmentally modulated hallmarks of TGCC directly related to the oncofetal 
pathogenesis of TGCC: (1) maintenance of pluripotency, (2) cell cycle control/cisplatin sensitivity 
and (3) regulation of proliferation/migration/apoptosis by KIT-KITL mediated receptor tyrosine 
kinase signaling. Briefly, TGCC exhibit identifiable stem cell components (seminoma and embryonal 
carcinoma) and progenitors that show large and consistent similarities to primordial/embryonic 
germ cells, their presumed totipotent cells of origin. TGCC pathogenesis depends crucially on a 
complex interaction of genetic and (micro-)environmental, i.e. genvironmental risk factors that 
have only been partly elucidated despite significant effort. TGCC stem cell components also show a 
high degree of similarity with embryonic stem/germ cells (ES) in the regulation of pluripotency and 
cell cycle control, directly related to their exquisite sensitivity to DNA damaging agents (e.g. 
cisplatin). Of note, (ES specific) micro-RNAs play a pivotal role in the crossover between cell cycle 
control, pluripotency and chemosensitivity. Moreover, multiple consistent observations reported 
TGCC to be associated with KIT-KITL mediated receptor tyrosine kinase signaling, a pathway 
crucially implicated in proliferation, migration and survival during embryogenesis including germ 
cell development. In conclusion, TGCCs are a fascinating model for onco-fetal developmental 
processes especially with regard to studying cell cycle control, pluripotency maintenance and KIT-
KITL signaling. The knowledge presented here contributes to better understanding of the 
molecular characteristics of TGCC pathogenesis, translating to identification of at risk individuals 
and enhanced quality of care for TGCC patients (diagnosis, treatment and follow-up). 
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Introduction 
Germ cell tumors (GCTs) represent a diverse group of tumors presumably originating from (early 
fetal) developing germ cells. Five GCT subtypes can be defined based on different stages in germ 
cell maturation. Most frequent are the (testicular) germ cell cancers ((T)GCC, type II GCTs). TGCC 
accounts for ¨1% of all solid cancers in Caucasian males. In contrast to other solid cancers, TGCC 
occurs in adolescents and young adults, accounting for 60% of all malignancies diagnosed in men 
between 20 and 40 years of age [1-3]. In the Netherlands, TGCC incidence in 2012 was 
9.43/100,000 (European standardized rate), an increase of 45% since 2002 (Dutch Caner 
Registration (IKNL), www.cijfersoverkanker.nl) which is consistent with increasing incidence outside 
The Netherlands (+3-6%/year) [4]. 5-year survival rates under current treatment regiments exceed 
96% (IKNL). Prognosis depends strongly on the composition / location of the tumor and patient 
characteristics [1, 2]. In spite of the overall success of treatment, TGCC remains an important cause 
of (treatment related) mortality in these young men [5, 6]. 
A common precursor lesion called carcinoma-in-situ (CIS) or intratubular germ cell neoplasia 
unclassified (IGCNU, WHO definition [7]) precedes TGCC [1, 2, 8, 9]. Because of the non-epithelial 
origin of TGCC, CIS is technically not a proper term but will be used throughout this review in the 
interest of consistency with existing literature. At least 70% of all CIS progresses into TGCC within 7 
years and the prevalence of CIS in autopsies was comparable to the lifetime risk of TGCC. This 
suggests that all patients with CIS eventually develop TGCC [10, 11], which has however not yet 
been proven conclusively. Invasive TGCCs are divided into seminoma (SE) and non-seminoma (NS, 
stem cell component embryonal carcinoma (EC)). ECs can differentiate into all somatic (teratoma) 
and extra-embryonic (yolk sac tumor and choriocarcinoma) lineages including germ cells, hence 
exhibiting the totipotent potential of TGCC [1, 2, 7, 12] (Figure 1). TGCC subtypes have distinct 
histopathological and molecular marker profiles used in research and diagnosis [1, 2, 13-27]. For 
follow-up, serum markers Alpha Feto-Protein (AFP), human Chorionic Gonadotrophine (hCG) and 
in a limited fashion Lactate DeHydrogenase 1 (LDH-1) are currently used, although they have 
limited specificity and are not sensitive for detecting TGCC stem cell components (SE or EC) or 
their precursor lesion CIS [4, 28-30]. Novel diagnostic strategies include immunohistochemical 
analysis of semen in search of CIS which has shown high specificity, but low sensitivity, warranting 
further investigation and optimization [31-34]. Quantifying the methylation status of specific 
regions (XIST promoter) of serum cell free DNA has been suggested as follow-up marker, but has 
so far not been validated [35, 36]. Very recently, a number of independent studies showed that 
serum levels of embryonic micro-RNA (miR) clusters 371-3 and 302abc/367 are predictive for the 
presence of TGCC. This tool proved especially sensitive for identifying the SE and EC components 
which are indeed known to express these miRs [13, 14, 37-41]. Many (suggested) TGCC markers 
are functionally related to the fetal origin and pluripotent biology of TGCC (see below, Figure 1). 
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Figure 1. Placing the TGCC cell of origin in an onco-fetal perspective as related to early embryonic germ cell 
development. The figure summarizes the observations reviewed in the main text. Panel A illustrates the physiological 
epigenetic reset and expression of core pluripotency markers during fetal germ cell development and the process of 
migration and maturation. Based on the reviewed evidence and anatomical localizations, the cell of origin of (T)GCC is 
positioned between the early PGC (extragonadal seminomas/germinomas) and gonocyte stage (testicular seminoma in 
the case of a male patient). ICR_P/M: imprinting control regions regulating expression of the paternal/maternal allele. 
Panel B summarizes the interrelation between the various types of TGCC and illustrates their totipotent potential. The 
methylation status and profile of mainstream diagnostic/onco-fetal markers is displayed as reviewed in the main text. * = 
miR-371/372/373 cluster & miR-302abcd/367 cluster. 
The strong association between TGCC and their totipotent ancestor (fetal primordial germ cell or 
gonocyte) makes these tumors highly relevant from an onco-fetal point of view, especially since a 
number of animal and cell line models are available for functional studies (supplementary data). 
Here, the fetal origin and intrinsic pluripotent oncofetal properties of TGCC cells are reviewed, 
especially with regard to their stem cell components SE and EC. Risk factors that might trigger 
malignant transformation of embryonic germ cells and disease progression are also discussed.  
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From fetal germ cells to CIS and beyond 
Normal germ cell development 
Embryonic germ cells or primordial germ cells (PGC) are detected in the proximal epiblast at week 
5-6 gestagional age in humans (E6.5 in mice). During fetal development these cells migrate along 
the midline of the body, where GCTs are also located: from the yolk sac, via the hindgut to the 
genital ridge. These cells are characterized by positive immunohistochemical staining for a number 
of pluripotency/germ cell markers: e.g. AP+/VASA+/OCT3/4+, [2, 42-44]. Part of the maturation 
processes is an epigenetic “reset”. This epigenetic reprograming includes early global 
demethylation followed by de novo methylation, imprinting reset (erasement Æ uniparental) and X 
chromosome reactivation (females only) after arrival at the genital ridge [45-56]. Most of the 
epigenetic studies showing this were done in mice, but even though germ cell development in 
mice and humans differs [57] similar methylation results were shown in human (fetal) germ cells 
[58, 59] (Figure 1A). PGCs at genital ridge are called gonocytes and further mature into oogonia 
and spermatogonia [2, 42-44] under strict regulation of the genomic constitution (XX vs XY) and 
the (gonadal) micro-environment. In an XX constitution the transcription factor SRY will be 
expressed leading to SOX9 expression and the formation of Sertoli cells: the supporting cells in the 
testis that guide gonocytes into maturation along the male germ cell lineage [60-63]. If SRY is not 
(sufficiently) expressed (physiological in XY condition), granulosa cells will be formed instead which, 
in the presence of e.g. FOXL2, support the formation of the female germ cell lineage [64, 65]. 
During maturation, germ cells lose expression of embryonic/pluripotency markers, although 
expression has been shown in the first years after birth. Delayed extinguishing of pluripotency 
markers does not necessarily indicate (pre-)malignant transformation, but might just indicate 
delayed maturation [66-70]; a distinction for which additional markers have been investigated [71, 
72].  
Malignant transformation of PGCs/gonocytes 
TGCC share many of the characteristics of PGCs/gonocytes and the standing hypothesis is that all 
TGCC arises from PGCs via a common precursor CIS (Figure 1). This hypothesis is based on various 
lines of evidence. Firstly, a number of targeted studies reviewed the marker profile of CIS and 
different developmental stages of (fetal) germ cells, identifying strong overlap between PGCs and 
CIS regarding pluripotency and germ cell markers, most notably KIT, POU5F1 NANOG and 
TCFAP2C (AP-2ǅ) [68, 70, 73-78] (Figure 1B). Gene expression analysis of CIS and SE also showed 
overlapping expression patterns related to early embryogenesis and fetal germ cells [13, 20, 79-
88]. Despite their common origin, significant differences in gene expression were observed 
between the histological subtypes of invasive TGCC [14, 82, 85, 89-91]. Chromosomal constitution, 
as well as cell cycle control and DNA repair have also been shown to work analogous to pre-
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meiotic germ cells in TGCC (the latter two are reviewed below and in [73, 74]). With regard to their 
epigenetic status there are strong similarities between TGCC and PGCs [57, 92-95]. Specifically, SE 
mirror the methylation profile of their hypomethylated progenitor CIS [96], which in turn reflects 
the generally hypomethylated state of PGCs [49, 51]. EC show higher levels of methylation [58, 97]. 
This presumably reflects a process of de novo methylation during tumor progression, potentially 
indicating a reversal to a more hypermethylated embryonic stem cell (ES) like phenotype. Because 
all CIS is strongly hypomethylated [96], this observation argues against different types of CIS 
leading to SE or EC as suggested in some studies [98, 99]. In a recent investigation of whole 
genome methylation profiling, we confirmed these global findings and relate TGCC to PGCs and 
early gonocytes based on methylation of specific functional regions (e.g. imprinting control 
regions) (Rijlaarsdam et al, 2014, submitted for publication) (Figure 1). 
The progression of CIS to invasive TGCC is not yet completely understood, although the loss of 
PTEN has been shown to be a common event [100]. Even though a role of the immune system in 
TGCC pathogenesis has been suggested [101, 102], studies regarding the specificity and the effect 
of immune response upon invasion contradict each other [103, 104]. With regard to their genomic 
constitution upon malignant transformation, polyploidization to a tetraploid stage is thought to be 
an early event, occurring before the formation of CIS [105, 106]. During progression, TGCCs are 
thought to acquire heterogeneous chromosomal gains and losses ending up in a near triploid 
state. A consistent causative relation of these copy number variations to disease (progression) has 
not been determined so far [107-116]. Most markedly, gain of predominantly the whole short arm 
of chromosome 12 (12p) is specific to invasive GCCs. This aberration might be functionally relevant 
in the pathogenesis of these tumors [79, 117-121], a hypothesis further inspired by the fact that 
induced pluripotent stem cells (iPS) with gain of chromosome 12 show selective advantage during 
reprograming and increased tumorigenic potential [122-124]. Allelotyping has suggested 
increasing amounts of loss of heterozygosity in coexisting CIS, SE and EC. Concordance rates 
between the allelic patterns were higher for CIS vs SE and SE vs EC than for CIS vs EC. This 
suggests possible progression from CIS to SE to EC [125], a rare transition in mixed tumors 
(SE+NS) that has also been suggested by anecdotal evidence at the RNA and protein level [126]. 
Why does a germ cell turn to the dark side? 
Genetic risk factors 
A 76 fold risk increase in male twins [127] and a ¨25 fold risk increase in patients with a 
contralateral tumor [128] illustrates the genetic component in GCC pathogenesis (Table 1). Indeed, 
25% of GCC susceptibility could be attributed to genetic factors according to an elegant 
epidemiological study by Czene and coworkers [129]. In targeted studies specific genomic risk loci 
26
AN ONCOFETAL AND DEVELOPMENTAL PERSPECTIVE ON TESTICULAR GERM CELL CANCER 
 
 
/ Single Nucleotide Polymorphisms (SNPs) were identified at the Y chromosome (gr/gr 
microdeletion) [130, 131] and in the FSH [132] / androgen receptors [133]. Risk loci were also 
found in PTEN [134] and loci related to genes involved in steroid hormone metabolism [135, 136], 
cAMP signaling [137], insulin like growth factor signaling [138], DNA damage response [139, 140], 
estrogen metabolism/signaling [141-143], gonadotropin regulation [144], TP53-KITL interaction 
[145], sex determination [146] and prostate/colorectal/breast cancer (8q24 locus) [147]. Larger 
scale GWAS studies consistently identified a number of (other) risk SNPs [148-155] which were 
validated in additional (targeted) studies: [156-158]. The results of genetic studies in subfertile 
patients [159] and familial TGCC [160, 161] populations  did not significantly differ from the 
general population, implying a common genetic base in these risk groups and sporadic GCC cases. 
Recently all major GWAS studies were combined in a very diligent meta-analysis by Chung and 
coworkers, verifying 14 previously identified risk SNPs and identifying 5 additional ones [162] 
(Figure 2A). The genes associated with these SNPs are associated with a surprisingly condensed set 
of biological functions: KIT-KITL receptor tyrosine kinase signaling (reviewed below), telomere 
maintenance, cell cycle/division control (reviewed below) and establishment of the germ cell niche. 
More details are presented in the legend of Figure 2. In line with the proposed combination of 
genetic and environmental risk factors making up total TGCC risk, the per-allele odds-ratio for 
each SNP was relatively low, the KITL loci being the only ones with ORs > 2 or ORs < 0.5. 
Table 1 Clinical risk factors for TGCC. The aim of this table is to give an overview of the risk factors and their impact as 
most frequently discussed in (recent) literature. Unless otherwise specified, studies were conducted with TGCC- & CIS- 
individuals (“healthy controls”) as reference although in some studies individuals were under medical evaluation for other 
conditions. In some cases Dieckmann et al present min-max RR/ORs which should be interpreted carefully as no 
information about variation is presented. Abbreviations RR=relative risk, OR=odds ratio, SIR=standardized incidence 
ratio, CI=confidence interval, T=testosterone, ns=not significant, arrows=(significantly) higher/lower in TGCC patients, 
?=not discussed in paper. CC=case control study; RC=retrospective cohort. 
Factor Risk Quantification Magnitude References Remarks/study design 
Familial GCC 
for review: [127] 
2.15-12.3 
Mono/dizygotic twin :  
76.5 (11.2-518.0)/35.7 (5.2-
244.7) 
Parent/sibling:  
4.31 (2.05-7.95)/8.50 (6.01-
11.68) 
Father/brother:  
3.78 (2.16-6.16)/8.58 (6.41-
11.26) 
OR/RR (min-
max) 
 
SIR (95%CI) 
 
SIR (95%CI) 
 
SIR (95%CI) 
[128] 
 
[163] 
 
[164] 
 
[165] 
Review (CC & cohort studies) 
 
Retrospective cohort of UK 
twins 
 
RC, Swedish Family Cancer 
Database 
 
RC, Swedish Family Cancer 
Database 
Contralateral tumor 24.8-27.6 OR/RR (min-
max) 
[128] Review (CC & cohort studies) 
Urological/Andrological     
Cryptorchidism 3.5-17.1 
4.1 (3.6-4.7) 
3.71 (3.29-4.19) 
3.18 (2.50-4.04) 
OR/RR (min-
max) 
RR (95%CI) 
RR (95%CI) 
OR (95%CI) 
[128] 
[166]  
[167]  
[168] 
Review (CC & cohort studies) 
Meta-analysis 
(cryptorchidism±TGCC) 
Retrospective cohort, Denmark 
Retrospective cohort, Sweden 
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Factor Risk Quantification Magnitude References Remarks/study design 
FSH/LH/T/Inhibin-B 
 
द/द/ns/- 
 
 
?/द/न/? 
 
ns/ns/ns/न 
 [169] 
 
 
[170] 
 
[171] 
Unilateral CIS vs bilateral CIS, 
testicular function after 
unilateral orchidectomy in 
Denmark. 
Orchidectomy for 
TGCC/benign lesions + healthy 
controls.  
RC in NL, microlithiasis±CIS. 
Infertility 2.8 (1.16-6.72) 
 
2.8 (1.5-4.8) 
 
1.6 (1.3-1.9) 
 
2.06 (0.64-7.18) 
 
 
2.4 (1.4-4.1) 
RR (95%CI) 
 
SIR (95%CI) 
 
SIR (95%CI) 
 
% 
 
 
% 
[128] 
 
[172] 
 
[173] 
 
[174]  
 
 
[175] 
New data in review 
(retrospective case-control, 
Germany) 
Retrospective (infertile patients 
vs general population, USA) 
Subfertile Danish RC; reference 
incidence in general population 
Incidence of CIS in biopsies 
from azoospermic men without 
spermatogenesis. 
Incidence of CIS in biopsies 
from infertile men. 
Hypospadias 2.13 (1.26-3.61) 
2.41 (1.27-4.57) 
RR (95% CI) 
OR (95% CI) 
[167]  
[168] 
RC, Denmark 
RC, Denmark 
Testicular aberrations     
DSD (gonadal 
dysgenesis) 
25% Life time risk [128] Review (CC & cohort studies) 
Microlithiasis 
for review: [176, 177] 
13.2 (8.3-21.5) 
 
3.42 (1.82-6.01) 
 
RR (95%CI) 
 
RR (95%CI) 
 
[178] 
 
[179] 
 
Prospective cohort (inclusion: 
ultrasound for various reasons, 
UK) 
Retrospective cohort (inclusion: 
ultrasound for various reasons, 
USA) 
Atrophy 20.5 (2.7-153) RR (95%CI) [128] Retrospective CC, Germany 
Environmental risk factors 
Apart from the limited magnitude of the observed genetic risk factors alone, the quickly increasing 
incidence in Western countries cannot be explained by genetic factors alone, drawing attention to 
the importance of factors related to the environment [2, 4]. This is strongly supported by first 
generation migrant studies showing a steep increase in incidence after migration to countries with 
a high TGCC incidence [180]. A comprehensive overview of all environmental and lifestyle factors 
that have been investigated with regard to TGCC risk lies outside of the scope of this review, has 
recently been presented by McGlynn and coworkers [181]. Examples include but are not limited to: 
birth weight, decreased gestational age, maternal smoking and parity and life style factors like 
dietary intake and physical exercise. In general, these associations with TGCC incidence are weak or 
inconsistent between studies, except for frequent marijuana use and NS [181-183]. The proposed 
common denominator in many risk factors is increased (fetal) exposure to estrogens and anti-
androgens, supported by disorders observed in sons of women exposed to diethylstilbestrol (DES) 
during pregnancy [184, 185]. Endocrine disrupting chemicals as present in our daily life are known 
disrupt sperm function and fertility [186]. The evidence pointing to specific substances that 
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contribute to GCC risk is however weak [187]. Alkylphenols act like estrogens and stimulated 
proliferation in the SE cell line TCam-2, possibly via modification of the epigenetic machinery [188]. 
However, in vitro studies using anti-androgens present in everyday life showed little effect on 
androgen receptor function (reviewed in [189]). In studies investigating prenatal estrogen 
(progenitor) levels, the association between high prenatal estrogen exposure and GCC risk was 
inconsistent or non-significant [190, 191], although higher levels of androgens during adolescence 
showed a protective effect [192]. The relation of TGCC pathogenesis with (environmental exposure 
to) estrogens and anti-androgens remains a mechanistically tempting hypothesis, but additional 
large scale studies are needed to provide more consistent epidemiological evidence of this 
association and point to specific substances of interest which can be functionally tested. 
 
 
Figure 2. A genvironmental risk model for TGCC. (A) Genetic risk factors. Forest plot of GCC risk SNPs identified in [162]. 
Four SNPs were located in KITL (reviewed extensively below). Three SNPs were located in SPRY4 (MAP kinase pathway 
[193]) and one in BAK1 (apoptosis [194]), which are both downstream targets of KITLG/KIT signaling. SPRY4 responds to 
KIT inhibition by imatinib [195]. TERT and its transcription factor ATF7IP influence telomere maintenance (normally only 
active in germ cells) [196, 197]. The TERT-CLPTM1L locus is a cancer-hotspot ([149] for review) and CLPTM1L is involved 
in cisplatin sensitization [198]. DMRT1 influences sex determination and germ cell development [199, 200]. PPM1E is 
serine/threonine-protein phosphatase implicated as an anti-diabetic drug target [201]. CENPE [202], MAD1L1 [203] and 
TEX14 [204] are implicated in spindle assembly and progression of cell division as is RFWD3 (G1 checkpoint) [205]. UCK2 
has been implicated in the efficiency of specific types of chemotherapeutic drugs [206]. HPGDS has been related to 
establishment of the fetal germ cell nice (e.g. disturbed nuclear SOX9 expression Sertoli cells in mice) [207]. A number of 
KITL and SPRY4 SNPs were in strong linkage disequilibrium (r2>0.8; Broad Institute (SNP reference dataset: 1000 
Genomes Pilot 1): KITL (rs4474514/rs3782179; rs4474514/rs1508595; rs3782179/rs1508595; rs4590952/rs1508595; 
rs4590952/rs3782179; rs4474514/rs4590952; rs995030/rs3782179; rs995030/rs4474514; rs995030/rs4590952) and 
SPRY4 (rs4624820/rs4324715; rs6897876/rs4624820). These SNPs should therefore not be interpreted as independent 
risk signals. (B) Global and schematic representation of the integrated role of genetic and environmental risk factors in 
the pathogenesis of TGCC inspired by the TDS model proposed by Sonne and colleagues [208]. 
The genvironmental hypothesis and its clinical manifestations 
In the previous paragraphs numerous genetic and environmental (T)GCC risk factors have been 
described. Multiple studies have shown evidence of genetic and environmental factors to interact 
in the pathogenesis of (T)GCC, i.e. an combined genvironment risk model [94, 172, 209-212] 
(Figure 2B). In this perspective, epigenetic (de)regulation  is a tempting bridge between genetics 
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and environment [94, 209, 213], even trans-generationally [212, 214]. Genvironmental disturbance 
results in a spectrum of clinical manifestations associated with increased risk of TGCC that has been 
baptized testicular dysgenesis syndrome (TDS) [208, 215] (Figure 2B). TDS is also associated with 
disorders of sex development (DSD). If the GBY region of the Y chromosome is present, DSD 
patients have 25% lifetime risk of TGCC [128, 216-218]. The spectrum of risk factors associated 
with GCC is reviewed in Table 1 and many of these are associated with decreased fertility. The 
(genetic) association between fertility and TGCC risk is emphasized further by lower fertility in 
TGCC patients [219] and their brothers [220]. Indeed, most studies report higher CIS prevalence in 
subfertile men as compared to the general population [174, 175, 221]. Taken together, TGCC risk 
is entwined with infertility and other urological/andrological aberrations and is determined by a 
complex set of interacting genvironmental modifiers of the germ cell micro-environment, each 
with individually moderate effect size, together making up the total TGCC risk (Figure 2, Table 1).  
How to survive as a germ cell tumor: TGCC make the most 
of their onco-fetal phenotype 
This section focusses on three genvironmentally modulated hallmarks of TGCC directly related to 
the oncofetal pathogenesis of TGCC: (1) maintenance of pluripotency, (2) cell cycle 
control/cisplatin sensitivity and (3) regulation of proliferation/migration/apoptosis by KIT-KITL 
mediated receptor tyrosine kinase signaling (Figure 3). These key factors show an inspiring overlap 
with the almost axiomatic hallmarks of cancer as defined by Hanahan and Weinberg [222, 223]. 
Other key associations with TGCC are sex determination and steroid/sex hormone regulation, in 
line with their fetal germ cell of origin. These and other TGCC related factors are excellently 
described in a number of recent reviews [2, 224, 225]. 
(Maintenance of) pluripotency 
In the previous sections, the early embryonic origin of TGCC was reviewed. The fact that 
mainstream TGCC markers OCT3/4 and SOX2 represent two out of four Yamanaka factors 
required to create iPS cells emphasizes this [226, 227]. This is of interest, especially as specific iPS 
reprogramming protocols have been shown to induce GCC like tumors [228]. The parallel between 
GCCs (teratomas) and potential complications of stem cell therapy also illustrates this point [228-
230]. OCT3/4, SOX2 and NANOG - together with a number of other factors - work in close 
harmony in regulating pluripotency. They bind to a large numbers of promoter regions, including 
their own [231, 232]. Apart from this complex crossover in auto-regulation of transcription they are 
all subjected to stringent post-translational control [230, 233, 234]. Key regulators of the 
pluripotency will be discussed in the context of TGCC in the following sections. 
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Figure 3. Crosstalk between pluripotency and cell cycle regulation is facilitated by (ES specific) microRNAs. This scheme 
fuses the evidence presented in the main text. Basically, two major onco-fetal mechanisms are at work in TGCC. The 
presence of pluripotency markers results in upregulation of ES specific miR families 371-2-3 and 302 which in turn 
(down) regulate G1/S checkpoint regulation to facilitate rapid transition through the cell cycle while at the same time 
preserving high sensitivity to DNA damaging agents (summarized schematically in the bottom right inlay). Along this 
integration of pluripotency and cell cycle control, KIT-KITL mediated receptor tyrosine kinase signaling also regulates 
proliferation, migration and survival during embryogenesis and germ cell development. * (miR) transcription is regulated 
by a complex of multiple transcription factors like OCT3/4, SOX2, NANOG, etc. For simplicity, only OCT3/4 is displayed. 
Colored boxes indicate known expression levels in TGCC (grey in no clear evidence). 
OCT3/4 & NANOG 
OCT3/4 (POU5F1) is detected in all stem cell components and CIS and is used as a mainstream 
diagnostic marker [2, 17, 235-238], but might also be present in maturation delayed (but non-
malignant) germ cells [71, 72, 239-241] (Figure 1). OCT3/4 is a long standing master regulator of 
self-renewal, pluripotency and prevention of apoptosis in embryonic stem (ES) cells and in the 
early developing embryo, including PGCs [242-247]. Expression is lost during differentiation [248-
252]. Reciprocally, OCT3/4 downregulation initiates differentiation [245] or, in PGCs, apoptosis 
[246, 253, 254].  
The gene encoding the OCT3/4 transcription factor is located on 6p21 and consists of 5 exons 
[255-257]. Investigations of OCT3/4 expression and protein availability are hampered by the 
presence of similar transcripts with different or complimentary functions, e.g. non-protein coding 
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pseudogenes (n=5) [235, 243, 258, 259], anti-sense transcribed pseudogenes [260] and splice-
variants (OCT4A: pluripotency, OCT4B: stress responseOCT4B1: possibly both) [237, 243, 261-266]. 
In addition, translation of OCT3/4 is mediated by micro-RNAs, specifically miR-145 [267, 268] and 
miR-34a [269]. Also, post-translational modification of OCT3/4, i.e. phosphorylation by AKT has 
been shown to change its affinity / specificity for DNA binding sites, potentially changing the 
functional impact of this transcription factor [270]. 
Like OCT3/4 and in line with their pluripotent phenotype, the homeodomain NANOG is only 
detectable in the TGCC stem cell components SE and EC and in CIS and not in differentiated NS 
derivatives [18, 271] (Figure 1). NANOG is physiologically responsible for maintaining pluripotency 
in the inner cell mass [272, 273] and is expressed in early germ cells [18]. Of interest, NANOG is 
located on chromosome 12 which frequently shows gain in TGCC [274]. Downregulation of 
NANOG causes differentiation into extra-embryonic lineages [275] or, in PGCs, apoptosis [276]. 
SOX2 & SOX17 
Two members of the SRY-related HMG-box family are important TGCC markers associated with 
pluripotency: SOX17 in CIS / SE and SOX2 in EC [23, 24, 277] (Figure 1). SOX2 is expressed in 
pluripotent and multipotent embryonic and extra-embryonic cells [278]. However according to a 
number of studies SOX2 is not expressed in developing human germ cells as is the case in mice 
[277, 279, 280]. A single study showed SOX2 in normal germ cells/CIS/SE, but the authors stated 
that this is likely an artefact of a single antibody showing this result [281]. Instead of SOX2, human 
germ cell progenitors express SOX17 [224, 277, 279] which is reflected in SOX17 expression in CIS 
and SE [23, 24, 277]. SOX17 is involved in regulating differentiation into primitive endoderm [247, 
282]. Interestingly, SOX2 and SOX17 both operate together with OCT3/4 in regulating 
transcription. However, the two protein pairs have different affinities for specific DNA binding 
motifs, presumably differentially regulating genes contributing to pluripotency or endodermal 
lineage commitment respectively [283]. 
microRNAs 
Knockdown of the micro-RNA (miR) machinery in ES cells showed that miRs are crucial to ES cell 
cycle progression and differentiation [284-288]. This implicated these 22 nucleotide long 
(predominantly) inhibitors of translation as potential regulators of pluripotency. Indeed, induction 
of specific miRs have been shown to greatly enhance the efficiency of creating iPS [289, 290]. 
Reciprocally, master transcription factors regulating pluripotency (OCT3/4, SOX2, NANOG, TCF3) 
have been shown to regulate transcription of ES cell specific miRs [291]. Another example is the 
inhibition of the tumor suppressor miR let-7 by LIN28 [292, 293]. LIN28 is a WNT signaling 
associated maintainer of pluripotency which is normally highly expressed in developing germ cells 
and the stem cell components of TGCC [19]. An ES specific subset of these ¨22 long nucleotide 
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inhibitors of mRNA translation has been identified including the miR-302abdc/367 (302), miR-371-
2-3, miR-290 and miR-17-19 clusters which show similarity in seed sequence [291, 294, 295]. 
Moreover, the miR-371-2-3 and 302 clusters are expressed highly in TGCC tumor tissues [13-15] 
and are detectable in serum of TGCC patients [14, 37-41]. These miRs will be discussed in more 
detail together with ES like cell cycle regulation and cisplatin sensitivity below.  
Cell division, apoptosis and cisplatin chemosensitivity 
ES cell cell cycle progression is mirrored in TGCC and is an important factor in its chemo sensitivity 
In normal somatic tissue TP53 represents the proverbial break on unlimited proliferation / survival 
and is therefore a key target for oncogenic transformation in many cancers [296-298] as well as in 
iPS generation [299]. TGCC however only rarely show TP53 mutations but generally exhibit 
relatively high TP53 expression [300-303]. An explanation for the abundant TP53 in TGCC 
combined with their seemingly contradictory exquisite sensitivity to DNA damaging agents might 
lie in the onco-fetal origin of TGCC. The stem cell components and progenitors of TGCC exhibit 
pluripotent ES-like properties and are therefore equipped with high chemosensitivity by design 
[304, 305] (see below). Of note, this argues against therapeutic agents that induce differentiation 
as suggested before [306, 307]. Another illustration of the innate chemosensitivity of TGCC is the 
fact that mutations in cisplatin resistant tumors are much frequent (up to 25%) [308] than in TGCC 
in general (rare) [309, 310], illustrating that TGCCs need additional hits to escape their instrinsic, ES 
like apoptotic response to DNA damage.  
ES cells exhibit very short gap phases in the cell cycle and rapidly progress through the G1/S 
checkpoint [311, 312]. This way they bypass TP53-p21 cell cycle mediated DNA damage response 
but instead choose a combination of rapid apoptosis as response to DNA damage and at the 
same time facilitate quick progression through the cell cycle. This allows rapid growth while 
protecting ES/germ line genomic integrity [224]. In TGCC this behavior is mirrored: high TP53 
expression is associated with cisplatin sensitivity specifically in the presence of low p21 [302, 313-
320]. A number of other downstream targets of G1/S cell cycle progression have been identified as 
mechanistic in TGCC cisplatin response. On the other hand, consistent defects in DNA damage 
response were only found in cisplatin resistant TGCC (reviewed in [224]) (Figure 3). 
(Embryonic) miRs facilitate crossover between pluripotency and cell cycle progression 
Two ES specific miR clusters both target cell cycle control at the G1/S checkpoint, but with different 
(quantitative) outcomes: miR-371-2-3 and miR-302abcd/367 (302). miR-371-2-3 has been shown 
to inhibit LATS2 and p21. These proteins normally facilitate TP53 mediated inhibition of cyclin 
dependent kinases involved in G1/S cell cycle progression and their inhibition allows rapid G1/S 
progression [13, 224, 321]. Interestingly, a positive feedback loop between TP53 and LATS2 
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prevents tetraploidization [322]. This is one of the earliest steps in TGCC pathogenesis, in this 
context possibly related to disruption of TP53 mediated LATS2 upregulation by miR-371-2-3.  
The net influence of miR-302 on cell cycle progression is still under debate [323-326]. Validated 
miR-302 targets include many players in G1/S regulation. For example, CCND1 is a validated target 
and his closely related family member CCNE2 has also shown to be downregulated upon miR-302 
expression [325]. Moreover, AKT - an upstream regulator of cell cycle progression - has been 
functionally validated as a miR-302 target leading to less MDM2 regulated inhibition of functionally 
active TP53 [326]. However, miR-302 has also been shown to interact directly with p21 mRNA, 
stimulating cell cycle progression [323, 324, 327]. Overall, cell cycle related ES specific miRs 
contribute to a complex, tightly controlled balance of rapid, but not uncontrolled proliferation. 
miR-34a also influences the cross-over between pluripotency and cell cycle control, targeting 
OCT3/4 as discussed previously. miR 34-a is TP53 regulated and involved in cell cycle regulation 
[269]. This miR has been shown to increase iPS generation efficiency [328] and has been implicated 
in TP53 mediated inhibition of WNT signalling / epithelial to mesenchymal transition [329]. Its 
family member miR-34c, which has been shown to induce TP53 mediated apoptosis of germ cells 
in dairy goats [330] and is present in human germ cells [331]. Interestingly, TP53 itself has also 
been shown to interact with the miR production machinery, illustrating the complex interactions 
that guard the pluripotent homeostatic state [332, 333].  
Because these miRs are at the TGCCs disposal [13-15], they can acquire rapid cell cycle 
progression without TP53 mutation, facilitating malignant transformation [334]. Indeed, mutations 
of the core regulator of the miR machinery (DICER1) are infrequent in sporadic and familial TGCC 
[335, 336]. The miR-371-2-3 family is highly expressed in TGCC as discussed above, but is not 
expressed in the only TP53 mutant GCC cell line NCCIT [337, 338] and only showed absence of 
expression in a fraction of the rare TGCC with a TP53 mutation [13]. Although expression levels are 
not necessarily associated with functional impact, the discrepancy between the levels of miR-371-
2-3 and miR-302 in TGCCs (371-2-3>302x) might point to an evolutionary selection of miR-371-2-
3, which most directly stimulates rapid proliferation and does not hypothetically stimulate 
apoptosis as well as is the case for miR-302 via AKT-MDM2-TP53 [224]. In summary, the ES like cell 
cycle progression facilitated by these fetal onco-miRs clearly illustrates the unique onco-fetal 
signaling that allows malignant transformation of totipotent embryonic germ cells into TGCC while 
retaining a chemo sensitive phenotype (Figure 3). Additional disturbances during progression 
might induce resistance to DNA damaging agents. 
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Receptor tyrosine kinase signaling: KIT-KITL 
KIT/KITLG tyrosine kinase signaling has been consistently and crucially implicated in in 
embryogenesis, germ cell development and TGCC. The function of this pathway includes many of 
the prerequisites for a cancer cell: proliferation, migration and survival. KIT & KITLG establish their 
effects via a large number of interacting signaling routes amongst which are PI3-kinase-AKT, Src 
family kinases (SFK), mitogen-activated protein kinase (MAPK) pathways and phospholipases 
(reviewed in [339]) (Figure 3). These signaling pathways are crucial in physiological functioning of 
many tissue types / diseases including other types of cancer (reviewed in supplementary data). The 
human KIT gene (c-KIT/Piebald Trait Protein, PBT) encodes the cellular homolog of the viral 
oncogene v-kit or Hardy Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog. The genetic 
structure of KIT, its transcriptional regulation and degradation (turnover) has been excellently 
reviewed before [339]. Briefly, the KIT gene is located on 4q11-q12 and encodes a type III receptor 
tyrosine kinase with four isoforms. Another KIT variant is truncated, has no kinase activity, but was 
still proven to be functional in signaling (see below) [339]. The ligand of the KIT receptor is KITLG 
(stem cell factor, SCF) which causes dimerization of KIT monomers and subsequent activation of 
downstream signaling cascades [339, 340]. KITLG is located on chromosome 12q21.32 and is 
mainly expressed as two forms: membrane bound and soluble. The soluble form is initially bound 
to the cell membrane, but contains an additional 6th exon encoding an extracellular cleavage site. 
Both forms activate KIT, but with qualitative and quantitative differences [339].  
KIT/KITLG in germ cell development 
Fetal development 
KIT and KITLG regulate PGC development and homing to the genital ridge [42, 339, 341-343]. In 
the embryonic phase the guidance of KIT positive PGCs from the hind gut epithelium to the 
gonads depends strongly on KITLG mediated chemo attraction [43, 342, 344, 345]. KIT or KITLG 
mutant mice show normal establishment of the germ cell lineage in het hind gut, but aberrant 
proliferation and unsuccessful migration during embryogenesis [42, 339]. Different mutations 
influence different phases in germ cell migration/proliferation [346]. KITLG or KIT mutant germ cells 
eventually go into apoptosis, effectively resulting in sterility (males worse than females) [42, 339]. 
This is in line with PI3K-AKT mediated inhibition of apoptosis being a major downstream effect of 
KIT signaling [347]. It also illustrates the characterization of KIT as a dependence receptor: without 
the ligand, the cells will go into apoptosis [339, 348, 349]. Upon arrival in the testis, estrogen 
signaling is an important regulator of KIT dependent embryonic gonadal development effecting 
both germ cell progenitors and supportive cells (Leydig cells) [350, 351]. More specifically, KIT 
phosphorylation is up regulated in PGCs by estrogen stimulation [350, 352].  Indeed, in the SE cell 
line TCam-2, representative of the malignant counterpart of committed germ cell progenitors [88], 
dependence on estrogen was also shown [353]. 
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The postnatal testis 
In the postnatal testis KIT-KITLG signaling takes place via paracrine signaling in the germline stem 
cell niche and is crucial for spermatogenesis from the pre-spermatogonial stage onwards [339, 
342, 354-356]. Spermatogonia are positive for KIT, as are Leydig cells in which KIT signaling 
triggers testosterone production [342, 357]. This is differently regulated in mice. Sertoli cells on the 
other hand produce KITLG [339, 358, 359] under the influence of FSH [339, 360, 361]. This 
hormonal sensitivity is activated upon puberty (rat & primate models) [362, 363]. A feedback loop 
between KIT positive germ cells and KITLG production by Sertoli cells has been suggested because 
of increasing Sertoli cell KITLG-levels in men with decreasing fertility (highest: Sertoli cell only) [364-
366]. This micro-environmental interplay is of crucial important for normal germ cell development, 
as was also shown in patients with non-obstructive azoospermia by (abnormal Sertoli cells) [367]. 
On a molecular level, KITLG contributes directly to PI3K mediated proliferation of germ cells as 
shown in cell cultures of spermatogonia [368]. Indeed, development of post-meiotic germ cells 
germ cells relies strongly on the presence of the PI3-kinase binding site in KIT, subsequently 
regulating AKT activation. If this p85 binding site is selectively mutated in mice, only the germ cell 
lineage suffers [369, 370]. Growth factors, hormones, cytokines and vitamins (e.g. BMP4 & retinoic 
acid) regulating KIT expression in male germ cells as well as the molecular basis for regulation (e.g. 
testis specific transcription factors (ZBTB16, AP-2ǅ, SOHLH1/2 [371], SIX5) and miR-221/222), has 
been reviewed before [342, 372, 373]. More mature mouse spermatids and spermatozoa express a 
C-terminal truncated form of KIT transcribed from an intronic promotor [358]. Transcription is 
presumably regulated by retinoic acid which is crucial to germ cell fate determination and timing of 
meiosis in mice [356, 366]. This truncated isoform lacks kinase activity via PI3K and does not have 
the extracellular/transmembrane components [374]. It is nevertheless able to activate egg 
activation of metaphase II activated mouse oocytes [358, 375-377]. It functions as a scaffold 
protein, interacting with Src-like tyrosine kinase Fyn [378]. In human testis, truncated KIT is 
expressed during spermatogenesis and maintained in ejaculated sperm. The protein is expressed 
in the equatorial region of human spermatozoa. This part enters the oocyte first, which is 
consistent with mouse oocyte activation by truncated KIT injection. Truncated KIT expression is 
correlated with sperm quality parameters [379]. 
KIT/KITLG in germ cell cancer 
Analogous to its role in germ cell development and consistent with the importance of the germ 
cell micro-environment, disrupted KIT/KITLG signaling is crucial in the development of TGCC. 
Indeed both SE cells [380] (Sertoli cell feeder) and spermatogonia [368] depend on KITLG in 
culture. In mice, loss of functional transmembrane, but loss of soluble KITLG, leads to an increased 
incidence of TGCC like tumors (teratomas) [381]. Mechanistically, constitutive paracrine or 
autocrine activation of KIT/KITLG signaling is implicated to be a crucial initiating event for the 
malignant transformation of maturation arrested germ cell progenitors [2, 224]. In the early stages, 
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KITLG positivity is a hallmark of maturation arrested germ cells, CIS and intratubular SE [2, 69, 74, 
382]. Progression into invasive SE is also strongly related to KIT/KITLG signaling while much less 
association with the NS phenotype has been shown [354, 383-386]. Indeed, KIT expression is 
significantly (19-fold) higher in SE as compared to NS (p<0.01, 2-sided t-test) while the inverse was 
true for KITLG (5-fold, p<0.01, 2-sided t-test, data from our group, published before in [72])). 
These results match with a previous study [387]. This suggests KIT dependence of SE and possibly 
a KITLG saturated micro-environment (threshold level for effect on viability already suggested for 
KIT in [383]). In the SE cell line TCam-2 [388-391] Goddard and coworkers identified a small but 
significant decrease in viability upon KIT knock down [383]. In a similar experiment from our group 
we could not replicate this result, nor did we detect a consistent effect of KITLG knock down or 
exogeneous KITL addition on TCam-2 viability (results in supplementary data). On the DNA level, 
KIT was the only consistently amplified gene in an amplicon present in 17-21% of all SE (rare in NS) 
[383, 392]. In a small series of adjacent precursor lesions, no amplification was identified [392] 
which, in contrast to KITLG positivity from the pre-malignant stage onwards, suggests KIT 
amplification or mutation to be a downstream event related to progression, coming into focus 
after the formation of the TGCC precursor lesion [383, 392].  
Activating KIT mutations are identified in ca 13-60% of the SE (rare in NS) and result in constitutive 
kinase activity because of ligand independent dimerization and phosphorylation [392-397]. Of 
note, KIT mutations are much less frequent in high GCC-risk patients with Disorders of Sex 
Development, a major risk factor for GCC. In these cases an alternative, TSPY related pathogenesis 
has been suggested [398]. The effect of mutations depends both on the mutation and the cell type 
[339, 399]. In SE KIT mutations are predominantly found in exon 17 / D816V [395, 398], which 
might explain why many TGCC are innately resistant to the tyrosine kinase inhibitor imatinib [400, 
401]. In bilateral germ cell tumors, somatic KIT mutations (codon D816X) were identified in 63-93% 
of the cases [402, 403], but this high frequency was not replicated in independent, smaller studies 
[383, 404, 405]. In addition, there is no indication of germ-line mutations of KIT in familiar GCC 
[406]. However, KITLG promoter methylation was significantly lower in blood of these patients 
[407] and SNPs in KITLG combined with aberrations in cAMP regulation were suggested to 
contribute to tumor risk in these patients [408]. In the end, no quantitative relation has been shown 
between overexpression and amplification / mutation status of KIT in SE [383, 392]. As reviewed 
under “genetic risk factors” and in Figure 2, many of the SNPs identified in GWAS studies 
investigating GCC risk loci were related to KIT-KITL signaling.  
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Concluding remarks 
This review focused on the early embryonic origin of TGCC and the onco-fetal associations in their 
pathogenesis. Most importantly, TGCC exhibit identifiable stem cell components (SE and EC) and 
progenitors that show large and consistent similarities to PGCs, their presumed embryonic 
totipotent cells of origin. TGCC pathogenesis depends crucially on a complex interaction of genetic 
and (micro-)environmental, i.e. genvironmental risk factors that have only been partly elucidated 
despite significant effort. TGCC stem cell components show a high degree of similarity with ES cells 
and embryonic germ cells in the regulation of pluripotency and cell cycle control, directly related 
to their exquisite sensitivity to DNA damaging agents (cisplatin). Of note, (ES specific) micro-RNAs 
play a pivotal role in the crossover between cell cycle control, pluripotency and chemosensitivity. 
Moreover multiple consistent observations reported TGCC to be associated with KIT-KITL mediated 
receptor tyrosine kinase signaling, a pathway crucially implicated in proliferation, migration and 
survival during embryogenesis including germ cell development. In conclusion, TGCCs are a 
fascinating model for onco-fetal developmental processes especially with regard to studying cell 
cycle control, pluripotency maintenance and KIT-KITL signaling. The knowledge presented here 
contributes to better understanding of the molecular characteristics of TGCC pathogenesis, 
translating to identification of at risk individuals and enhanced quality of care for TGCC patients 
(diagnosis, treatment and follow-up). 
 
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CHAPTER 3 
Abstract 
Background: OCT3/4 (POU5F1) is an established diagnostic immunohistochemical marker for 
specific histological variants of human malignant germ cell tumours (GCTs), including the 
seminomatous types and the stem cell component of nonseminomas, known as embryonal 
carcinoma. OCT3/4 is crucial for the regulation of pluripotency and the self-renewal of normal 
embryonic stem- and germ cells. Detection of expression of this transcription factor is complicated 
by the existence of multiple pseudogenes and isoforms. Various claims have been made about 
OCT3/4 expression in non-germ cell tumours, possibly related to using non-specific detection 
methods. False positive findings undermine the applicability of OCT3/4 as a specific diagnostic tool 
in a clinical setting. In addition, false positive findings could result in misinterpretation of 
pluripotency regulation in solid somatic cancers and their stem cells. Of the three identified 
isoforms - OCT4A, OCT4B and OCT4B1 - only OCT4A proved to regulate pluripotency. Until now, 
no convincing nuclear OCT4A protein expression has been shown in somatic cancers or tissues.  
Methods: This study investigates expression of the various OCT3/4 isoforms in GCTs (both 
differentiated and undifferentiated) and somatic (non-germ cell) cancers, including representative 
cell lines and xenografts.  
Results: Using specific methods, OCT4A and OCT4B1 are shown to be preferentially expressed in 
undifferentiated GCTs. The OCT4B variant shows no difference in expression between GCTs (either 
differentiated or undifferentiated) and somatic cancers. In spite of the presence of OCT4A mRNA 
in somatic cancer-derived cell lines, no OCT3/4 protein is detected. Significant positive correlations 
between all isoforms of OCT3/4 were identified in both tumours with and without a known stem 
cell component, possibly indicating synergistic roles of these isoforms.  
Conclusion: This study confirms that OCT4A GCTs, embryonal carcinoma and representative cell 
lines. Furthermore, it emphasizes that in order to correctly assess the presence of functional 
OCT3/4, both isoform specific mRNA and protein detection are required. 
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Introduction 
OCT3/4 (also known as POU5F1) is a well-known marker for pluripotent stem cells, both 
physiologically and artificially induced (iPSC) [1, 2]. In addition, it is also expressed in primordial 
germ cells (PGCs) [1], the stem cell of gametogenesis later in life. OCT3/4 is a transcription factor 
involved in self-renewal and pluripotency [3, 4], and might counteract apoptosis in PGCs [5]. 
During further development (differentiation/maturation) of these types of embryonic cells, 
expression is down-regulated and finally lost in the differentiated derivatives. Owing to this specific 
pattern of expression during embryogenesis, which is retained during the process of malignant 
transformation, OCT3/4 is an established and highly informative diagnostic marker for defined 
types of malignant germ cell tumours (GCTs), especially those of the seminomatous cell type 
(seminoma, dysgerminoma and germinoma) and embryonal carcinoma [6-9].  
The OCT3/4 gene is located on human chromosome 6 band p21 and consists of 5 exons [10, 11]. 
It encodes a protein belonging to the family of octamer binding proteins that specifically binds to 
the conserved ATTTTGCAT motive in transcriptional control elements of genes. This sequence is 
recognized by the highly charged POU domain of the OCT3/4 protein, explaining its alternative 
name. The POU domain consists of two subdomains: a C-terminal homeodomain and an N-
terminal POU-specific region separated by a short non-conserved linker [12].  
Various investigations of OCT3/4 expression are reported, both on mRNA and protein level. Most 
are complicated by the existence of pseudogenes and splice variants (isoforms) [2, 7, 13], possibly 
leading to findings of false positive expression. Till date, five OCT3/4 pseudogenes have been 
identified. These will be amplified by most of the published primer sets, due to their high sequence 
similarity to OCT4A [14, 15]. However, proper DNase pre-treatment of the samples will exclude this 
technical artefact, which is a rather simple and straightforward step to include in the experimental 
setup.  
In addition, three splice variants (isoforms) of OCT3/4 have been identified [2]. The best known 
isoform is referred to as OCT4A. This variant is reported to be stem cell specific, while the 
function(s) of the other two variants, that is, OCT4B and OCT4B1, are still under investigation [2, 
16, 17]. However, it has been demonstrated that OCT4B is unable to activate or repress 
transcription of known OCT4A responsive genes [18]. Therefore, OCT4B seems unlikely to be 
directly involved in transcriptional regulation of pluripotency and self renewal. OCT4B1 on the 
other hand, has recently been suggested to have a role in both regulation of pluripotency [16, 19, 
20]  and OCT4B mediated functions [17].  
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As indicated, OCT3/4 has mainly been linked to pluripotency, for which it is a well known and 
established marker. Pluripotency refers to the capacity of an (embryonic) stem cell to generate all 
different tissues (endo- ecto- and mesodermal differentiation). Indeed, differentiation induction is 
associated with down-regulation of OCT3/4 [21-25]. The other way around, OCT3/4 down-
regulation results in loss of stem cells and induction of differentiation [4]. A high throughput 
immunohistochemical screen of many different types of human cancers demonstrated that 
OCT3/4 is a specific and highly informative diagnostic marker for seminomatous tumours, which 
are the malignant counterparts of PGCs/gonocytes, as well as embryonal carcinomas, the stem cell 
component of nonseminomas [6, 26]. This observation is confirmed by multiple independent 
studies, as reviewed before [9]. The overall findings resulted in the conclusion that OCT3/4 is an 
excellent, and currently successfully used, diagnostic marker for the detection of undifferentiated 
variants of so-called type II GCTs (UNDIF-GCTs = seminoma (SE) or dysgerminoma/germinoma, 
and the stem cell component of non-seminoma (NS, specifically embryonal carcinoma)), as well as 
their precursor stages (carcinoma in situ of the testis (CIS) and gonadoblastoma of dysgenetic 
gonads) [6-8, 26, 27]. Most recently, OCT3/4 protein detection has been used as a diagnostic tool 
for the non-invasive diagnosis of CIS [28].  
In non-GCTs (N-GCTs), a highly heterogeneous expression pattern of OCT3/4, both mRNA and 
protein, is reported. This might be due to the use of non-specific primers detecting other isoforms, 
improper DNAse pre-treatment (resulting in amplification of pseudogenes) and incorrect 
interpretation of immunohistochemical stainings. The results of the various articles  [29-35] to 
whether or not there is expression of (functional) OCT3/4 in solid cancers are therefore 
inconclusive. To further investigate this issue, the current study was undertaken. It investigates 
expression of the different isoforms of OCT3/4 mRNA and protein in various types of solid cancers: 
undifferentiated GCTs (UNDIF-GCTs) and GCTs without an embryonic stem cell component (DIF-
GCTs = yolk sac tumours and teratomas) as well as N-GCTs. Also, representative cell lines (-CL) of 
UNDIF-GCT and N-GCT are included. 
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Materials and Methods 
Materials 
The cell lines and tumour samples included in this study are indicated in Table 1. All samples/cell 
lines were obtained from different Departments in the Josephine Nefkens Institute (Erasmus MC - 
University Medical Center, the Netherlands). The prostate carcinoma cell lines and xenografts are 
extensively reviewed elsewhere [36, 37]. This also goes for the GCT-CLs [38-40]. 
Table 1. Samples and cell lines included in the study. 
Group Subgroup Cell lines / Number of tumor samples 
Undifferentiated GCT cell lines 
(UNDIF-GCT-CL) 
Seminoma 
Embryonal carcinoma 
Other 
TCam-2 
TERA1, NCCIT, NT2 
JKT-1 
Non GCT cell lines 
(N-GCT-CL) 
Oesophaguscarcinoma ESO26, ESO51, I2425 
 Cervixcarcinoma HeLa 
 Lungcarcinoma H460 
 Coloncarcinoma H716, HCT116, SW620 
 Prostatecarcinoma Cell lines: LNCaP, 22Rv1, VCaP, LAPC-4, 
MDA PCa 2b 
Xenografts: PC324, PC329, PC339, PC346B, 
PC346C, PC374, PC133, PC82, PC135, 
PC295, PC310 
 Breastcarcinoma MDA175, ZR75 
Undifferentiated GCTs 
(UNDIF-GCT) 
Seminoma (SE) 5 
 Embryonal Carcinoma (EC) 4 
Differentiated GCTs 
(DIF-GCT) 
Teratoma (TE) 5 
 Yolk sac tumor 1 
Non-GCT 
(N-GCT) 
Bladdercarcinoma 5 
 Lungcarcinoma 4 
 Ovariuncarcinoma 5 
 Prostatecarcinoma 5 
 Rectalcarcinoma 4 
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RNA isolation 
High-quality total RNA was extracted from the above mentioned cell lines and tumour samples 
using TRIzol Reagent (Invitrogen) according to the manufacturer’s instructions.  Samples were pre-
treated with DNase-I, checked for residual DNA contamination by PCR, after which cDNA synthesis 
was performed as described before [38, 41]. For each sample, a no-reverse transcription (No-RT) 
control was used, and HPRT was used as reference level of expression. Quantitative PCR was 
performed using the Real-Time PCR HT7900£ (Applied Biosystems, Foster City, CA, USA). 
Sequences for the OCT3/4 splice variant specific primers were as described before [19, 38]. These 
are highly specific for the different isoforms and even discriminate between OCT4A and its 
pseudogenes. The following forward (-F) and reverse (-R) primers used (annotation between 
brackets = annotation from [19]): HPRT: HPRT244-exon2-F, 5'-AATTATGGACAGGACTGAACGTC-3 
'; HPRT243-exon3-R, 5'-CGTGGGGTCCTTTTCACCAGCAAG-3'. OCT4A: OCT4A-F (OCT4-AF) 5’-
CTTCTCGCCCCCTCCAGGT-3 '; OCT4A-R (OCT4-RB1) 5'-AAATAGAACCCCCAGGGTGAGC-3 '. 
OCT4B: OCT4B-F (OCT4-FB) 5’-AGACTATTCCTTGGGGCCACAC-3'; OCT4B-R (OCT4-RB5) 5'-
GGCTGAATACCTTCCCAAATAGA-3. OCT4B1: OCT4B-F (OCT4-FB), 5’-
AGACTATTCCTTGGGGCCACAC-3'; OCT4B1-R (OCT-RB4) 5'-CTTAGAGGGGAGATGCGGTCA-3'. 
The localization of the different primers is depicted in Figure 1. The efficiency and specificity of 
these primers was extensively tested before [19]. The specificity for human RNA is proven by the 
absence of any OCT4A/B/B1 expression in most of the xenografts, specifically in PC82 which has a 
large stromal component. Quantitative values were obtained from the Ct.  OCT3/4 mRNAs (A, B 
and B1) were quantified relative to HPRT (OCT3/4 mRNA = 2 (mean Ct HPRT-mean Ct OCT3/4  (A,B or B1)) as 
described before [42]. The OCT4B1 PCR-products were sequenced using OCT4B1-F and a primer 
in exon 5 (OCT4B1-R2: (OCT4-RB3) 5'-CCCCCTGTCCCCCATTCCTA -3 ') to verify the nature of this 
splice variant. MicroRNA expression was measured as described previously [43]. 
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Immunohistochemistry 
Immunohistochemistry was performed on paraffin-embedded tissue sections of 4 ǌm thickness. 
Endogenous peroxidase and biotin were blocked. A mouse monoclonal antibody directly against 
OCT3/4 was used to detect OCT3/4 protein (1:350; SC5279), Santa Cruz, USA), which recognizes 
amino acids 1-134 of the protein and therefore recognizes OCT4A more specifically than the 
polyclonal antibody. Expression of OCT3/4 protein was double checked for most samples using a 
polyclonal antibody (1:350; SC8629), Santa Cruz, USA). Previously [26], a similar specificity and 
sensitivity of these antibodies in GCT tumour diagnostics has been shown, but did not yet 
differentiate between the different OCT3/4 isoforms. The proteins of the different isoforms only 
differ at their N-terminus. Therefore, the monoclonal antibody is specific for OCT4A. However 
strong similarities still exist in this regions between OCT4A and OCT3/4 pseudogenes [2, 19]. Slides 
were incubated as described earlier [6]. For different tissues and cell lines known positive controls 
we used to verify tissue integrity. The following antibodies were used: E-cadherin (1:200; clone 
nch-38, DAKO, Denmark), Ki-67 (1:50; clone BIB-1, code M7240, DAKO, Denmark), AFP (1:100; 
code A008, DAKO, Denmark), Pankeratin (1:400; Cat #MS-743-P, Neomarkers, USA), ERG (1:100; 
clone EPR3864, Epitomics, USA), TTF1 (1:200; Cat #MS-699-P, Neomarkers, USA), SOX2 (1:250; 
AF2018, R&D systems, USA), NANOG (1:400; AF1979, R&D systems, USA), ER (1:50); clone 1D5, 
Neomarkers, USA). 
Statistics 
Differences in gene expression between the groups were evaluated using the Mann-Whitney U 
test, using VassarStatsa . A p-value of less than 0.05 was considered statistically significant. 
Correlation analysis was performed by calculating the Pearson correlation coefficient using SPSS 
15.0.1. SPSS was also used to design the logistic regression model predicting the presence of a 
malignant GCT stem cell component based on mRNA expression of the three OCT3/4 variants. 
Results 
Isoform-specific expression of the various isoforms OCT4A, OCT4B and OCT4B1 was analyzed in a 
series of UNDIF-GCTs and DIF-GCTs as well as N-GCTs. Moreover, expression of these isoforms 
was also investigated in a panel of cell lines (both GCT-CL [38, 39] and N-GCT-CL, the latter 
including the prostate xenografts). For this purpose, a highly specific set of verified primer pairs 
was used (see Materials & Methods section and Figure 1 for details). The primer pair used to 
identify OCT4A was specifically designed to avoid false positive results caused by sequence-based 
similarities between the OCT4A transcripts and OCT3/4 pseudo-genes [19, 38]. The obtained 
results will be discussed in the following paragraphs for each OCT4A, OCT4B and OCT4B1 
                                                 
a http://vassarstats.net/  
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Figure 2. Expression patterns of OCT4A, OCT4B and OCT4B1 in UNDIF-GCT, DIF-GCT and N-GCT. X-axis: tumour 
samples/groups (see Materials & Methods section). Y-axis: 2^dCt (normalized to HPRT). Error bars depict SEM (Standard 
Error of Mean): variation within the groups (A-C). (A) Average expression for UNDIF-GCT, DIF-GCT and N-GCT groups. 
(B) Average expression for the UNDIF-GCT and DIF-GCT samples grouped per tumour type (SE = seminoma; EC = 
embryonal carcinoma; YS = yolk sac tumour; TE = teratoma). (C) Average expression for the N-GCT samples grouped 
per tumour type. CA = carcinoma. 
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OCT4B mRNA expression 
OCT4B was expressed at equally low levels in UNDIF-GCTs and DIF-GCTs (Figure 2A, Table 2). No 
significant difference was detected between UNDIF-GCTs or DIF-GCTs and N-GCTs (Figure 2A, 
Table 2). Among the UNDIF-GCTs, seminomas expressed a low level of OCT4B, while OCT4B was 
virtually undetectable in embryonal carcinoma. The DIF-GCTs showed low expression in teratomas 
and practically absence of OCT4B in yolk sac tumours (Figure 2B, Table 2). Expression levels of 
OCT4B were highly variable within the N-GCT group. The bladder carcinoma samples showed the 
highest level of expression, which was rather similar between the different samples. The ovarian 
and renal carcinomas showed an intermediate level of expression, due to a number of high outliers 
within these groups. Almost no expression was found in lung, prostate and breast cancer samples 
(Figure 2C, Table 2).  
The cell lines showed a highly variable expression of OCT4B (Figure 3). All UNDIF-GCT-CLs showed 
no or a very low level of OCT4B mRNA. No significant difference between N-GCT-CLs and UNDIF-
GCT-CLs was detected (p=0.76). Most of the cell lines showed very low levels or absence of OCT4B 
expression. Relatively high levels of OCT4B were detected in HeLa, as well as in H716 and PC329. 
Moderate levels were detected in ESO51, VCaP and PC374 (Figure 3). 
Table 2. Comparison of OCT4A/B/B1 expression in tumor samples. mRNA expression is scored as high (red, 2^-dCt  > 
1), intermediate (black, 2^-dCt  0.25-1) or low (green, 2^-dCt  < 0.25). The main tumor groups are tested for differential 
expression of the three OCT3/4 variants: ns=not significant, arrow means relative overexpression of X in X vs. Y 
comparison. p-values: OCT4A (UNDIF-GCT vs. DIF-GCT p=0.02, UNIF-GCT vs. N-GCT p<0.01, DIF-GCT vs. N-GCT 
p=0.50); OCT4B (UNDIF-GCT vs. DIF-GCT p=0.95, UNDIF-GCT vs. N-GCT p=0.89, DIF-GCT vs. N-GCT p=0.89); OCT4B1 
(UNDIF-GCT vs. DIF-GCT p=0.04, UNDIF-GCT vs. N-GCT p<0.01, DIF-GCT vs. N-GCT p=0.39). Protein expression is 
scored as positive (high & nuclear or cytoplasmic) or negative (-,low) for absent or non-specific background staining. 
Staining with the monoclonal antibody was used for scoring. 
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OCT4B1 mRNA expression 
UNDIF-GCTs showed a significantly higher level of expression of OCT4B1 than N-GCTs and DIF-
GCTs (Figure 2A, Table 2). DIF-GCTs and N-GCTs exhibited no significant difference (Figure 2A, 
Table 2). Expression in the UNDIF-GCT group was high in seminoma and intermediate in 
embryonal carcinoma (Figure 2B, Table 2). Regarding DIF-GCTs, teratomas expressed intermediate 
levels of OCT4B1 whereas expression in yolk sac tumours was low (see Figure 2B). Overall, 
expression of OCT4B1 was low in N-GCTs. Bladder carcinomas showed, just as in the case of 
OCT4B, a relatively high expression level of OCT4B1 when compared to other types of N-GCTs 
(Figure 2C). 
Levels of OCT4B1 expression varied between the cell lines. No significant difference between 
UNDIF-GCT-CLs and N-GCT-CLs was detected (p=0.92). High expression was observed in TCam-2, 
ESO51, HeLa, H716, 22Rv1, PC329, PC374. Moreover, intermediate expression levels were present 
in NCCIT, ESO26, SW620, VCaP, PC324, PC339, PC135, PC295. In many cases (ESO51, SW620, 
H716, VCaP, PC329, PC374) intermediate or high levels of OCT4B1 were combined with 
comparable levels of OCT4B (Figure 3). 
During the sequencing process to confirm the PCR products for the different splice variants, a 
consistent TC insertion was found in exon 2B of OCT4B1, being a single nucleotide polymorphism 
(rs34631505). This SNP is located behind the stop codon and therefore has no consequence at the 
protein level. 
Correlation between mRNA expression of different OCT3/4 isoforms and association of specific 
isoform expression and presence of a malignant germ cell component 
When all samples were combined, OCT4A showed a strong positive correlation with OCT4B1 and 
a less strong correlation with OCT4B. OCT4B and OCT4B1 did not correlate significantly (Table 3). 
However, when the samples were split into undifferentiated (UNDIF-GCT) and differentiated 
tumours (DIF-GCT + N-GCT), strong, positive and highly significant correlations were found 
between all OCT3/4 variants. Overall, the strength of the correlation approached perfect positive 
correlation in the UNDIF-GCT. In general, the correlations were less strong in the differentiated 
tumours, but still highly significant and positive (Table 3). In a binary logistic regression model, 
OCT4A and OCT4B proved to be significant in predicting the presence of a malignant GCT stem 
cell component. OCT4A was strongly predictive for the presence a malignant GCT stem cell 
component (E=-4.92, p=0.045), while OCT4B proved to be associated with the absence of such a 
component, but this association was less strong (E=-1.28, p=0.048). [correction: OCT4A was 
predictive for the presence a malignant GCT stem cell component (E=1.28, p=0.048), while OCT4B 
proved to be associated with the absence of such a component (E=-4.923, p=0.045).] 
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Figure 3. Expression patterns of OCT4A, OCT4B and OCT4B1 in cell lines. (A) mRNA levels in all investigated cell lines, 
both of GCT origin (GCT-CL) and non-GCT origin (N-GCT-CL). * = cervix carcinoma, ** = lung carcinoma. X-axis: cell 
lines (see Materials & Methods section) and corresponding tumour class. Y-axis: 2^dCt (normalized to HPRT). (B) 
Interpretation of the expression of OCT3/4 isoforms relative to HPRT. mRNA expression is scored as high (red, 2^-dCt  > 
1), intermediate (black, 2^-dCt  0.25-1) or low (green, 2^-dCt  < 0.25). CA = carcinoma. Æ 
 
 
 
 
Figure 4. Immunohistochemical detection of OCT3/4 expression in tumour samples. For each tumour type, two different 
samples are shown. Magnification 100x. (A) Protein expression of OCT3/4 in UNDIF-GCTs and DIF-GCTs. Shown are two 
seminomas (SE), embryonal carcinomas (EC), yolk sac tumours (YS) and teratomas (TE), of which only  the first two types 
are positive. (B) Protein expression of OCT3/4 in N-GCT tumour samples, including two carcinomas of the bladder, lung, 
breast, ovary, prostate and kidney, respectively, all are negative. All samples were stained using an antibody that is most 
specific for OCT4A (see Materials & Methods). Æ 
Table 3. Correlation between OCT4A/B/B1 mRNA expression in tumor samples. Correlation was assessed using the 
Pearson correlation coefficient on the mRNA expression data of all tumor samples, the UNDIF-GCT group and the 
differentiated tumors (DIF-GCT and N-GCT). LEGEND: +++ = U > 0.75, ++ = U > 0.5, + = U < 0.5, ns = not significant. 
CORRELATION COEFICIENT/SIGNIFICANCE: All: UOCT4A,OCT4B = 0.37 (p=0.01), UOCT4A,OCT4B1 = 0.89 (p<0.01), UOCT4B,OCT4B1 = 
0.12 (p=0.44). UNDIF-GCT: UOCT4A,OCT4B = 0.98 (p<0.01), UOCT4A,OCT4B1 = 1.00 (p<0.01), UOCT4B,OCT4B1 = 0.99 (p<0.01). DIF-
GCT + N-GCT: UOCT4A,OCT4B = 0.63 (p<0.01), UOCT4A,OCT4B1 = 0.97 (p<0.01), UOCT4B,OCT4B1 = 0.68 (p<0.01). 
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Protein detection 
Immunohistochemical staining of the various GCT samples and cell lines was performed to assess 
OCT3/4 protein expression. Clear nuclear staining of tumour cells was shown in UNDIF-GCTs. No 
expression was detected in the DIF-GCT components or the N-GCT samples (Figure 4). In 
accordance with the findings in the tumour samples, nuclear staining of tumour cells was shown in 
GCT-CLs, while being absent in all N-GCT-CLs and xenografts. Both the EC cell lines (NCCIT and 
NT2) and the SE cell line TCam-2 were OCT3/4 positive. The nonspecific staining in the xenografts 
was based on necrosis and again no cytoplasmic or nuclear staining was detected in these samples 
(Figure 5). Positive controls for all samples prove that all samples were suitable for 
immunohistochemistry (Figure S1AB, Figure S4A) and HE staining was used to assess tumour 
morphology (Figure S2AB). Finally, a double check for OCT3/4 expression was performed by 
staining the same tumour samples (Figure S3AB) and cell lines/xenografts (Figure S4B) with a 
second (polyclonal) antibody directed against OCT3/4. This confirmed our findings that OCT3/4 
protein expression is specific to UNDIF-GCTs and the related cell line models (GCT-CLs). These 
data are completely in accordance with previously published findings [6, 26]. 
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Å Figure 5. Immunohistochemical detection of OCT3/4 expression in cell lines and xenografts. Stained are the 
undifferentiated GCT-CLs NT2, NCCIT and TCam-2 which are all positive. All somatic cancer cell lines (ESO26, ESO51, 
I2425, ZR75, HELA, H460, SW620, H716, HCT116, VCaP, 22Rv1, LAPC-4, LNCaP) and xenografts (PC310, PC295, 
PC346C, PC374, PC135, PC324, PC82) are negative (some nonspecific staining of necrosis). All samples were stained 
using an antibody that is most specific for OCT4A (see Materials & Methods). Magnification 200x GCT-CLs, 100xN-GCT-
CLs.  CA = carcinoma. 
Discussion 
Specificity: the pitfalls of pseudogenes and isoforms 
Detection of OCT3/4 pseudogenes can and should be avoided by sufficient DNAse pre-treatment 
of the sample, because the respective sequences might be amplified based on their high level of 
similarity with the protein encoding variant (OCT4A) and the absence of introns. Therefore, their 
amplification in PCR might be falsely interpreted as actual OCT4A expression, suggesting possible 
translation into OCT4A protein. Moreover, specific PCR primer pairs followed by antibody-based 
analysis should be used to detect the different isoforms of OCT4 at the mRNA level and the 
presence of protein [19, 33, 38, 44].  
By using such a validated, isoform-specific primer pair setup, this study shows that OCT4A is highly 
expressed in UNDIF-GCTs, which are known to have a pluripotent stem cell component, originating 
from PGCs/gonocytes [9, 45]. DIF-GCTs and N-GCT show virtually no OCT4A expression, which is 
in line with the notion that OCT4A is responsible for formation of the protein involved in regulation 
of pluripotency. In contrast, OCT4B is not differentially expressed between the three groups, while 
OCT4B1 is expressed significantly higher in the UNDIF-GCTs when compared to DIF-GCTs and N-
GCTs, as found for OCT4A. These results indeed support the general consensus that OCT4A is the 
marker for stem cell populations in GCTs, and a similar specificity could be suggested for the 
OCT4B1 variant. However, OCT3/4 protein is only detected in GCTs and representative cell lines, 
also in this study. No specific signal could be detected in any of somatic cancers or cell lines 
investigated, irrespective of mRNA expression pattern. Because OCT4A protein is the only one of 
the three isoforms that directly regulates pluripotency, expression of this protein is a prerequisite 
for any cell that uses OCT3/4 as a regulator of pluripotency. Therefore, even specific mRNA 
detection of OCT3/4 isoforms does not yet conclusively prove the applicability of OCT4A, OCT4B 
or OCT4B1 in the detection of pluripotent cancer stem cells (see below) or somatic stem cells 
without protein confirmation.  
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Functions of OCT3/4 isoforms 
OCT3/4 is a known marker for pluripotency and has been shown to have a role in regulation of 
pluripotency [1-3]. Moreover, it is an important diagnostic marker for specific types of GCTs [6, 7, 
9, 26, 45]. Recently, investigations into the broader applicability of OCT4 as a marker in (cancer) 
stem cell biology showed that only OCT4A (and not OCT4B and OCT4B1) is  specific to stem cell 
(like) populations [2, 19, 30, 32, 33, 46]. It has been shown that basic levels of OCT3/4 mRNA (even 
OCT4A) and expression its pseudogenes, are detectable in somatic (tumour) cells [2, 47]. However, 
OCT4A protein expression has so far never been conclusively shown in non-pluripotent cells [2]. In 
addition, it has been described that OCT4A is primarily localised in the nucleus, while OCT4B(1) 
primarily resides in the cytoplasm. 
OCT4B might have a role in stress response [2]. The role of OCT4B1 is more elusive. It has been 
associated with both pluripotency and tumorigenesis (via inhibition of apoptosis and cell cycle 
deregulation) [16]. Also, a recent report suggested OCT4B1 to be superior to OCT4A in the 
detection of stemness, at least in human embryonic stem cells  [20]. These results are mainly based 
on statistical correlation and lack a biological explanation as to how OCT4B1 contributes to 
pluripotency, since this variant cannot be directly translated into a functional transcription factor 
[19]. Moreover, the presence of OCT4B1 expression in cancer tissues, which consists of mainly 
differentiated tissue, is not satisfactory linked to a specific hypothetical in situ population of cancer 
stem cells. In contrast, Gao and coworkers conclude that OCT4B1 can be alternatively spliced and 
subsequently be translated into all OCT4B protein forms [17], linking OCT4B1 to OCT4B mediated 
functions like stress respons. 
The various OCT3/4 isoforms might also have an integrated function as interchangeable decoys in 
microRNA (miR) regulated OCT3/4 protein expression. miRs, specifically miR-145 which targets 
OCT3/4, have been suggested to play a role in the regulation of pluripotency in general and 
OCT3/4 translation specifically [48]. Competitive microRNA (miR) binding has been suggested as a 
biological function of pseudogenes [49]. This function might also apply to alternative splice variants 
that, such as the OCT3/4 variants share their 3’UTR. OCT4B and/or OCT4B1 might prevent 
translation inhibition of OCT4A mRNA in stem cell components of GCTs or the other way around 
in differentiated GCTs or somatic cancer cells. The latter could explain OCT4A mRNA expression 
without translation into detectable protein in somatic cancer cells. This hypothesis is supported by 
a correlation analysis on the OCT4A/B/B1 mRNA expression data (Table 3). We showed strong 
correlations between OCT4B and B1 (Table 3) (expected based on similar function [17]) and 
OCT4A and B/B1 (strongest in UNDIF-GCT where OCT4A is active at the protein level). However, 
functionally studies are required to support this hypothesis. 
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Finally, individuals homozygous for a polymorphism at the initiating codon of OCT3/4 (rs3130932) 
are not able to transcribe OCT4B(1), and are therefore lacking the putative encoding proteins [11, 
50]. Depending on race, minor allele frequencies of 23-33% are reported [50]. So far, no 
abnormalities have been found related to the absence of this protein in these individuals, but it 
would be interesting to investigate the relative frequency of this SNP in GCT patients, specifically 
with respect to OCT3/4 (protein) expression, tumour characteristics and clinical course. 
OCT3/4 isoforms in (cancer) stem cells 
Our results disprove the applicability of OCT3/4 mRNA [30] for the detection of pluripotent cells 
(possibly cancer stem cells [51, 52]) in solid cancers. Bladder carcinomas showed high mRNA 
expression of OCT4B and OCT4B1, but no OCT4A. This explains earlier reports of high non-specific 
OCT4 expression in this type of cancer [31], but does not indicate the presence of OCT4A positive 
cancer stem cells. Moreover, our analysis identified no OCT4A expression in prostate carcinoma, 
which has been reported before [33] using a specific primer set [44]. In contrast, low but 
detectable levels of OCT4A mRNA were found in lung-, ovary- and renal carcinoma samples. Also, 
some of the studied cell lines showed OCT4A mRNA expression, suggesting the presence of 
pluripotent cells in these cultures. However, no OCT3/4 protein expression could be identified in 
any of the N-GCT samples or N-GCT-CLs, using both monoclonal and polyclonal antibodies. Also 
the “stem cells” in cell lines do not necessarily represent in vivo cancer stem cells, illustrated by the 
absence of OCT4A mRNA in five lung carcinoma samples and the presence of OCT4A mRNA in 
lung carcinoma cell line H460. 
OCT4A is therefore no marker of cancer stem-cellness in N-GCT, despite its undisputed crucial role 
in physiological (maintenance of) pluripotency (in germ cell precursors and their malignant 
counterparts) [1, 3]. OCT4B1 does have a significant tendency towards specificity for the 
pluripotent stem cell component of UNDIF-GCTs (Figure 2AB, Table 2, Table 3). It is however also 
(highly) expressed in differentiated tumours and cell lines (Figure 2C, Figure 3, Table 2, Table 3). 
OCT4B1 has been associated with detection of pluripotency before, but no functional relation has 
been proven and recent research has functionally linked OCT4B1 to OCT4B (stress response) 
rather than pluripotency [17].  
Conclusion 
This research confirms that different OCT4 isoforms (and pseudogenes) contribute to non-specific 
findings of OCT3/4 expression in various tissues and cell lines. This observation emphasizes the 
necessity of using highly specific primer sets and antibodies to investigate the presence of 
expression of functional (nuclear) OCT3/4 (protein). The presented data confirms the specificity of 
OCT4A as a marker for the seminomatous and the stem cell component of nonseminomatous 
GCTs and illustrates the varying mRNA expression levels of OCT3/4 isoforms in other types of solid 
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cancer and cell lines. OCT4A and OCT4B1 were both confirmed to have a significantly higher 
expression in tissues with a known stem cell component, but until now, only OCT4A can be directly 
functionally linked to pluripotency. Moreover, this study shows that OCT3/4 protein detection is of 
crucial importance, because of clear discrepancies between even isoform-specific mRNA 
expression and protein detection, possibly due to post-transcriptonal regulation. A synergistic role 
for the different OCT4 splice variants, possibly by competitive miR binding, might be an interesting 
model to investigate.  
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Supporting information 
Figure S1. Positive controls for immunohistochemistry on GCT and N-GCT samples. To investigate the tissue integrity for 
immunohistochemistry, all samples were stained with a known positive control for each tumour type. For each tumour 
type, two different samples are shown. See legend of Figure 4 for explanation. The protein against which the staining was 
directed is displayed between brackets. Ki-67: proliferation-related Ki-67 antigen; TTF1: transcription termination factor; 
ER: estrogen receptor; pankeratin: staining of fibrous structural proteins (keratin family) present in ovarium carcinoma; 
ERG: a transcriptional regulator present in prostate carcinomas. Magnification 100x. (A) GCT samples. The SOX2 positive 
areas in the TE sections are EC components surrounded by mature teratoma. (B) N-GCT samples. CA = carcinoma. 
Figure S2. Tumor morphology for GCT and N-GCT samples. Hematoxylin-eaosin staining. Magnification 100x. CA = 
carcinoma. (A) GCT samples. (B) N-GCT samples. See legend of Figure 4 for explanation. 
Figure S3. Immunohistochemical detection of OCT3/4 expression in tumour samples: polyclonal antibody. A double 
check for OCT3/4 expression was performed by staining the same tumour samples with a second polyclonal (less 
specific) antibody directed against OCT3/4. This antibody is known to display more non-specific background staining. For 
each tumour type, two different samples are shown. See legend of Figure 4 for explanation. Magnification 100x. CA = 
carcinoma. (A) Protein expression of OCT3/4 in UNDIF-GCTs and DIF-GCTs. (B) Protein expression of OCT3/4 in N-GCT 
tumour samples. Prostate carcinoma samples were not included (shortage of material). The staining in breastcarcinoma-
2 is nonspecific, non-nuclear and is absent in the monoclonal staining (Figure 4B). 
Figure S4. Positive controls and confirmation of OCT3/4 expression in cell lines. (A) Positive controls for 
immunohistochemistry on GCT-CLs and N-GCT-CLs. To investigate the tissue integrity for immunohistochemistry, all cell 
lines were stained with a known positive control. See legend of Figure 5 for explanation. The protein against which the 
staining was directed is displayed between brackets. Magnification 200x GCT-CLs, 100xN-GCT-CLs. (B) Confirmation of 
OCT3/4 protein expression. A double check for OCT3/4 expression was performed by staining the N-GCT cell lines with 
a second polyclonal (less specific) antibody directed against OCT3/4. All were confirmed as negative. See legend of 
Figure 5 for explanation. Prostate carcinoma cell lines/xenografts and GCT-CLs were not included (shortage of material). 
CA = carcinoma. 
Supporting information is available at: http://dx.doi.org/10.1038/bjc.2011.270  
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CHAPTER 4 
Abstract 
Motivation: Algorithms predicting miR-mRNA interactions generate high numbers of possible 
interactions, many of which might be non-existent or irrelevant in a certain biological context. It is 
desirable to develop a transparent, user-friendly, unbiased tool to enrich miR-mRNA predictions. 
Results: The miMsg algorithm uses matched miR/mRNA expression data to enrich miR-mRNA 
predictions. It grades interactions by the number, magnitude and significance of misplacements in 
the combined ranking profiles of miR/mRNA expression assessed over multiple biological samples. 
miMsg requires minimal user input and makes no statistical assumptions. It identified 921 out of 
56,262 interactions as top-scoring and significant in an actual germ cell cancer dataset. Twenty-
eight miR-mRNA pairs were deemed of highest interest based on ranking by miMsg and 
supported by current knowledge about validated interactions and biological function. To conclude, 
miMsg is an effective algorithm to reduce a high number of predicted interactions to a small set of 
high confidence interactions for further study. 
Availability and Implementation: Matlab source code and datasets available onlinea 
  
                                                 
a www.martinrijlaarsdam.nl/mimsg 
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Introduction  
MicroRNAs (miRs) are a subclass of a large group of non-coding RNAs that play an important role 
in post transcriptional regulation of gene expression, crucially influencing development and 
physiology [1-5]. In addition, miRs also contribute to initiation and progression of diseases, 
including cancer [3, 6, 7]. Around 2000 miRs have been identified in mammals so far (miRBaseb, 
[8]), each possibly regulating (protein levels of) hundreds of different mRNAs according to 
available prediction algorithms [9]. Much research has been done to elucidate the regulation of 
mRNA levels by miRs. Initial results showed that in plants mRNA degradation occurs by fully 
complementary binding of miRs to open reading frames (ORFs) [10]. In animals, miRs were 
hypothesized to predominantly repress translation by binding of partially complementary 
sequences to their target’s mRNAs 3’-untranslated region (UTR), hence not leading to mRNA 
degradation [3, 10-12]. However, mRNA degradation as a consequence of miR binding has also 
been demonstrated in animals [3, 10, 13-18]. In general, induction of miR expression results in 
reduced levels of their mRNA targets, while depletion of a specific miR will lead higher target levels 
[19-22]. Inactivation of the miR processing pathway also leads to higher overall levels of mRNA 
targets [10, 23]. Therefore, the current dogma acknowledges that both translational repression and 
mRNA degradation are present in plants and animals [3, 10, 13-18, 24]. These effects on mRNA 
levels are also detectable in gene expression data [10, 17]. 
Degradation of mRNAs by miRs can be detected in high-throughput expression data and can be 
successfully applied to enrich the many possible interactions suggested by sequence based 
prediction algorithms [25], e.g. TargetScanc  [26], Mirandad [27] or PicTare [28]. In this paper a 
novel method (miMsg) will be presented to enrich predicted miR-mRNA interactions within a 
specific biological context. The algorithm uses matched high throughput miR and mRNA 
expression data of biological samples. The miMsg algorithm is based on relative ranking profiles of 
the expression data and does not directly assess the absolute expression levels. Therefore, the 
algorithm can be applied to detect small effects of miRs on mRNA, inferring power by detecting 
patterns over multiple biological samples. In recent literature, various other computational 
methods have been applied to matched mRNA and miR expression data including regression, 
correlation analysis and Bayesian learning algorithms (detailed comparison and review of 
previously published related methods is provided in Supplementary data A and [25]). In 
comparison, miMsg is independent of the methods used to measure expression levels and the 
statistical properties of the data. It also only needs a minimal number of user-defined parameters 
and has built-in quality control. Finally, it yields a result which is directly related to the observed 
                                                 
b http://www.mirbase.org/  
c http://www.targetscan.org/  
d http://www.microrna.org/  
e http://pictar.mdc-berlin.de/ 
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expression patterns and also supplies a visualization tool for individual interactions. miMsg is 
extensively benchmarked against other methods using sixteen different (sub)sets of cancer related 
expression data. Benchmarking shows that non-parametric correlation methods are inferior to the 
other algorithms tested. For the remaining algorithms, results vary strongly depending on the 
dataset and overlap is minimal, identifying miMsg as a valuable alternative. As a proof of principle, 
miMsg is applied to germ cell tumor data, investigating mRNA degradation as most miRs have an 
inhibitory effect on mRNA/protein levels. In this deregulated (cancer) context, miMsg identified 
validated, relevant interactions and miRs/mRNAs. 
System and methods 
Biological samples, expression profiling, data normalization and statistics. 
The following matched germ cell tumor (GCT) samples were included: five spermatocytic 
seminomas (SS, type III GCT), three seminomas (SE, type II GCT) and three embryonal carcinomas 
(EC, type II GCT) [29]. mRNA expression data (Human Genome U133 Plus 2.0 Array) was acquired, 
pre-processed and normalized as described in [30]. Matched miR expression data (multiplex qPCR, 
Applied Biosystems) was acquired as described in Supplementary Data M. Raw Ct values were 
normalized to RNU6b (results main text, Table S1) or their global average ([31], Table S2, 
significant overlap with RNU6b based normalization  (30% overlap, p<0.01 based on simulation)). 
Unless specified otherwise, a t-test was used to compare groups (Excel 2010 / Matlab 2012a). 
Annotation and target prediction matching 
mRNA target predictions were downloaded from TargetScan’sf website (conserved miR families). 
The most recent annotation files for the Affymetrix GeneChip HG-U133-Plus2 were downloaded 
from the manufacturer’s website g . Data was carefully parsed to fit the miMsg format 
(Supplementary data, B). miR annotations were split and matched on miR family, class and 
member separately to prevent missed matches. Gene symbols were used to merge Affymetrix 
probe annotations with TargetScan‘s predictions. Only predictions for humans were included 
(speciesID=9606) and only probes marked as specific for one transcript were selected (suffix “_at”). 
In the end, 37,956 mRNA probes and 293 miRs were available for analysis. Of these 5,919 mRNA 
probes and 148 miRs were predicted to interact (inhibition, 56,262 interactions, Table 1).  
  
                                                 
f http://www.targetscan.org/  
g http://www.affymetrix.com/  
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Algorithm 
miMsg uses miRNA / mRNA expression and publicly available databases with predicted 
interactions to enrich miR-mRNA interactions within a specific biological context. The miMsg 
algorithm is based on the dogma that low mRNA target levels as a result of degradation are 
detectable in real targets of a specific miR and are absent in non-interacting predicted targets. 
miMsg is preeminently applicable to miR-mRNA interactions because the relevance of miR-mRNA 
interactions in a biologically coherent set of samples depends on how the samples interrelate (i.e. 
ranking) rather than individual expression levels. In an ideal interaction profile high expression of a 
miR in a tissue should be coupled with low mRNA expression. By observing this over multiple 
tissues, miMsg creates a combined ranking profile of miR/mRNA expression for each interaction 
(Relative Ranking, RR, Figure 1). The output of the miMsg algorithm is straightforward and focuses 
on biological interpretation. It detects interactions with similar or inverse RR depending on the 
predicted functional relation. The algorithm computes only three scores for each interaction. These 
are intuitively related to the observed RR and describe the quality and significance of the deviation 
from the ideal interaction profile. These scores are used to identify relevant and significant 
patterns, which can be further studied.  
Definitions 
As explained in Figure 1A, the miMsg algorithm uses two matched sets of expression data: A and 
B. CC contains the hypothesized interactions between A and B and their direction (inhibition for 
miR-mRNA interactions). The relative ranking of the expression levels is presented in RRj for each 
interaction j and used to calculate the following quantities: (1) ıj as an estimate for the number of 
misplacements in RRj (Definition 1), (2) Ĳj as a measure for the magnitude of these misplacements 
(Definition 2) and (3) ǋj (effect size) which combines the ıj and Ĳj (Definition 3). Also, associated 
levels of (empirically derived) significance and false discovery rate (FDR) are presented. Next, these 
quantities are formally defined (also see: Supplementary Data B-E). Let n denote the total number 
of interactions between the two datasets and m the total number of biological samples per 
interaction. Furthermore, let j=1,…,n denote the interaction and i=1,…,m the biological sample.   
Definition 1: ıj (relative number of misplacements) 
The relative number of misplacements ıj is defined as follows: 
ߝ௝ ൌ
߰௝
ሺ݉ െ ͳሻ א ሾͲͳሿ 
where ǔj = 0,1,…,m-1 denotes the number of misplacements in the RR of interaction j involving m 
samples. A misplacement is defined as a difference between adjacent ranks being unequal to 1, i.e. 
ordering differs from ideal profile. (Supplementary Data, D) 
87
CHAPTER 4 
  
88
MIMSG –  MIR TARGET ENRICHMENT USING EXPRESSION DATA 
 
 
Å Figure 1. Flowchart of miMsg. (A) (User defined parameters) į, the desired level of significance (usually į  0.05); umin, 
the minimal number of unique samples required in an interaction to qualify for analysis (umin  3); tol, the accepted 
variation at convergence of the empirically derived cumulative distribution function (cdf) of (ı,Ĳ) / ǋ (default:  10-4).  The 
following steps are executed: (1) Define two sets of measurements: A and B. Columns represent matched biological 
samples and rows contain measurements for miRs (A) or mRNAs (B). (2) A and B are linked using table CC containing 
predicted miR-mRNA interactions. This results in sets Av and Bv. (3) Using Av and Bv, the relative ranking (RR) for each 
interaction is calculated. This process is depicted graphically in Figure 1B. (4) Using RR, the measures ı, Ĳ and ǋ 
(Definition 1-3) are calculated, describing the deviation of RR from the ideal interaction profile for each interaction. (5) An 
empirical 2-dimensional cdf for (ı,Ĳ) is computed using iterative permuted versions of Av and Bv (Avp and Bvp, gray 
area). This cdf is then used to derive the significance of the scores for each interaction. (6) ǋ, the associated level of 
significance and the FDR (Definition 3-5) are used to identify biologically relevant and significant interactions. *An 
empirically derived cdf of ǋ is generated by permuting A and B. Using this cdf, the false discovery rate (FDR) of ǋ is 
calculated for all significant interactions to determine which values of ǋ are sufficiently low and thus represent relevant 
interaction profiles. (B) Example of the calculation of RR. 5 tissues (T1-T5) are analyzed for a single interaction j 
(hypothesis= inhibition). Values in A and B are equal to their rank x 100. Avj/Bvj are sorted according to Bvj. The ranks of 
Avj in this sorted set constitute RRj and are used to compute ıj, Ĳj, and ǋj: ƻj={3-2=1; 4-3=1; 1-41; 5-11}=2, ıj=2/(5-
1)=0.5; Ĳj=(|3-2-1|+|4-3-1|+|1-4-1|+|5-1-1|)/ceil(52/2)=7/13, ǋj=0.5+7/13-(0.5*(7/13))=0.8 (Supplementary data B-G). (C) 
Graphical representation of the selection of interaction patterns that are both significant and relevant (Ƈ). ALL = all 
interactions. Areas are not to scale. (D) Examples of two RRs (10 tissues) with larger (dashed black) or smaller (dashed, 
gray) displacements. Dotted gray line represents the ideal RR. ıgrey=ıblack=2/(10-1)=0.22; Ĳgrey (|8-5-1|+|6-10-
1|)/ceil(10^2/2)=7/50=0.14Æ ǋgrey=0.3229; Ĳblack=(|1-7-1|+|8-3-1|)/ceil(10^2/2)=11/50=0.22 Æǋblack=0.3616. This 
illustrates definitions 2 and 3: larger displacements are penalized more severely. It also shows that miMsg is tailored to 
detect linear patterns with multiple “line segments”, only penalizing discontinuities at their boundaries. Non-parametric 
correlation methods  (Spearman & Kendall) identify the whole discontinuity as a disturbance of the overall pattern and 
repeatedly penalize all ranks involved (Supplementary data L). Because groups of biological samples can behave 
differently but still correlate well per group, this leads to underappreciated patterns.  
The relative number of misplacements alone is an incomplete measure for how well the profile in 
RRj correlates to the ideal profile. The magnitude of the difference between adjacent ranks is 
important as well. Small differences between adjacent ranks (small misplacements) are considered 
less serious than larger ones (Figure 1D). Therefore, consider the following measure for the 
magnitude of the misplacements in RRj. 
Definition 2: Ĳj (magnitude of misplacements) 
The relative magnitude of the misplacements Ĳj, measured by its relative variance, is defined as 
follows:  
ߪ௝ ൌ
σ หܴ ௝ܴǡ௜ାଵ െ ܴ ௝ܴǡ௜ െ ͳห௠ିଵ௜ୀଵ
݂݈݋݋ݎ ൬݉ଶʹ ൰
א ሾͲͳሿ 
where RRj,i denotes the ith biological sample in the jth interaction and floor(m2/2) is the maximum 
obtainable variance in a RR containing m biological samples. 
To quantify the combined effect of the number and magnitude of the misplacements, a combined 
score (effect size) is defined.  
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Definition 3: ǋj (combined effect size) 
The number and magnitude of misplacements (Definition 1,2) are combined in ǋj using: 
ߣ௝ ൌ ߝ௝ ൅ ߪ௝ െ ൫ߝ௝ ή ߪ௝൯ א ሾͲͳሿ 
ǋ is a monotonically decreasing function of ı and Ĳ which approaches zero if and only if both ı 
and Ĳ approach zero (ı:[0 1] and Ĳ:[0 1]). It is a measure for the combined effect size of ı and Ĳ 
and is used to easily rank selected interactions. Low values of ǋ indicate a better match to the ideal 
RR (Figure 1D).  
Finally, a statistical test is required to show relevance and statistical significance of the scores. 
Significance & relevance 
The final steps of the algorithm determine (1) which interaction patterns are statistically unlikely to 
occur by chance and (2) which values of ǋ should be considered relevant (=sufficiently low) (Figure 
1C). These independent steps will be discussed below. 
Significance 
In the preceding computations, the absolute values of ı, Ĳ and ǋ that result for each interaction 
may be coincidental. Hence, a measure of statistical significance is required.  As no a priori 
knowledge about the statistical properties of the data is present, an empirically derived, 2-
dimensional cumulative distribution function (cdf) is generated to assess the probability of 
coincidental (ı, Ĳ) combinations. This cdf is iteratively approximated using permuted (shuffled) 
versions of the original expression data. After each iteration, the cdf is evaluated at all possible 
combinations (ık, Ĳm) present in the real data, k=1,2…,K and m=1,2…,M. This yields a cdf ǐ(ı, Ĳ) 
that can be compared between iterations at (ı, Ĳ). The process of adding (ı, Ĳ) combinations from 
permuted data is repeated until the difference between the current and previous iteration is 
neglectable (i.e. < tol). This difference is defined as the relative root mean square error (rrı): 
ݎݎߝ௜ ൌ ඨ
σ σ ൫ߩ௜ሺߝ௞ǡ ߪ௠ሻ െ ߩ௜ିଵሺߝ௞ǡ ߪ௠ሻ൯ଶெ௠ୀଵ௄௞ୀଵ
σ σ ߩ௜ଶሺߝ௞ǡ ߪ௠ሻெ௠ୀଵ௄௞ୀଵ
 
After convergence, the resulting ǐdef(ı, Ĳ)  is evaluated at all combinations from the real data (ık, 
Ĳm) to assess their respective p-values (Supplementary Data, E). ǐdef(ı, Ĳ)  is uniquely generated for 
each group of interactions with the same number of unique biological samples as this number 
defines the theoretical variability of ı and Ĳ  (i.e. the shape of ǐdef(ı, Ĳ)). (Supplementary Data, F for 
more information about repetitive values.) Formally, an interaction is deemed significant if the 
following holds. 
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Definition 4: statistical significance 
Consider the jth interaction, the corresponding measures ıj and Ĳj (Definition 1, 2) and a user 
defined level of significance į. Moreover, consider the cdf ǐdef(ı,Ĳ) obtained using the procedure 
discussed in section Significance. Then, the jth interaction is defined to be significant if ǐdef(ı,Ĳ)  į. 
Relevance 
Apart from the significance of an interaction pattern, it is required to determine which values of ǋ 
should be considered low enough (i.e. relevant). High values of ǋ might still be statistically 
significant, but do not constitute relevant interaction patterns. By iteratively using permuted 
expression data as input for miMsg, a cdf of ǋ is generated, denoted by ĳ(ǋ) (analogous to the 
section Significance). Using ĳ, the FDR for all significant values of ǋ is determined. The researcher 
can determine a maximal acceptable FDR (Ǆ, usually  1% / 5%). See also Supplementary Data, E. 
Formally, an interaction is deemed relevant if the following holds. 
Definition 5: relevance of the size of ǋ 
Consider the jth interaction, the corresponding measure ǋj (Definition 3) and a user-defined 
maximal acceptable FDR Ǆ. Moreover, consider the cdf ĳ(ǋ) obtained using the procedure 
discussed in the section Relevance. Then, the jth interaction is defined to be relevant if ĳdef(ǋ)  Ǆ. 
Output 
The final output of miMsg is a table with all significant interactions and associated values of ı, Ĳ 
and ǋ as well as the associated p-values (example: Table S1) and FDRs. Also, an overview of the 
raw expression levels is supplied. A detailed runfile with settings and properties of the input/output 
is generated as well as a visualization of the quality of the results. An additional tool is supplied to 
visualize individual significant interactions (example: Figure 2, see also Supplementary data G). 
 
Table 1. Number of miRs/mRNAs in miMsg results (GCTa). a parameters: į=0.05, umin3, tol=10-4 b miR-29a was 
measured twice using two independent primers on the qPCR. c validated = present in miRTarBase as validated 
interaction.  
(Sub)set 
m
iR
s 
b  
Pr
ob
es
 
(g
en
es
) Unique interactions 
based on probes 
(Gene Symbol) Va
lid
at
ed
 c  
All interactions 148 5,919 (2,762) 56,262 (23,429) 170 
Significant interactions 146 2,447 (1,521) 6,093 (5,137) 51 
Top-scoring (FDR 5%, ǋ0.8750) 145 1,891 (1,248) 3,473 (3,176) 39 
Top scoring (FDR 1%, ǋ0.8000) 137 682 (560) 921 (896) 10 
Top-100  (FDR 0.1%, ǋ0.6867) 56 93 (90) 100 (99) 2 
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Figure 2. Visual representation of the relative rankings (RR) and miR/mRNA expression levels. (A) Top-scoring significant 
interaction. (B) Worst scoring significant interaction. (RR-plot) The RR is plotted on the y-axis (see also: Figure 1B and D). 
A straight ascending line is expected when there is a perfect inverse relation between miR and mRNA expression. High 
values of ǋ (B) are associated with a noisier RR, not necessarily with inverse ranking patterns. (miR/mRNA expression 
plots) Bars represent relative mRNA levels (I, mean centered intensity) or  miR expression (पCt values, high value=low 
expression). Ideally, identical descending patterns would be observed. X-axis: biological samples. Suffix of sample name is 
arbitrary. 
Application & Benchmarking 
A selection of histologically diverse GCTs was analyzed to illustrate the applicability and 
functionality of miMsg. Firstly, the performance of miMsg was studied by assessing the response to 
permuted or random data. Secondly, a selection of top-scoring and highly significant interactions 
was further investigated. Finally, extensive benchmarking was done including 16 datasets / subsets 
and 5 different algorithms for the selection of miR-mRNA interactions. 
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Germ cell tumor data 
Response to permuted / random data and noise 
To assess the robustness of the miMsg-algorithm and the relevance of the patterns detected, 
various tests with random, permuted and modified data were run. When compared to 800 runs 
with permuted or random expression data, miMsg identified significantly more and better scoring 
interactions in the real, biologically relevant data (p<0.01). This suggests detection of relevant 
patterns in biological data (Supplementary data, H). Replacing a fraction of the predicted 
interactions with random interactions did not prevent miMsg from identifying the originally top-
scoring interactions. Moreover, random or targeted reduction of the dataset did not change 
miMsg’s identification and grading of originally selected interactions. This shows that miMsg is 
relatively insensitive to (introduced) noise and the number of predicted targets (Supplementary 
data I). 
Detection, selection & verification of interactions 
High quality RRs were identified by both a low p-value (significant) and a low value of ǋ (relevant 
profile, Figure 2). A selection of 6,093 significant interactions was identified from the original pool 
of 56,262 predicted interactions (Table S1). Top-scoring sets with 1% / 5% FDR  and a top-100 
(FDR 0.1%) were defined based on the accumulated data of 400 runs with permuted expression 
data (Table 1). These top-scoring and highly significant subsets were matched with miRTarBaseh to 
identify experimentally validated interactions. miRTarBase is a literature-based database of 3,969 
experimentally validated interactions between 625 miRs and 2,433 genes in 14 species (version: 
April 15, 2011) [32]. Only human interactions were included (n=2,817). The fraction of validated 
interactions in all predicted interactions was relatively small as most of the predicted miR-mRNA 
interactions used as input are not yet experimentally validated. However, enrichment of validated 
interactions (%) in the selected subset was of interest as a quality measure (rather than the a priori 
% of validated interactions). Still, enrichment might not be present because interactions validated 
in non-GCT systems are not necessarily active in GCTs. However, from all algorithms tested in the 
benchmarking, miMsg showed the highest enrichment for validated interactions in the GCT dataset 
(37%, Supplementary data L: Figure 22). 
  
                                                 
h http://mirtarbase.mbc.nctu.edu.tw/  
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Benchmarking 
miMsg was compared to existing algorithms for miR-mRNA interaction analysis using common 
non-parametric correlation methods (Spearman & Kendall), a method using Bayesian learning 
(GenmiR++ [33]) and a LASSO based regression algorithm [34] (Supplementary Data A). Sixteen 
dataset/subsets were investigated. Three were obtained from the original LASSO publication: 
Madison (nasopharyngeal cancer), Broad (various types and normal tissues, also used in the 
GenmiR publication) and MSKCC (prostate cancer). The other datasets included parallel miR-mRNA 
data from different genetic subtypes of multiple myeloma (MM, [35]) and our primary GCT dataset. 
Several subsets of the GCT and MM sets were analyzed. To start with, random subsets of 
interactions were constructed that were comparable to the (LASSO) datasets from [34] with regard 
to the number of (validated) interactions. Also, biologically coherent subsets were created 
including only validated interactions or only genes differentially expressed between tumor types 
(analogous to [34]).  
 
Figure 3. Overlap between interactions selected by the various algorithms (GCT: 56,262 interactions). Maximum total 
overlap between 5 algorithms is (5-1)x100%=400% (inner ticks). Outer ticks identify the % of this maximal overlap that is 
realized for a specific algorithm / dataset. The width of the ribbon identifies the overlap between two algorithms as a % 
of the number of selected interactions by each algorithm separately. Algorithm labels: “name – total nr. of selected 
interactions - % of all interactions selected.” (Example of interpretation) Overall, miMsg shows ¨25% overlap with all 
other methods. Consider the ribbon from miMsg to LASSO: Of the 3,473 interactions selected by miMsg, 54% overlaps 
with the selection of the LASSO algorithm. On the hand, this overlap with miMsg constitutes only 7.5% of the 25,337 
interactions selected by LASSO. Figure generated  using Circos [36].  
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Algorithms were benchmarked based on several criteria (Table 2, Figure 3). For all algorithms, 
highly variable performance and very little overlap between results were observed between 
datasets. Overall, common non-parametric correlation methods (Spearman/Kendall) are clearly 
outperformed by miMsg, LASSO and GenmiR (also see Figure 1D). Between miMsg, LASSO and 
GenmiR there is no obvious best choice. Although we favor miMsg because of the limited number 
of interactions selected and the unbiased, distribution-free approach, application of different 
algorithms can aid the selection of relevant interactions. (Table 2, Figure 3, Benchmarking in detail: 
Supplementary data, L) 
Table 2. Results of benchmarking. Supplementary data, L describes the benchmarking in detail. 
Criterion Motivation/Result 
Fraction of interactions selected & 
enrichment for validated 
interactions 
Motivation: Selection of a high fraction (=high number) of interactions is not 
feasible when applying the results to research. In addition, if validated interactions 
are active in the studied tissues, there should be a higher fraction of validated 
interactions in the selected interactions as compared to the complete dataset. 
Result: Different algorithms select quite constant fractions from almost all datasets. 
LASSO selects ca. 50% of all interactions; the other algorithms select ¨ 5%. 
Enrichment for validated interactions varies greatly between datasets with no clear 
trend toward one optimal algorithm (correlation = worst). In the very large 
datasets (GCT & MM), miMsg outperforms the other algorithms by achieving 37% 
and 33% enrichment for validated interactions (į0.05, FDR0.05). 
Performance  
x of all / selected interactions 
against permuted data 
x of (selected) validated 
interactions against permuted 
interactions 
Motivation: Unpermuted data in general should perform better than random data. 
Also, validated interactions should outperform permuted data (ROC analysis). 
Result: The total set of (validated) interactions most likely contains a very high 
number of not interacting miR-mRNA pairs / validated interactions which are not 
active. These are not expected to perform better than random data. For most 
datasets, the algorithms therefore have difficulty outperforming permuted data 
when considering all (validated) interactions. GenmiR performs well on some 
datasets followed by miMsg; correlation analyses show the worst overall 
performance. When only the selected interactions are considered LASSO, miMsg 
and to a lesser extend GenmiR perform much better in assigning higher scores to 
unpermuted data and validated interactions.  
Overlap between selected 
interactions 
Motivation: Algorithms using different approaches, but identifying many of the 
same interactions might be more trustworthy 
Results: There is very limited overlap between the interactions selected by the 
various algorithms even when only very good scoring interactions (top-100 or 
less) are considered. Spearman & Kendall overlap ca. 100% because of high 
similarity in methodology.  
Influence of dataset size and % of 
validated interactions 
Motivation: The size of the dataset and the fraction of validated interactions might 
influence performance of the algorithms. 
Results: For all algorithms, performance does not consistently improve when using 
smaller, random subsets with a higher fraction of validated interactions.  
Influence of pre-selecting 
interactions 
Motivation: Pre-selection of relevant interactions based on (gene) expression / 
validated interactions might influence performance of the algorithms.  
Results: For all algorithms, performance does not consistently improve when using 
preselected / validated only sets of interactions. 
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Discussion 
miMsg: considerations (input and application) 
Predicted interactions. A sensible, trusted set of predicted interactions is a requirement to generate 
biological relevant output when using miMsg. Supplementary Data H illustrates the effect of 
random, non-sense interactions. Inverse expression patterns may occur by coincidence in 
expression data which is not permuted / randomized. miMsg might still identify top-scoring, 
significant interactions in these experiments. This effect disappears when expression data is 
permutated / randomized. 
Biological samples. miMsg generates optimal results when using biological samples which are 
clearly related to the studied hypothesis and include multiple comparable as well as 
clinically/biologically diverse samples in roughly equally sized groups. More samples indicates a 
lower probability of coincidental RRs. Moreover, rankings become more sensible when the samples 
differ biologically/clinically (Figure 2A). However, clustering on biological/histological subtype may 
occur for many genes/miRs simultaneously, independent of miR/mRNA interaction. Multiple 
samples per cluster are required to reduce this non-specific effect.  
Expression data. Adequate measurement precision of the data is of particular importance as 
miMsg relies heavily on ranking. Samples with identical expression levels for certain miRs/mRNAs 
due to rounding off will be excluded in the analysis of interactions involving these miRs/mRNAs 
(Supplementary Data, F). On the other hand, precision outside of the detection method’s sensitivity 
/ thresholds will not contribute to better results in miMsg. 
Scope of the study, limitations & future plans. In this paper, miMsg is applied to mRNA inhibition 
by miRs. Although there is strong evidence that miRs influence mRNA levels, the combined effect 
of mRNA inhibition and translational repression without influencing mRNA levels [10] will not be 
detected by miMsg. Moreover, miMsg is applied to cancer related datasets. Cancer is a 
deregulated state in which interactions might be detected easier. Theoretically miMsg is also 
applicable to other datasets/directions (non-cancer, other than miR/mRNA interactions, 
stimulation). miMsg might also be used to create a reference database of miR-mRNA interaction 
signatures in different tissues / cells. These applications need to be investigated further. 
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Preliminary assessment of GCT results 
miMsg was applied to expression data from a defined set of human GCTs. They represent the so 
called type II (seminoma (SE) and embryonal carcinoma (EC)) and type III (spermatocytic seminoma 
(SS)) subtypes. Despite a good response to systemic treatment, metastatic type II GCTs are a major 
cause of death in young adults. Both SE and EC originate from primordial germ cells (PGCs) / 
gonocytes. These cells have an intrinsic totipotent capacity and mimic totipotent ES cells. Type III 
GCTs originate from more differentiated germ cells and show no embryonic features [29, 37]. GCTs 
and their precursor lesions (either carcinoma in situ or gonadoblastoma) can be detected and 
classified by specific immunohistochemical markers and show distinct patterns / aberrations in 
DNA copy number and mRNA/miR expression [30, 38, 39].  
Based on a systematic literature review top-scoring (top-100) and validated (FDR  5%) 
miRs/mRNAs associated with GCs/GCTs were shown to be involved in: (1) pluripotency / germ line 
development, (2) TP53 & TFGǄ mediated apoptosis + therapy sensitivity, (3) fetal development (4) 
germ cell micro-environment, (4) proliferation and (5) carcinogenesis in general (extended review 
and references presented in Supplementary data K). 
Moreover, miR-23ab and miR-27ab were highly enriched in the top-100 top-scoring subset 
(n=19/100, Figure 4). These miRs are part of the miR-23 paralog clusters: miR23a/27a/24-2 (cluster 
A, chromosome 19) and miR23b/27b/24-1 (cluster B, chromosome 9). The miRs in these clusters 
are not necessarily regulated identically, but are thought to be closely related based on their 
evolutionary conservation, sequence homology, genomic clustering and simultaneous expression 
level changes in human diseases including cancer [40, 41]. There was significant differential 
expression of these miR families, clusters and individual miRs between EC, SE and SS (p<0.05). The 
low expression in SE as compared to EC (both type II GCTs) is interesting because these tumor 
types differ in prognosis and biological behavior. Moreover, around half of the 19 top-scoring 
miR-23 paralog-targets were shown to be targeted by miRs in human ES cells [42]. (Also see 
Supplementary data K). 
This overview does not imply proven functional relations, but shows that miMsg can be successfully 
applied to identify relevant targets for further study and validation in GCT-specific models. 
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Figure 4. Visualization of top-scoring significant interactions in the GCT data. Circular representation of the human 
karyotype, generated using Circos [36]. Lines represent interactions between miRs and mRNAs. Black text/lines = miR-
23ab/27ab cluster (top-100) or validated interactions in top-scoring significant interactions (FDR 1%). Gray text/lines= 
other miRs/mRNAs (top-100). Circles represent miRs (open circles) and targets (mRNAs, closed circles). Larger circles 
indicate better scoring interactions. Depending on the local density of the plot and the available space, the location of 
the circles cannot always exactly correspond to the genomic position of the miR/mRNA. Based on the known functions of 
the miRs/mRNAs, four top-scoring interactions were identified as most important. (PHF17/miR-23a) PHF17 promotes 
apoptosis, is a known renal tumor suppressor and associates with OCT3/4  [43], a key protein in germ cell cancer [37]. 
Moreover, miR23a has been shown to function as a tumor suppressor-miR via repression by c-Myc. (IRF1/miR-23b) IRF1 
is involved in the pathogenesis of infertility in men with germ cell maturation arrest (validated in GCT cell line NT2) [44]. 
Moreover, miR-23b is associated with the hormone regulated process of spermiation in Sertoli cells [45]. (IRS1/miR-7) 
IRS1 is present in peritubular myoid and interstitial cells [46], which migh suggest a role in the micro-environment of 
germ cells. miR-7 interferes with germ line differentiation in Drosophila [47]. (HIPK2/miR-27a) This interaction is validated 
in ovarian carcinoma cell lines when studying multidrug resistance [48]. miR-27a has also been shown to influence 
oncogenesis, proliferation and differentiation in various forms of cancer [40]. This interaction was present twice in the 
FDR  1% top set.  
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Conclusion 
To conclude, the miMsg algorithm is an unbiased tool to enrich predicted miR-mRNA interactions 
for a specific biological context using matched high-throughput miR/mRNA expression data 
(Figure 1). As interactions are graded on scores directly related to combined ranking profiles of 
miR/mRNA expression, miMsg is very suitable to detect subtle miR-mRNA interactions (Figure 2). 
miMsg selected 0.18% / 1.64% / 6.17% (FDR 0.1% / 1% / 5%) highly relevant and significant 
interactions in the GCT data (Table 1, Figure 4). In the largest datasets (GCT/MM: 56,262/27,129 
interactions) miMsg outperforms the other algorithms by achieving 37/33% enrichment for 
validated interactions. Overlap between interactions selected by different algorithms is very limited. 
Overall, the benchmarking results illustrate that there is no obvious best choice between miMsg, 
LASSO and GenmiR++. Spearman’s and Kendall’s correlation methods perform worst. Results 
depend strongly on the dataset used. Although we favor miMsg because of its limited fraction of 
selected interactions (¨5% vs ¨50% (LASSO)) and unbiased, distribution free approach, application 
of different algorithms can aid selection of relevant interactions. 
A systematic literature review of the GCT results showed association of top-scoring miRs/mRNAs 
with processes regulating germ cells (proliferation/differentiation) and GCT development. 
Moreover, interactions involving miR-23 paralogs were highly enriched in the top-100. 50% of the 
mRNAs involved in these interactions were shown to be miR-binding in ES cells. Based on: (1) top-
100 ranking by miMsg / FDR  1%, (2) involvement of the enriched miR-23 paralog cluster, (3) 
known miR-mRNA interaction and/or (4) experimental validation, 28 high confidence interactions 
were selected. Literature review identified four of these as most relevant for further study (Figure 
4). To conclude, miMsg was highly effective in reducing a high number of predicted miR-mRNA 
interactions in GCT data, generating a small high confidence set directly applicable to further 
research. 
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CHAPTER 5 
Abstract  
Germ cell cancers (GCC) are the most frequent malignancy in young Caucasian males. GCC can 
consist of seminomas (SE) and non-seminomas (malignant NS: embryonal carcinoma (EC), yolk sac 
tumor (YS), choriocarcinoma (CH) and teratoma (TE)). Current serum-markers used for diagnosis 
and follow-up (AFP, hCG) are predominantly related to YS and CH and marker positivity can vary 
during disease. Therefore, stable markers consistently identifying more GCC components, 
specifically the stem cell components SE and EC, are of interest. Expression of the embryonic stem 
cell miR-371-3 and miR-302/367 clusters in SE/EC/YS suggest possible application of these micro-
RNAs as GCC tumor-markers. The TSmiR protocol constitutes a complete, quality-controlled 
pipeline for the detection of miRs in serum, based on magnetic bead-based purification and qPCR 
quantification. As a proof of principle, TSmiR was applied to five independent serum sample series 
including 80 GCCs, 47 controls, 11 matched pre/post orchidectomy samples and 12 no-GCC 
testicular masses. GCC serum samples showed a consistent, significant (p0.00064) increase of 
miR-371/372/373/367 levels. Analogous, serum levels returned to baseline after orchidectomy 
(stage-I disease). Moreover, there was a trend toward higher miR levels in patients with metastasis. 
These results imply suitability for diagnosis and follow-up. TSmiR showed an overall sensitivity of 
98%, clearly outperforming the traditional serum markers AFP/hCG (36%/57%, 
sensitivityAFP=3%/45%; sensitivityhCG=62%/66%, SE/NS). TSmiR misclassified one tumor as a control. 
Serum AFP/hCG and TSmiR combined identified all T samples correctly. In conclusion, TSmiR 
constitutes a highly sensitive and reproducible serum test for GCC patients, suitable to be 
prospectively tested for diagnostic and follow-up purposes. 
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Introduction 
Human germ cell tumors are a heterogeneous group of neoplasms, derived from the germ cell 
lineage and originating at various stages of development with different cells of origin and 
pathogenesis [1]. The proposed classification system has been adopted by the World Health 
Organization (WHO) [2], and specialized pathologists [3, 4]. Malignant germ cell tumors, referred 
to as germ cell cancer (GCC), include seminoma (SE) and nonseminoma (NS) and are 
predominantly found in adolescents and young adults, although also diagnosed in neonates and 
infants [5]. It is the most frequent malignancy in young Caucasian males and incidence is 
increasing. GCC originate from a pluripotent embryonic germ cell (primordial germ cell/gonocyte) 
blocked in its maturation. This is referred to as carcinoma in situ (CIS) [6] or intratubular germ cell 
neoplasia unclassified (IGCNU) [2] in the context of testicular GCC of adolescents and adults. Their 
pluripotency is reflected in the capacity to form the germ cell lineage (CIS/IGCNU, SE, de novo 
germ cells [7]), embryonic stem cell components (embryonal carcinoma, EC) and all differentiation 
lineages (teratoma (TE), yolk sac tumor (YS) and choriocarcinoma (CH)) as found in adolescents 
and adults. In neonates and infants, TE and YS are distinguished, in which YS is the malignant 
component. Pluripotent GCC (including their precursor lesions) exhibited expression of various 
embryonic pluripotency markers of significant diagnostic value (OCT3/4 (POU5F1) [8, 9], NANOG 
[10], SOX2/SOX17 [11] and LIN28 [12, 13]). In addition, CIS/SE/EC/YS components, diagnosed at 
pediatric and adult age, express a specific set of embryonic stem cell related micro-RNAs (miRs), 
including the miR-371-372-373 (miR-371-3) and miR302a,b,c,d/367 (miR-302/367) clusters [14-
17].  
Depending on tumor stage and histology, pediatric and adult GCC (SE/EC/YS/CH) are effectively 
treatable by surgery, possibly followed by either irradiation and/or chemotherapy [18]. However, 
significant long term effects of the systemic treatment protocols have become evident [19, 20]. 
Therefore, early and accurate diagnosis as well as detailed follow-up of GCC patients is of crucial 
relevance for optimal treatment, preventing possible under- or overtreatment. In clinical 
management of GCC, evaluation of a set of serum markers is informative for diagnosis, risk 
assessment and follow-up. Alpha Feto-Protein (AFP) is predominantly informative for YS and 
sporadically positive in EC and human Chorionic Gonadotrophine (hCG) is predominantly 
informative for CH with sporadic positivity in SE/EC [18]. LDH-1 has also been reported as a (less 
informative) serum marker [21]. So far, no consistent markers for the stem cell components SE and 
EC are available, which limits the use of serum markers for diagnosis/follow-up in a large 
proportion of GCC patients.  
Recently, three studies reported that a higher expression of members of the embryonic miR 
clusters miR-371-3 and miR-302/367 can be detected in serum of GCC patients (adult and 
pediatric) as compared to controls [22-24]. One study showed a decline to normal levels after 
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surgical removal of stage I GCC [23]. These findings could be a significant step forwards in clinical 
management (diagnosis and follow-up) of GCC patients, especially for the high number of 
“marker-negative” cases, i.e., those without elevated AFP or hCG serum levels. 
The TSmiR protocol described in the manuscript constitutes a complete, quality-controlled pipeline 
for the detection of miRs in serum, based on magnetic bead-based purification and qPCR 
quantification. Using five independent sample series we show that TSmiR shows high sensitivity and 
specificity (GCC vs control). Also, the effect of metastasis / surgical removal of the tumor on miR 
levels, is investigated. This proof of concept indicates TSmiR as a potential additional tool for 
diagnosis & follow-up of GCC. 
 
Figure 1. Sample series, histological classification / markers & TSmiR pipeline. (A) Sample series investigated. Five 
independent series were investigated: the Rotterdam-Learning (RL) and Validation (RV) sets including GCC cases and 
controls, a series of serum samples of patients with a testicular tumor other than GCC (no-GCC) and two previously 
published series: UK, including GCC samples (pediatric and adult) and controls [22, 24] and Germany (D), composed of 
pre- and post orchidectomy samples (local disease only, stage I) [23]. (B) Histological classification & overview of 
immunohistochemical, molecular and serum GCC markers [8, 10-17]. GCC originates from a common progenitor, further 
developing into the stem cell components SE and EC. EC can further differentiate into the various types of differentiated 
NS. Markers are summarized as described throughout the main text. + = consistently positive; - = consistently negative; 
(+) = sporadic positivity (inconsistent). (C) Complete pipeline of the TSmiR test. See Materials and Methods section for 
explanation. SiC=Spike in control; RefN=reference miRs/normalizers, ToI=Target of interest. 
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Materials and Methods 
Patient and control serum samples 
Detailed information on the composition of the various independent sample series 
(RV/RL/UK/D/no-GCC) is presented in Figure 1A. Samples in the RV/RL/no-GCC series were selected 
to be distributed over different clinical stages and histological subtypes. RV/RL samples were 
extracted at the Department of Pathology, Erasmus MC, Rotterdam, the Netherlands. Use of tissue 
samples for scientific reasons was approved by an institutional review board (MEC 02.981 and 
CCR2041). Samples were used according to the “Code for Proper Secondary Use of Human Tissue 
in The Netherlands” developed by the Dutch Federation of Medical Scientific Societies (FMWV 
(Version 2002, update 2011). The UK and D samples were sent frozen to Rotterdam, handled 
similarly, and used in accordance to regulations set by the local institutional review boards.  
miR analysis of primary GCC and normal testis 
Small RNA was prepared from 47 primary, independent GCC and three normal testis samples as 
described in [15]. Expression of 156 miRs was analyzed, quantified and normalized according to 
[25]. 
miRNA purification using anti-miRNA Magnetic Beads and quantification 
For the purification, target-specific anti-miRNA magnetic beads were supplied by Applied 
Biosystems, Foster City, California, USA (Part Number 4473087, TaqMan® miRNA ABC Purification 
Kit - Human Panel A). This panel consists of superparamagnetic Dynabeads® covalently bound to 
a unique set of ~380 anti-miRNA oligonucleotides including endo-/exogenous controls, allowing 
for purification and quantification without pre-amplification step. Detailed protocol was provided 
by the supplier (Applied Biosystems/Invitrogen). miRs were purified from 50μl serum using the 
Taqman miRNA ABC Purification Buffer Kit (PN 4473084, Applied Biosystems).  100 μl of lysis buffer 
was added as provided by the supplier as well as 2 μl of a 1nM Spike in Controls (SiC: 6 different 
non-human control miR) solution and 80x106 washed human panel A magnetic beads in 1.5ml 
LoBind tubes (Eppendorf). Of note, hsa-miR-302d is not represented in the panel A bead set and 
was therefore not included in the study. After shaking at 12,000 rpm at 30oC for 40 minutes, 
unbound RNA was removed by three wash steps using a magnetic bead separator. Bound miRs 
were eluted from the beads with 100 μl of elution buffer (Applied Biosystems) at 12,000 rpm at 
70oC for three minutes and stored at -80oC. DNA synthesis was performed using the TaqMan 
Micro-RNA Reverse Transcription kit (Applied Biosystems, PN: 4366597) according to the 
instructions of the supplier. Quantification of miR levels was performed in duplicate (except for the 
RL series) using the various TaqMan assays (Applied Biosystems catalogue ID: hsa-miR-371-3p 
(002124); hsa-miR-372 (000560); hsa-miR-373 (000561); hsa-miR-302a (000529); hsa-miR-302b 
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(000531); hsa-miR-302c (000533); hsa-miR-367 (000555); hsa-miR-200c (002300); RNU6b 
(001093); RNU44 (001094); RNU48 (001006); U6snRNA (001973); ath-miR-159a (000338); cel-miR-
39 (000200); hsa-miR-103 (000439); hsa-miR-16 (000391); hsa-miR-192 (000491); hsa-miR-20a 
(000580); hsa-miR-451 (001105); hsa-miR-93 (000432), hsa-let-7a (000377). Expression levels were 
measured on the TaqMan 7900HT using standard procedures.  
Quality control and missing data 
miR-200c, implicated in carcinomas (e.g. breast cancer) but not in GCC was included as a control 
[26]. This miR is of additional interest because it is mapped to the short arm of chromosome 12 
which is found to be consistently gained in invasive GCC [27]. Amplification curves of all targets 
and samples were inspected individually. Only in the RL set nine samples showed irregular curves 
with no semi-linear phase. These were set to UNDETERMINED, and replaced with the top Ct value 
measured per assay in the RV set +2 (Ctmax). Ctmax indicates a miR level just outside the known 
sensitivity of the assay. This way the risk of underestimating the miR-level by choosing a fixed Ctmax 
(for example the total number of runs) is reduced. Assay-specific cDNA was generated separately 
from TCam-2 cells (SE cell line [28]) diluted in serum from a healthy donor to be used for inter-
plate calibration (plate controls (PlC)) and positive control (PC). Four tubes (50,000 TCam-2 cells in 
50 ǌl normal serum) were pooled for lysis, followed by RNA pull down as described above. The 
resulting RNA was used as positive control (PC) for cDNA synthesis when analyzing patient 
samples. cDNA was generated separately as well to be used for inter-plate calibration (plate 
controls (PlC)). Reference measurements for the PlCs were calculated as the average of triplicate 
PCRs for each assay. PlC and PC were included in duplicate (per assay) on each plate with patient 
samples. Inter-plate variation and variation in assay efficiency was investigated in most samples 
and found to be constant (below 0.3 Ct) with the exception of the miR-93 and miR-302b assays 
(0.6-0.8 Ct, consistent between plates), without affecting suitability for usage. Non-human Spike In 
Controls (SICs) (ath-miR-159a and cel-miR-39) were included to monitor RNA recovery. One 
sample (N-UK) showed 22-fold less recovery and was discarded. For negative control (No 
Template Control: NTC) elution buffer was added instead of the bead eluate. Ct values >NTC were 
treated as UNDETERMINED (RV set, n=1).  
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Calibration & Normalization 
Stable target recovery using the magnetic bead method was investigated and demonstrated using 
SiCs in all subgroups with occasionally different distributions between subgroups (p<0.01, Kruskal-
Wallis test), warranting calibration for recovery before determination of the most stable reference 
miRs for normalization. Some samples in the UK set were corrected for <50ul input volume. A 
panel of possible targets for normalization (RefN) was selected based on published data: RNU44, 
U6snRNA, hsa-miR-16, -93, -103, -192, -451 (haemolysis effects), miR-20a, let-7a [29]. Based on 
established algorithms for stability analysis (Normfinder [30] and geNorm [31]), miR-20a and miR-
93 were the most stable combination for normalization in the RL set after calibration, which was 
validated in the RV set (Figure S3). Normalization was carried out using the mean of these 
normalizers according to the dCt method [32]. 
Statistical analysis & Software 
Data pre-processing was performed in Microsoft Excel 2010 & GenEx 5.3.7.332. Comparison of 
mean miR levels (dCt) was performed using a Mann-Whitney U test, two-sided in GenEx. If not 
otherwise specified, significant indicates p0.000639, yielding a risk of type I error of 5% after 
correction for multiple testing (Bonferroni).  Uncorrected comparisons are indicated separately 
(p<0.05 = significant), as putative additional interesting results might be lost because of too 
stringent selection. Principal Component Analysis (PCA), Kohonen Self Organizing Map (SOM) and 
Heatmap analysis were performed in GenEx. ROC analysis and SiC stability testing were performed 
in SPSS 18 & 20. Visualizations were generated using Microsoft Powerpoint & Excel 2010 and 
Photoshop CS4 & 5.5. Analyses were performed on a 64-bit Windows 7 system. 
Results 
A quality controlled pipeline for miR purification, recovery and quantification from serum (TSmiR) 
was developed as discussed extensively in the Materials and methods and Figure 1B. To ensure 
standardized results, the pipeline includes a number of quality control steps and spike in miRs to 
assess and compensate for differences in assay efficiency, inter-plate variability and cDNA/qPCR 
reaction efficiency. Regarding normalization, a panel of nine potential reference miRs was 
investigated, identifying miR-93 and miR-20a as the most stable combination for normalization in 
both a learning and a validation sample series (RL, RV, Figure 1A).  
The miR-371-3 and miR-302/367 clusters are known to be expressed in SE, EC and YS (Figure 1C) 
[14-16]. In this study their serum levels were evaluated in five sample series (Figure 1A). First, the 
strength of the various miRs to distinguish between GCC samples (T) and controls (N) (or the 
presence/absence of metastasis) was investigated in the Rotterdam learning (RL) series. These 
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results were verified in three independent series (Rotterdam validation (RV, Erasmus MC Rotterdam 
Pathology), UK [24] and D [23]). Specificity of the miRs was verified in twelve serum samples from 
patients with testicular masses other than GCC (no-GCC). Next, The RL, Rv, UK and D series were 
combined to investigate the performance (sensitivity / specificity) of the most discriminative miRs. 
Finally, results from cases with and without metastasis and eleven matched stage I pre- and post 
orchidectomy serum samples (D series) were investigated to draw preliminary conclusions 
regarding the applicability of TSmiR to follow-up. Additional results, methods and raw data are 
presented in the supplementary data. By applying TSmiR to these sample series, the potential 
value in GCC diagnosis and follow-up of the serum levels of these GCC specific miRs was assessed 
in a controlled setup. 
Serum miR-371-3/367 levels were significantly higher in tumor samples and were strongly 
correlated. 
miR-371-3/367 showed significant high differences between tumor and control samples, also when 
stratified for histological subtype. These observations were consistent between the learning and 
validation sample series. miR-373 showed higher differences between N and T in the Rv as 
compared to the RL series due to lower baseline levels in N samples and consistently higher levels 
in both the SE and the NS groups. Although there is no known difference between the samples in 
these series, this observation does not challenge the hypothesis that T samples exhibit higher miR 
levels than N samples. Even though miR-371 and miR-367 (uncorrected p-value) showed 
consistently higher levels in tumor versus normal, the results in the UK series were less consistent 
possibly due to the low number of samples and the inclusion of pediatric GCCs. miR-302a and to a 
lesser extend miR-302c showed significantly higher levels in in many comparisons of T vs N but the 
fold difference was lower than that of miR-371-3/367, limiting their usefulness (Figure 2AC). As 
expected miR-200c showed no increased levels in T vs N. There were no consistent significant 
differences between SE and NS. miR-371-3 and miR-302abc levels correlated most strongly within 
their own clusters but miR-367 correlated most strongly and consistently with the miR-371-3 
cluster instead of its own miR-302abc cluster. 
 
 
 
Figure 2. Bars represent times (x) difference between groups, defined as difference between the mean of the dCt of 
group A vs B (fold change=2^(dCtA-dCtB)). High values represent relatively higher levels in group B. Error bars depict 
standard error of the mean. * = group A and B show significantly different levels based on the dCt values (Bonferroni 
corrected)). RL/RV series: (A, C) Comparison of N versus histological subtype (SE or malignant NS) and all tumor samples 
(T=SE+NS); (B, D) Comparison of miR levels in serum samples from patients with localized and metastatic disease (stage I 
vs pooled stage II, III and IV) for all tumor samples together (meta+/meta-) and SE/NS separately.  Æ 
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Combined serum miR-371-3/367 levels allowed for clear separation of tumor samples and 
controls. 
Based on the consistent, significant and large fold differences in serum miR-371-3/367 levels 
between tumor and control samples, only these miRs were selected for further analysis. The power 
of these miRs to separate tumor from control samples was investigated using a Kohonen Self 
Organizing Map (SOM), principal component analysis (PCA) and hierarchical clustering / heat map 
visualization (Figures 3A, 3B and S4). The SOM was generated using the RL data and then applied 
to the other datasets. The results of these different analyses were highly consistent. In the RL series 
a tumor-only group and a second group containing all control and some tumor samples were 
distinguishable. Tumor and control samples were even more stringently separated in the RV series. 
The UK series showed separation of most of the controls from the tumor samples and illustrated a 
trend in which the pediatric cases showed more similarity to the control samples than the adult 
GCC serum samples. 
Serum levels of miR-371-3/302abc/367 were not increased in patients with testicular masses other 
than GCC. 
A number of no-GCC testicular masses were investigated. Consistently, none of the miRs showed 
significant elevation in the serum compared to all pooled controls (N) samples. All no-GCC 
samples group together with the unaffected cases in PCA/SOM analysis. This confirmed the 
specificity of the investigated serum miR markers for GCC in the context of differentially diagnosing 
testicular masses (Figure S5). 
 
 
 
Figure 3. (A) A Kohonen Self-Organizing-Map (SOM) was generated using the RL series as training data. The SOM was 
set to identify two groups (alpha=0.40, 500 iterations). Only miR-371-3/367 data were included because these showed 
the highest, most significant and most consistent difference between serum samples of patients with a GCC and controls. 
The generated SOM was then applied to the RV, D and UK series. RL: In the RL series, the right group only contained 
tumor samples, however the left group contained a mixed set of samples; RV: The same SOM identified a left group with 
almost only control samples (N) and one SE in the RV series. The right group contained all other tumor samples and one 
control sample; UK: The same SOM proved to also be able to separate all but one N samples from the T cases in the UK 
samples; D: All post-orchidectomy samples from the D set clustered together, together with some pre-orchidectomy 
samples. (B) Principal component analyses for all individual datasets. In all cases the first and second PC based on 
miR371-3 explained > 99% of the variance. RL: although most of the tumor samples are clearly clustered and separated 
from the controls, there are some T (n=7) intermixed with N; RV: All T and N samples cluster separately. One N (testicular 
torsion) is situated on the edge of the T/N border; UK: all N samples and T samples cluster separately. The pediatric YS 
are situated between the N samples and the adult GCC clusters; D: all but two pre-orchidectomy samples cluster 
together. All post-orchidectomy samples cluster together. This cluster also included two pre-orchidectomy samples. Æ 
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miR-371-3/367 levels in serum showed high sensitivity / specificity in the classification of tumor 
versus control samples and outperformed current markers (AFP/hCG).  
The trade-off between specificity and sensitivity was assessed for all miRs by receiver operating 
curve (ROC) analysis using all samples (pooled). As expected, the discriminative power was very 
high for miR-371-3/367 (Figure 4A-E) and much lower for miR-302abc/200c. 
Classification/inclusion of the post-orchidectomy samples as part of the control group did not 
significantly influence the Area Under the Curve (AUC) and results only differed marginally when 
the SE or NS subgroups were analyzed separately. Cutoffs of miR levels were set for a sensitivity of 
90%, preserving a specificity of 60-91% for individual miRs (Figure 4F). Combining the resulting 
classification (T/N) for miR-371-3/367 lead to a sensitivity of 98% (specificitymiR-371-3/367=48.3%). 
Addition of miR-302abc reduced the discriminative power and was therefore omitted (specificityall 
miRs=8.6%).  
Sensitivity was compared to markers currently used as golden standard (AFP and hCG, only 
available for tumor samples). miR-371-3/367 levels were more informative than AFP and hCG, 
particularly for SE (Figure 4C-E). Even when the YS subgroup was investigated specifically, 
investigation of the miR levels showed higher sensitivity than AFP. Overall, application of the serum 
markers AFP and hCG alone resulted in ¨50% false-negative cases. Investigation of only the miR-
levels resulted in one false negative NS serum sample (sensitivity=98%). Combined interpretation 
of the established serum markers AFP/hCG and miR-371-3/367 levels led to the correct 
classification of all cases with a malignancy. 
 
Figure 4. (A) ROC curves were generated for the four most differentiating miRs (371-3/367). Samples from the 
RL/RV/UK/D series were pooled for analysis.; (B) The AUC varied from 0.89 to 0.96 for all ROCs. Separate ROCs generated 
for only the SE or the NS showed minor differences between the quality of these miRs as marker. (C, D, E) Stacked bar 
diagrams of the sensitivity and false negative rate for the conventional “gold standard” in current clinical use (AFP, hCG) 
and the four miRs: miR-371-3/372/373/367. Sensitivity was calculated when all miRs were assessed in combination, and 
again in combination with AFP/hCG. Missing values were discarded in the calculation of the frequencies; C) All tumors; D) 
SE; E) NS; (F) A sensitivity of 90% (green) in the ROC analysis lead to an acceptable remaining specificity (y-axis). A 
sensitivity of 95% (brown) resulted in a big loss of specificity, especially for miR-371-3p/372. Cutoffs for dCt values 
indicating T were identified using the ROC including all pooled samples: miR-371-3p15.62, miR37211.02, miR-
37310.45, miR-36712.48. 
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miR levels returned to baseline after surgical removal of a local tumor & there was a trend towards 
higher GCC-specific miR levels in metastasized disease. 
A series of matched sera from patients with local GCC was analyzed before and after orchidectomy 
to assess the reduction in serum miR levels after surgery. As expected, miR-371-3/367 showed 
significantly higher serum levels in the pre-orchidectomy samples. miR-302ac showed a similar 
trend without correction for multiple testing. SOM, PCA and clustering analysis illustrated that the 
majority of the pre- and post-orchidectomy cases could be clearly separated based on serum miR-
371-3/367 levels (Figure 3), analogous to the results of the T vs N comparisons discussed above. 
After surgery serum miR-371-3/367 levels returned to baseline, i.e. they were not significantly 
different from the levels in all pooled controls (Figure 5A). Consistent with the observations 
described above, miR-371-3/367 showed an overall steeper reduction in serum levels than miR 
302abc (Figure 5B). 
When metastasized disease was compared to local GCC, miR-371-3/367/302ac showed overall 
higher levels in metastasized cases. However, the fold difference in serum miR levels was much 
lower than in the tumor vs control comparisons, results were not always consistent between the 
different sample series and the statistical strength was limited. miR-372-3/367/302a remained 
significant after correction for multiple testing (Figure 2BD).  
These results indicate possible applicability of serum miR-371-3/367 levels not only for diagnosis as 
discussed in the previous sections, but also for follow-up. However, these observations need to be 
validated and extended in a larger, prospective setup with longer follow-up period. 
 
Figure 5. (A) When all N from the RL, RV and UK series are pooled and compared to the post-orchidectomy D samples, 
there is no significant difference between the serum-miR levels in both groups for the most differentiating miRs (371-
3/367). X-axis: most consistently differentially present miR (between N and T). Y-axis: dCt; (B) Plot of all pre (left) and post 
(right) orchidectomy dCt levels per miR per case. Grey area indicates the average baseline level in all pooled N. This does 
not necessarily constitute a valid cutoff (see Figure 4).  
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Discussion 
GCC patients require intensive follow-up after primary diagnosis and treatment [18]. For diagnosis 
and follow-up, various approaches are currently used, including the established diagnostic/follow-
up serum-markers AFP and hCG (Figure 1C). AFP is primarily related to YS and hCG to CH 
although they can be positive in sporadic cases of SE and SE/EC respectively as well. Therefore, a 
significant number of GCC patients without YS and CH, will be negative for these serum markers. In 
addition, positivity for either marker can change during disease progression. Because of this, there 
is need for additional serum markers, particularly ones that are consistently positive in SE and EC. 
Several possible candidates have been suggested, including demethylated promoter regions of the 
XIST gene [33] (sensitivity of 64% in serum of GCC patients, small single series). More recently, a 
selected number of miRs are reported to be highly expressed in SE, EC and YS (both pediatric and 
adult patients). They belong to the embryonic stem cell miR-371-3 and miR-302/367 clusters and 
were validated in multiple independent GCC series [14-16].  
Levels of these miRs have proven to be detectable in the serum in the serum of GCC patients [22-
24]. Although exosomes have been suggested as a miR-transporters / -repository, the mechanism 
behind miR release into serum remains to be elucidated [34, 35]. The protocols applied in earlier 
studies lacked the relevant quality controls, calibration and normalization steps required for clinical 
implementation. Although amplification steps were performed, no specific miR 
purification/recovery step was included, resulting in possible underscoring of miR levels in serum 
by qPCR. The TSmiR protocol addresses these quality control issues, resulting in a robust and 
informative pipeline to detect the levels of these miRs in serum of GCC patients and controls 
(Figure 1B). Specific quality control steps for miR purification and recovery artifacts were 
implemented and suitable targets for normalization of Ct values in serum identified. Moreover, 
inter-plate and inter-assay variations were evaluated and corrected for. The described pipeline is 
potentially suitable for clinical serum analysis in the context of other malignancies. miRs identified 
as candidate markers need to show a specific and consistent high level of expression in serum 
samples from patients with cancer compared to those from normal, healthy individuals. 
The value of GCC specific miR-detection in serum using the TSmiR pipeline was demonstrated in 
learning and validation sets of independent serum samples from controls and GCC patients. miR-
371-3 and miR-367 were most informative (Figure 2). At time of diagnosis, these specific serum 
miR levels allowed almost complete separation of control- and patient samples (Figure 3). When 
the miR-371-3 and miR-367 results were combined, only one tumor sample was misclassified as 
control, independent of the histology of the tumor (no consistent difference between SE and NS). 
(sensitivity 98%). In contrast, the sensitivity of AFP/hCG was worse (max ¨60%), especially in the SE 
(max ¨40%) samples (Figure 4). This proof of concept demonstrates the additional value of TSmiR 
as a “liquid biopsy” in primary GCC diagnosis, indicating superiority over the currently applied 
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AFP/hCG test for the detection of the stem cell components (SE/EC). This is further confirmed by 
investigating a series of patients with a testicular mass of other origin, showing a pattern similar to 
the control group (Figure S5). Although the primary aim of this study was to investigate the 
additional value of quality controlled detection of GCC specific miRs in primary diagnosis of GCC, 
differences between cases with and without metastasis (Figure 2B and D) and complete 
normalization of levels after complete resection of a local tumor (Figure 5) suggest an important 
role for TSmiR in follow-up as well as diagnosis (prospective setup currently initiated).  
Conclusions 
TSmiR constitutes a pipeline with stringent QC for the detection of miRs in serum, based on 
magnetic bead-based purification and qPCR quantification. In five independent GCC-sample 
series, TSmiR shows high sensitivity and specificity (GCC/control), especially for GCC stem cell 
components not consistently identified by current markers. Moreover, higher miR levels in patients 
with metastasis were identified as well as normalization of miR levels after surgical removal of local 
disease. This proof of concept indicates that TSmiR has the potential to be of significant 
importance in the context of additional diagnostic (“liquid biopsy”) and follow-up tools for GCC 
patients, warranting further investigation. 
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Supporting information 
Figure S1. Expression analyses of the ToI (miR-371-372-373, miR-302, miR-367, 200c) in a series of GCC tumor samples 
and controls. All miRs (n=156) on the plate were used to normalize using the mean expression of all genes (threshold Ct 
40). Samples included are N (n=3), TE (n=10), SE (n=15), EC (n=14), YS (yolk sac tumor) (n=8). Clustering was performed 
using Ward’s algorithm; both dendrograms were formatted according to Euclidean distance. The clustering clearly 
distinguished between N+TE (differentiated tumor types with expected low level) and SE/EC/YS (known high level). The 
vertical dendrogram correctly separated the miR clusters (miR-371-3 vs miR302abc/367). miR-200c clustered separately 
and did not contribute significantly to the clustering. Mean expression levels were significantly higher in the pooled 
SE/EC/YS or SE/EC groups when compared to N for all miRs shown, except 200c (as expected.) 
Figure S2. Spike in levels in the various sample series. (A, B) Stable spike in control (SiC) expression was observed in both 
the RL and the RV datasets. However, the distribution of the values was different between the N/SE/malignant NS groups 
(p<0.01, Kruskal-Wallis test). This warranted calibration for recovery efficiency as applied in all cases before analysis; (C) 
SiC expression in the D and UK series; no significant difference between the groups (UK and GM compared separately) 
(p>0.05, Mann Whitney, two-sided); (D) Spike-in levels in the no-GCC samples were highly stable, although statistical 
testing revealed non-similar distributions for ath-miR-159a based on n=3 per group (p=0.04, Kruskal-Wallis test, cel-
miR-39 p=0.79). Calibration was applied. 
Figure S3. Selection of stable normalizers in serum. In both sets: miR-93 and miR-20a were top-scoring with respect to 
(inter-/intragroup) stability. Ct values (series RV: average of technical replicates) were normalized against the average 
expression of these RefNs using GenEx. (A) Normfinder was used to assess intra-group variability (N/SE/malignant NS). 
RefNs with variation > 1 for one or more groups were discarded; (B) Normfinder was run again on the remaining RefNs 
using all samples WITHOUT group classification. From this analysis the optimal number of RefNs was assessed; (C) 
geNorm was run separately using all RefNs to obtain an independent ranking of the stability of the RefNs. geNorm does 
not take group classification into concern; RL set: A) Normfinder WITH groups: miR-192/451, U6 snRNA & RNU44 were 
discarded; B) Normfinder WITHOUT groups: Combining 2 RefNs showed the lowest acc. SD (variation) = miR-20a/93 
(sorted desc.); C) geNorm: 3 RefNs reached the arbitrary threshold of <0.5 (M-value) = miR-93/20a/16 (sorted 
descending); RV set: Normfinder WITH groups: miR-16, U6 snRNA & RNU44 were discarded; B) Normfinder WITHOUT 
groups: Combining 4 RefNs showed the lowest acc. SD (variation) = miR-20a/192/93/103 (sorted desc.); C) geNorm: 0 
RefNs reached the arbitrary threshold of <0.5 (M-value).  
Figure S4. Heatmaps of the four main data sets. (A) RL dataset. Clustering showed one group with only tumor samples 
(SE/NS) and a second group containing all N samples and 11 SE and 6 NS; (B) RV dataset. Clustering completely 
separated the SE/NS and the N samples; (C) UK dataset. The N and T samples cluster separately, but two controls and 
one tumor were placed under one branch; (D) D dataset. The clustering separated the pre- and post-orchidectomy 
samples quite well, although one post-orchidectomy sample was placed in the pre-orchidectomy branch and two pre-
orchidectomy samples were situated in the post-orchidectomy branch. Clustering was performed using Ward’s 
algorithm; both dendrograms were formatted according to euclidean distance. These results matched the patterns 
observed in the SOMs and PCA. 
Figure S5. Analysis of no-GCC samples in comparison to the GCC series. Comparison of control (N), Post-orchidectomy, 
Non-GCC testicular tumor (no-GCC), Non-seminoma (NS) and Seminoma (SE) groups. Samples from all series were 
pooled. (A) Bar graph of dCt values (high values = low expression), indicating similar (miR371-3p/373/367/302abc/200c, 
p>0.05) or even significantly lower expression (miR-371-3p, p=0.002) in the no-GCC cases as compared to all N (two 
sided Mann-Whitney test, black vs. green bar). The difference between the top-miRs (371-3/367) for the N/post-
orchidectomy/no-GCC groups as opposed to the NS/SE groups is again much more apparent than in the miR-
302abc/200c cluster; (B) PCA applied to all pooled samples. PCA separates the N/post-orchidectomy/no-GCC samples 
with some SE/NS samples intermixed in the area of the controls, especially on the border of both groups.  Only one N 
sample is clearly clustering with the SE/NS samples; (C) The SOM learned from the RL series was applied to all pooled 
samples. The right group contains almost exclusively tumor samples: only two N samples cluster with the SE/NS samples. 
The left group contains all other N samples, all post-orchidectomy samples and all no-GCC samples together with some 
SE/NS samples. 
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Figure S6. Extended ROC analysis. (A) ROC curves were generated for all TOIs using different datasets & subsets of 
samples (columns). ALL indicates the analysis of the aggregated samples of the RL, RV, UK and D datasets. AUC = Area 
Under Curve (0-1) of each ROC. AUCs > 0.8 are displayed using increasing shades of grey to indicate better 
discriminative power. The inclusion of the D dataset in ALL does not significantly change the AUCs of any of the miRs 
investigated (ALL vs. no D column): (B) ROC curves were generated for all TOIs using the aggregated data of all datasets 
(ALL). Top-miRs (371-3p/372/373/367) are indicated in solid lines while the rest are plotted using a dashed pattern; (C, 
left) A sensitivity of 90% (grey) in the ROC analysis lead to an acceptable remaining specificity (y-axis). A sensitivity of 
95% (black) lead to a big loss of specificity, especially for miR-371-3p/372/302ab. Cutoffs for dCt values indicating T were 
identified using the ROC (sensitivity 90%) including all samples: miR-371-3p15.6175, miR37211.0175, miR-37310.45, 
miR-36712.4825, miR-302a13.9075, miR-302b19.025, miR-302c13.255, miR-200c9.4175; (C, right) Using the 
chosen sensitivity of 90%, the array of miRs including miR-302abc shows a much lower specificity than the array of the 
top-miRs; (D) Stacked bar diagrams of the sensitivity and false negative rate for the golden standard (AFP, hCG) and 
miR-371-3p/372/373/367/302abc/200c. Sensitivity was calculated when all combining all or only the top-miRs with and 
without the established GCC serum markers AFP and bHCG (coded as elevated (1) or normal (0) as indicated in medical 
information or based on the cutoffs used in the Erasmus MC Rotterdam (AFP <=9, hCG<=1.9). The minimal detected 
concentration of <2 (hCG, UK) was interpreted as normal. miR expression data was also dichotomized (0 normal, 1 
elevated) per miR based on the ROC data, retaining a sensitivity of 90%. Missing values were discarded in the calculation 
of the frequencies. The observations for the tumor markers are in line with the known hGC positivity of some SE and a 
higher sensitivity of AFP/hCG in NS (especially YS) as opposed to the SE subgroup. (left top) All tumors; (right top) SE; 
(left bottom) NS; (right bottom) YS. 
Table S1. (A) Constitution of sample series & fold differences between groups. Numbers indicate times (x) difference 
between two group identified as “A vs B” in column headers, for example N vs T). Numbers >1 indicate relative higher 
levels in group B. Numbers between brackets indicate SEM (Standard Error of Mean), asymetric because of exponential 
transformation of ddCT values. Black background indicates significant difference between mean dCt values of both 
groups after Bonferroni correction; grey without correction for multiple testing. Abbreviations used: RL: Rotterdam 
Learning set; RV: Rotterdam Validation set; UK: United Kingdom set; D: Germany set; N = Normal (control); T = Tumor; SE 
= seminoma; NS = Nonseminoma; meta: metastasis; The T samples in the RL and RV were classified as stage I (nRL,SE=8, 
nRV,SE=6, nRL,NS=7, nRV,NS=6), stage II (nRL,SE=6, nRV,SE=6, nRL,NS=0, nRV,NS=6) and stage IV (nRL,SE=2, nRV,SE=0, nRL,NS=9, 
nRV,NS=6). The N series constituted of serum of healthy individuals (nRL=2, nRV=10), patients with testicular torsion (nRL=10, 
nRV=10) and patients with epididymitis (nRL=0, nRV=10). The UK dataset consisted of N (n=6) and T (nadult=4, npediatric YS=3) 
samples. In the D dataset 11 matched pre and post orchidectomy samples were included of patients with stage I (local) 
disease (nSE=2x6, nNS=2x5). The no-GCC series consistent of serum of patients with a Sertoli/Leydig cell tumor (n=3/3), 
testicular B-cell lymphoma (n=3) or epidermoid cyst (n=3).  (B) P-values of pairewise comparisons. 
Table S2. dCt values 
Table S3. Correlation between miRs (RL & RV) 
Supporting information is avaliable at: http://dx.doi.org/10.1016/j.molonc.2013.08.002  
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CHAPTER 6 
Abstract 
MicroRNAs (miRs) are short non-coding RNA molecules (¨21 nucleotides) involved in regulation of 
translation. As such they are crucial for normal cell development and differentiation as well as 
cellular maintenance. Dysregulation of miRs has been reported in various diseases, including 
cancer. Interestingly, miRs can be informative as tumor classifiers and disease biomarkers. Recent 
studies demonstrated the presence of miRs in body fluids like serum, thus providing a putative 
non-invasive tool to study and monitor disease state. Earlier targeted studies by several 
independent groups identified specific embryonic miRs as characteristic for germ cell tumors (miR-
371-2-3 & miR-302/367 clusters). This study reports a high throughput miR profiling (¨750 miRs) 
approach on serum from testicular germ cell tumor patients (14 seminoma and 10 non-seminoma) 
and controls (n=11), aiming at independent identification of miRs as candidate biomarkers for 
testicular germ cell tumors. A magnetic bead capture system was used to isolate miRs from serum. 
Subsequently, the TaqMan®Array Card 3.0 platform was used for profiling. The previously 
identified miRs 371 and 372 were confirmed to be specifically elevated in serum from germ cell 
tumor patients. In addition, several novels miRs were identified that were discriminative between 
GCC and controls: miR-511, -26b, -769, -23a, -106b, -365, -598, -340 and let-7a. In conclusion, 
this study validates the power of the embryonic miRs 371 and 372 in detecting malignant germ cell 
tumors (SE and NS) based on serum miR levels and identifies several potential novel miR targets.  
 
 
124
IDENTIFICATION OF GCC SPECIFIC MIRS IN SERUM BY HIGH THROUGHPUT PROFILING 
 
 
Introduction 
Germ cell tumors (GCT) are a heterogeneous group of malignancies originating from developing 
germ cells. Five subtypes have been identified (I-V). The type II GCTs are also referred to as germ 
cell cancer (GCC) and occur most frequently. GCC comprises 60% of all cancers in Caucasian males 
between 20 and 40 years of age and 1% of all male cancers in general. Testicular GCC arise from 
carcinoma in situ cells (CIS) and closely resemble embryonic germ cells, either primordial germ 
cells or gonocytes. CIS can progress to either seminoma (SE) or embryonal carcinoma (EC). EC is 
the stem cell component of all non-seminomas (NS), i.e. teratoma (embryonic lineages, TE) and 
yolk sac tumor (YS) / choriocarcinoma (CH) (extra-embryonic lineages) [1-6]. GCC show an 
exquisite sensitivity to current treatment protocols. Over 90% of patients with SE are cured 
independent of stage (100% in case of local disease). For NS patients the cure rate is more variable 
(95% for stage I and II disease, about 70% for stage III and IV disease) [7, 8]. Intensive follow-up of 
these young patients is required, e.g. surveillance of stage I disease after orchidectomy alone and 
follow-up for (late) recurrences.  
A number of serum markers are available for GCC follow-up, including į-fetoprotein (AFP), human 
chorionic gonadotropin (hCG), and to a lesser extend lactate dehydrogenase (LDH) [7, 9-11]. 
Approximately 80% of the NS, and 20% of the SE show increased levels of these markers. AFP and 
hCG are primarily related to the presence of respectively a YS or CH component while they show 
little sensitivity for the stem cell components SE and EC. AFP levels might be elevated due to liver 
damage/disease, while hCG can be induced by chemotherapy [10, 11]. In addition, serum levels of 
these markers can change during disease progression, e.g. because of the development of 
different histological components. Therefore, better biomarkers are welcome, particularly markers 
with a high sensitivity for SE and EC.  
microRNAs (miRs) have been shown to be an alternative to conventional serum markers. miRs are 
short non-coding RNA molecules regulating translation. miRs are highly tissue specific and play a 
key role in cellular differentiation and maintenance of tissue identity. Dysregulation of miRs has 
been linked to cancer development and tumor progression [12]. A number of independent recent 
studies showed that serum levels of the miR-371-2-3 and miR-302/367 clusters are predictive for 
the presence of malignant germ cell tumors, including (testicular) GCC. These miR clusters are 
normally only expressed during embryogenesis (embryonic germ/stem cells) [13-15]. These 
observations enhance the close relation of GCC to early/fetal germ cell development. Indeed, 
these embryonic miRs are expressed by SE and EC [16, 17]. Palmer and colleagues profiled miRs in 
tissues from malignant pediatric GCT patients and controls, and also showed that the miR-371-2-3 
and miR-302 clusters were some of the few very highly overexpressed miRs in GCT [18]. In a case 
study, Murray and colleagues showed elevation of the levels of these miRs in serum of a 4-year-
old boy presenting with a YS [19]. Levels dropped during chemotherapy and returned to normal 
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during an uneventful clinical follow-up [19], which was confirmed in a larger case series/cohort 
(eight patients versus six controls) [20]. This rapid drop in serum levels was confirmed by Belge and 
colleagues, who examined sera of six SE and five NS patients with stage I disease before and after 
orchidectomy. Only two of these patients initially presented with elevated levels of the classical 
serum tumor markers [21]. Dieckmann and colleagues verified these findings in an additional 24 
pre- and post orchidectomy GCT patients and additionally showed that miR levels in the tumor do 
not necessarily correlate with serum levels [22]. 
In a larger study we presented the Targeted Serum miR (TSmiR) test [23]. A para-magnetic bead 
capture system was used to isolate and purify miRs from serum of 80 GCC patients, 47 controls, 11 
matched pre- and post-orchidectomy samples and 12 non-GCC testicular masses. miR levels were 
quantified using targeted RT-PCR. Pre- and post-orchidectomy samples concerned samples also 
described in [22]. The high specificity of the miR-371-2-3 cluster and miR-367 was confirmed, as 
was the drop in serum levels after orchidectomy. A trend towards higher miR levels in patients with 
disseminated disease was observed. While application of the markers AFP and hCG resulted in 
about 50% false-negative cases, the TSmiR test showed an overall sensitivity of 98%, and a 
specificity of 48% (control versus tumor) [23]. These findings were validated in a recent 
independent study [24]. 
The studies reviewed above imply that specific miRs are potentially suitable as markers for the 
diagnosis and follow-up of GCC patients. So far however, studies have predominantly been limited 
to selected miR targets. However, other miRs might also be of interest for this application, which is 
the subject of this study. Here, we investigate serum levels of ¨750 miRs in 24 GCC samples and 11 
controls using a high throughput approach to validate the previously identified markers and 
identify novel potential miRs as serum biomarkers for testicular GCC. 
Materials and methods 
Patient samples 
Samples were extracted at the Department of Pathology, Erasmus MC, Rotterdam, the 
Netherlands. Use of tissue samples for scientific reasons was approved by an institutional review 
board (MEC 02.981 and CCR2041). Samples were used according to the “Code for Proper 
Secondary Use of Human Tissue in The Netherlandsa” developed by the Dutch Federation of 
Medical Scientific Societies (FMWVb (Version 2002, update 2011). 35 serum samples were profiled 
for ¨750 miRs. These consisted of serum from 10 patients with NS (2 YS: NS-1/2, 2 TE: NS-3/4, 2 
                                                 
a http://www.federa.org/codes-conduct  
b http://www.federa.org/  
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EC: NS-5/6, 2 EC+YS: NS-7/8 and 2 EC+TE: NS-9/10) and 14 pure SE cases. Controls (C) consisted 
of serum from 3 individuals with normal testis tissue showing adequate spermatogenesis (Johnson 
Score 8-10) (CONTROL-9/10/11) and serum from 8 patients with non-germ cell tumor related 
testicular masses. The latter group contained one epidermoid cyst (CONTROL-1), three epidermis 
cysts (CONTROL-2/3/4), one low grade liposarcoma (CONTROL-5), two neuro-endocrine tumors 
(CONTROL-7) and a case of paratesticular hemorrhage (CONTROL-8). 
miR isolation from serum 
miRs were purified from serum sample using TaqMan® ABC Purification Kit - Human Panel A and 
B (Life Technologies, PN 4473087 and 4473088). All reagents are provided in the kit. These panels 
consist of superparmagnetic Dynabeads® covalently bound to a unique set of ~380 anti-miR 
oligonucleotides for each panel. The miRs in each panel match the miRs in Megaplex™ Pools A 
and B described below. Each panel includes exogenous and endogenous controls. Briefly, for each 
panel 100ul of lysis buffer was added to 50 μl of serum. 2 μl of 1nM of an external control (ath-
miR-159a) was added to monitor the extraction process, followed by the addition of 80 μl of beads 
( 80 X 10^6 beads). The tubes were shaken at 1200 rpm at 30ÜC for 40 minutes then washed three 
times with wash buffer using a magnetic bead separator. The bound miRs were eluted from the 
beads with 100 μl elution buffer and incubation at 70ÜC for 3 minutes. The eluted miR pool was 
stored at -80ÜC until ready to use. 
For miR profiling, Megaplex™ Primer Pools A and B v3.0 (PN 4444750) were used in conjunction 
with their matching TaqMan® MicroRNA Array Cards A and B (PN 4444913). Each Pool contains 
either reverse transcription primers or pre-amplification primers that target 377 unique miRs and 
additional control targets and allows for profiling up to of 754 unique miRs across the two pools. 
Each sample was run separately with Pool A and B according to an optimized protocol for blood 
plasma outlined in the Life Technologies Application Note: “Optimized blood plasma protocol for 
profiling human miRs using the OpenArray® Real-Time PCR System”, 2011, PN 4399721 rev C. 
Reaction volumes, dilutions and the number of pre-amplification cycles were optimized to improve 
sensitivity for miRNA detection in blood serum samples. Briefly, 3 μl of the miR sample that was 
isolated with the ABC kit was reverse transcribed with the Megaplex™ RT Primer Pool A or B in a 
10 μl final volume. The RT reaction was thermal cycled (2 min at 16ÜC, 1 min at 42ÜC, 1 sec at 50ÜC, 
for 40 cycles) and the enzyme was inactivated at 85ÜC for 5 min. The entire RT reaction was 
combined with its matching Megaplex™ PreAmp Primer Pool and TaqMan® PreAmp Master Mix 
(PN 4391128) in a final volume of 50 μl. Pre-amplification was run using the following cycling 
conditions: 10 min at 95ÜC; 2 min at 55ÜC; 2 min at 72ÜC; 15s at 95ÜC, 4 min at 60ÜC for 14 cycles; 
99ÜC for 10 min. The final pre-amplification product was diluted 1:100 in 1X TaqMan® Universal 
Master Mix II; loaded onto the matching TaqMan® MicroRNA Array Card and run on a 
QuantStudio™ 12K Flex System (using a TaqMan® Array Card Block, universal cycling conditions). 
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miR quantification 
Raw data files (.eds) were imported and analyzed in using ExpressionSuite v1.0.4 (Life 
Technologies), a software data analysis tool that can easily import and analyze large raw data files. 
In these experiments the quantification cycle (Cq) is defined as the fractional cycle at which the 
amplification plot crosses the fluorescence threshold (Ct). The baseline was set automatically and 
the threshold was manually set at 0.2. To capture as many differentially expressed miRs as possible 
the threshold was set at 40 instead of 30-32 which is generally recommended by Life Technologies 
for relatively high miR levels. A larger number of replicates or low standard deviation of Ct 
increases the confidence and power of results in this range. Statistical analysis was applied to 
identify the most relevant and consistent (i.e. significant) results. 
Undetermined values were replaced with the maximal number of cycles (40). Non-human RNAs 
were removed from the dataset before normalization. Each assay was treated as an independent 
target. Ct values were normalized using global normalization according to [25]. RNU44, RNU48 
and U6 snRNA were removed from the dataset before further analysis because these have been 
shown to be absent in serum [23]. Batch effects were corrected using Combatc as implemented in 
the svad Bioconductor package (v3.10.0). All raw and processed data is available at GEO (accession 
ID: GSE59520e) 
Software and statistics 
Data was extracted using ExpressionSuite v1.0.4 (Life Technologies/Applied Biosystems). Data pre-
processing was performed in Microsoft Excel 2010 & GenEx 5.3.7.332. Further processing, was 
carried out in R 3.1.0 alpha, 64 bits. The ggplot2f 2.1.0.0 and gplotsg 2.13.0 packages were used for 
visualization. The gplots:heatmap.2 function was used to generate the heatmaps and dendrograms 
using the default settings. To build the randomForesth classifier in R, the implementation according 
to the method of Breiman and Cutler was used (v4.6) because this algorithm also supplies 
information about the importance of the miRs in the classifier besides determining the classification 
strength, does not overfit and is relatively insensitive to the choice of its parameters [26, 27]. 
Comparison of miR levels (dCt) between the tumor and control groups was performed using a 
Mann-Whitney U test. If not otherwise specified, significant differences are indicated by a 
Benjamini-Hochberg adjusted p value of less than or equal to 5% [28]. A median |dCt| of 2 
between the tumor (T) and control (C) groups was considered relevant. 
                                                 
c http://www.bu.edu/jlab/wp-assets/ComBat/Abstract.html  
d http://www.bioconductor.org/packages/release/bioc/html/sva.html  
e http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE59520  
f http://cran.r-project.org/web/packages/ggplot2/index.html  
g http://cran.r-project.org/web/packages/gplots/index.html  
h http://cran.r-project.org/web/packages/randomForest/index.html  
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Results 
This study aims to verify known miR markers for testicular GCC and identify new targets by 
comparing the profile of ¨750 miRs in serum of 14 NS and 10 NS patients with the serum-miR 
profile of healthy individuals and patients with non-GCC testicular lesions (ncontrols=11).  
Discriminative power of the microRNA profiles of GCC 
The discriminative power of the miR profile between GCC (tumor=T=SE+NS) and controls (C) was 
evaluated using principal component analysis (Figure 1). No distinction between SE and NS was 
observed and some of the controls were indistinguishable from the tumors. However, many 
controls were positioned at distance of the tumor cluster. This indicates a difference between T and 
C. A random forest approach was applied to investigate the value of the miR profiles in classifying 
samples as T or C (Table 1). The random forests™ methodi constructs many decision trees using 
bootstrap samples from the original data. For each bootstrap sample a decision tree is trained and 
used to obtain class predictions (T or C) for the unseen samples by taking the majority vote from 
all individual decision trees [26]. In the miR classifier, the estimated misclassification error was 20% 
(out of bag error rate). In the tumor group 8% (n=2) of the samples were misclassified as controls. 
These concerned NS1 (yolk sac tumor, 31 year old male) and SE6 (seminoma). In line with our 
previous findings the sensitivity of the classifier was much higher than the specificity: 91.7% [80.5%-
98.4%] versus 45.5% [21.1-60.2%] (95% confidence intervals between square brackets) [23].  
 
Table 1 Random forest classifier. The number of random variables per tree was set to the square root of the total 
number of variables (miRs) in the dataset. The number of trees was set to 20 times the ratio of [the total number of 
variables / the number of variables per tree] to ensure that each variable is included in several trees. Classification was 
stable when the number of variables per tree was multiplied by 2 or ½ (out of bag error: 20% and 23% respectively). 
C=control, T=tumor (SE or NS). Of the tumors only NS1 (yolk sac) and SE6 (seminoma) were misclassified. 
 Classified as C Classified as T Classification error 
True C 6 5 45% 
True T 2 22 8% 
 
  
                                                 
i http://www.stat.berkeley.edu/~breiman/RandomForests/cc_home.htm#features  
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Figure 1. Principal Component Analysis on serum levels of all miRs. Co=controls, SE=seminoma, NS=non-seminoma. The 
first 2 principal components (PC) explained 24.38% + 9.38% = 33.76 % of the total variance. The third principal 
component explained 6.59% of the variance and did not show any more separation of the sample classes than PC1 and 
PC2 (data not shown). 
 
Figure 2. Differentiating miRs between tumor and control groups. Difference in median dCt between tumor (T: SE or NS) 
and control (C) is plotted against the -log10 of the Benjamini-Hochberg adjusted p-value resulting from a Mann-Whitney 
U test comparing these two groups. An adjusted p<5% was considered significant and a difference in median |dCt| > 2 
was considered relevant. Grey dots, all miRs; green dots: known GCC associated miRs (miR-371-2-3 and miR-302d/367 
clusters). 
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GCC specific miRs in serum 
Following up on the observed differences in global miR-profile between T and C, specific 
differentiating miRs were identified. When comparing the distribution of the serum levels between 
T and C, fifteen miRs showed significant and relevant differential serum levels (Figure 2, left and 
right upper areas). Ten miRs showed higher serum levels in T (4.77-621.29 fold difference). miR-
372 showed the strongest difference (621.29 fold), followed by miR-511 (79.00 fold) and miR-371 
(76.32 fold). miR-372 and -371 are known informative GCC miRs. Five miRs showed higher serum 
levels in C (4.14-147.57 fold difference) (Figure 3A, S1A). Of interest these included the GCC 
specific miR-302c with a moderate 8.83 fold difference. This is in line with the miR-302 family 
showing less consistent results and small differences between patients and controls than the miR-
371-2-3 cluster in previous studies [23]. Even though it is a member of the miR-302 cluster, miR-
367 showed high levels in serum from GCC patients in previous studies [23, 24]. In line with miR-
302c however, miR-367 was expressed moderately lower in tumor than in control cases in the 
current study (पmedian_dCTN-T=-0.88764, p<0.01).  
miR relevance can also be evaluated based on its importance in the decision trees that make up 
the random forest classifier. Between each downstream node (parent-child) in each tree the 
reduction in incorrect classification (impurity) can be estimated. By averaging this value for all 
nodes containing a certain miR, the relative importance of this miR in the total classifier can be 
estimated [26]. Analogous to the fifteen differentially expressed miRs discussed above, the top-
fifteen miRs that contributed strongest to the classifier were selected (Figure 3B, S1B). Two miRs 
overlapped between both approaches: miR-372 and miR-511 (Figure 3, 4). Expression levels of 
miRs previously associated with GCC are shown in Figure 3C and S1C. Most convincing is miR-372 
with very high levels in almost all T samples and low levels in all controls. In the two pure TEs (NS-
3/4) and one EC+TE (NS-9) sample which consisted mainly of TE based on the pathology report, 
miR-372 showed only moderate levels. These samples were therefore clustered with the controls. 
miR-511 was moderately expressed in these samples, in line with the tumor samples. A single 
seminoma sample (SE-12) also clustered with the controls based on low miR-511 expression 
(Figure 4). miR-371 was less consistent and miR-302c showed the aberrant pattern described 
above (Figure S1). Additional differentiating miRs are presented in Figure 3A, 3B, 4A and 4B and 
more details are presented in Table S1 and Figure S1. 
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Figure 3. Fold difference between tumors and controls. (A) Differentially expressed miRs. These miRs are depicted in the 
upper-right and upper-left areas in the volcano plot (Figure 2). Order: fold difference between T and C (decreasing) (B) 
Most important miRs in the random forest classifier. Please see main text. Order: variable importance (decreasing). (C) 
GCC related miRs from previous studies. miR-371-2-3 and miR-302/367 clusters. Order: Genetic cluster. (all) X-axis: 
2^(median C – median T). Positive values indicate higher serum levels in the T group. Y-axis: miRs, prefix “hsa-miR-” is 
omitted. ID after miR name indicates the assay. A/B indicates one of the TaqMan® MicroRNA Array Cards. C: controls. T: 
SE or NS. Overlapping miRs between panels A, B and/or C are indicated in grey. 
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Figure 4. Heat map of the most discriminative miRs. Red=high levels. Green=low levels. CONTROL=sera from controls, 
SE=seminoma, NS=non-seminoma. Details of the histological composition of the NS and CONTROL samples is 
presented in the Materials and Methods section. Detailed heatmaps of all miRs mentioned in Figure 3 are presented in 
Figure S1. 
Discussion & Conclusion 
Serum of 24 GCC cases and 11 controls were profiled with regard to the levels of ¨750 miRs using 
a miR specific magnetic bead purification system followed by profiling with Megaplex Pools and 
TaqMan Array cards. miR profiles did show moderate global differences between tumors (T) and 
control (C) samples (Figure 1). A random forest classifier was able to identify T samples with high 
sensitivity and moderate specificity (Table 1), indicating that the miR profiles include information to 
distinguish between T and C.  
The germ cell cancer specific miRs identified in this study contained a number of earlier described 
miRs. The top differentiating miR between controls and tumors was the embryonic miR-372, in line 
with previous studies, closely followed by its cluster member miR-371 (Figure 2, 3). The absence of 
other previously reported GCC related miRs as well as the aberrant observation that a single GCC 
related miR (miR-302c) was moderately, but relevantly higher in C compared to T is potentially be 
related to very low levels of these miRs in the serum samples. This could be associated with 
selective release of specific miRs into the blood (e.g. 371 > 302c). Also, less sensitive detection in a 
high throughput setting as compared to earlier targeted studies might contribute to these findings 
[19-24]. 
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A number of new differentiating targets was also identified which might be of future interest. Most 
markedly miR-511 was consistently higher in serum samples from GCC patients (Figures 3A, 3B 
and 4). This miR has been reported to have possible tumor suppressing activity in adenocarcinoma 
and modulates tumor associated immune response [29-31]. Other potential targets that showed 
significantly higher levels in T or were important in the classifier included miR-26b, -769, -23a, -
106b, -365, -598, -340 and let-7a (Figure 2, 3A, 3B, S1A, S1B). Enrichment of miR-23a and its 
targets has previously been shown in an integrated genome wide study into GCC gene and miR 
expression, possibly indicating a function of this miR in GCC pathogenesis [32]. miR-23a and miR-
106b have been reported to be related to spermatogenesis in dogs [33] and mice [34].  
Pure TE have previously been shown not to express the embryonal set of germ cell cancer specific 
miRs in tumor tissue or serum from patients (miR-371-2-3 and miR-302 clusters) [18, 22]. It has to 
be kept in mind however that the testis in which the TE is diagnosed might contain CIS and EC 
components which do express these miRs [1-6, 35]. Clustering based on the most differentiating 
miRs (372 and 511) showed consistent clustering of TE samples (NS-3 and NS-4) with the controls, 
although miR-511 showed levels comparable to the tumors. A sample consisting of TE and a small 
EC component also clustered with the controls based on low miR-372 expression (NS-9, Figure 4).  
In contrast however, the two tumor samples that were misclassified as controls in the random 
forest classifier did not concern the TE samples but NS-1 (yolk sac tumor) and SE-6 (seminoma) 
(Table 1). In contrast to tissue findings, our results suggest that TE samples show an overall serum 
expression pattern of all miRs that makes them more similar to GCC than to controls. This is further 
supported by the finding of CIS in at least NS-3 and NS-9 by the pathologist. However, this does 
not contradict the fact that the targeted studies mentioned above as well as this study were unable 
to shown high levels of specific embryonal miRs (miR-371-2-3, miR-302/367) in tumor tissue or 
serum of TE patients. This potentially allows distinction of pure TE cases from mixed tumors 
including a teratoma component based on individual miRs.  
In conclusion, this study shows the discriminative power of miR profiles in separating serum from 
GCC patients and controls. It also validated the strength of members of the embryonic miR-371-2-
3 cluster in detecting GCC, both of the SE and NS subtype. As shown previously, high serum levels 
of miR-371 and miR-372 are predominantly related to the presence of SE and EC. Several other 
discriminating miRs with high serum levels in GCC cases were identified. Targeted validation of 
these novel targets and optimization of the sensitivity of the detection system will be crucial next 
steps. Investigation of differences in miR profile between the various histological components 
would also be of interest, but requires more power. Currently we are also investigating the 
correlation between miR profiles in serum and matched frozen & FFPE tumor samples. 
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CHAPTER 7 
Abstract 
Background: Array based methylation profiling is a cost-effective solution to study the association 
between genome methylation and human disease & development. Available tools to analyze the 
Illumina Infinium HumanMethylation450 BeadChip focus on comparing methylation levels per 
locus. Other tools combine multiple probes into a range, identifying differential methylated regions 
(DMRs). These tools require groups of samples to compare. However, comparison of unique, 
individual samples is essential in situations where larger sample sizes are not possible. 
Results: DMRforPairs was designed to compare regional methylation status between unique 
samples. It identifies probe dense genomic regions and quantifies / tests their (difference in) 
methylation level between the samples. As a proof of concept, DMRforPairs is applied to public 
data from four human cell lines: two lymphoblastoid cell lines from healthy individuals and the 
cancer cell lines A431 and MCF7 (including 2 technical replicates each). DMRforPairs identified an 
increasing number of DMRs related to the sample phenotype when biological similarity of the 
samples decreased. DMRs identified by DMRforPairs were related to the biological origin of the cell 
lines. 
Conclusion: To our knowledge, DMRforPairs is the first tool to identify and visualize relevant and 
significant differentially methylated regions between unique samples. 
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Background 
Epigenetic (de)regulation, including DNA (CpG) methylation, is associated with development, 
differentiation and many human diseases [1-3] including the initiation and progression of various 
cancers [3-8]. While the primary DNA sequence is mostly stable during the lifetime of an individual, 
the epigenome is highly dynamic and responsive. Because of this, it provides valuable information 
about (past) (micro-)environmental conditions in the context of human disease and development 
[9,10]. 
DNA CpG methylation is routinely investigated on a genome wide scale [2,3]. The methylation 
profile can be assessed using micro-arrays or sequencing by applying (1) methylation-sensitive 
restriction enzymes or immunoprecipitation (anti-5mC) or (2) bisulfite-based treatment, which 
converts unmethylated cytosines into uracils [11]. The Illumina Infinium HumanMethylation450 
BeadChip (450 K) is a bisulfite-based, cost-effective, two-color array querying over 480,000 
independent genomic positions (99% Refseq genes, 96% CpG islands) [12-14]. Various tools are 
available to pre-process and analyze the 450 K data, but differential methylation is primarily 
detected per locus or by comparing differential patterns across regions using groups of samples 
[15]. The latter is implemented in IMAa and bumphunterb. Indeed, IMA offers region based analysis 
[16], but it does not work when using unique samples. Bumphunter identifies regional changes in 
the regression coefficient between methylation status and phenotype. Therefore, bumphunter (like 
IMA) requires groups of samples of sufficient size to estimate this coefficient for each probe [17]. 
However, when analyzing small numbers of samples with unique characteristics (e.g. normal and 
affected tissue of a clinically unique patient or a manipulated cell model), large series of samples 
are not available and current methods cannot be applied. Although larger series of samples are 
preferred (biological replicates or more patients), comparison of unique samples is desired in such 
a situation. DMRforPairs was designed to address this problem by comparing regional methylation 
status between unique samples. 
  
                                                 
a http://ima.r-forge.r-project.org/  
b http://www.bioconductor.org/packages/release/bioc/html/bumphunter.html  
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Implementation 
The algorithm consists of a number of phases (Figure 1A) with fully customizable parameters which 
will be discussed below: 
1. Recoding of the probe classes 
2. Identification of regions with sufficient probe density 
3. Quantification and testing of (difference in) methylation status. 
Data import and pre-processing 
As input DMRforPairs requires the methylation percentage of each CpG site in each sample. It was 
originally designed for the 450 K array, but is applicable to any platform that generates a 
methylation percentage per CpG site and has sufficient coverage. For example, Additional file 1 
illustrates the algorithm’s applicability to data generated using Nimblegen microarrays and the 
McrBC protocol (CHARM). DMRforPairs does not provide functions to import, filter (cross-
hybrization, SNPs in probe sequence) or pre-process 450 K data because of the existence of a 
number of excellent, well maintained pre-processing R-pipelines [11,15,16,18-22]. In the package 
documentation examples are provided on how to extract 450 K data for DMRforPairs using the 
lumic, IMAd and minfie pipelines. The output of these pipelines serves as input for DMRforPairs. 
Recoding of the probe classes 
Illumina assigns the majority of probes to eleven specific classes according to their association to 
one or more functional regions (relation to gene: Body, 5'UTR, 3'UTR, 1st exon, TSS1500, TSS200; 
relation to CpG island: Island, Northern/Southern Shelf & Shore [12]). Highly detailed classification 
may result in too low probe density per class as DMRforPairs investigates probes in close proximity 
to each other within each class individually. DMRforPairs therefore allows custom grouping and / 
or selection of classes. Three commonly used schemes are hard-coded in the software: (0) retain 
all eleven classes, (1) group on relation to gene/transcription start site/CpG island or (2) put all 
probes in one class. The last option ignores the assigned classes as it might be desirable to just let 
DMRforPairs identify DMRs without providing information about probes that belong to the same 
functional class. This option can also be used in case this functional classification is unknown. 
  
                                                 
c http://www.bioconductor.org/packages/release/bioc/html/lumi.html  
d http://ima.r-forge.r-project.org/ 
e http://www.bioconductor.org/packages/2.12/bioc/html/minfi.html 
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Figure 1. Flowchart and overview of DMRforPairs results of the Illumina data. (A) The subsequent steps of recoding probe 
classes, identifying regions, quantifying and testing methylation differences and exporting the results are described in 
detail in the main text. Briefly, 473,151 probes remained after quality control. Subsequently, probes not associated to any 
of the 11 classes or not included in any of the regions are discarded. 145,537 probes (35%) were included in 29,404 
potential regions of interest. Finally, these were assessed for methylation differences. (B) Number of regions identified in 
the various pairwise analyses. * = relevant indicates regions with |©M| > 1.4, ** = significant indicates relevant + padjusted  
0.05. “repl.” indicates technical replicates. (C, D) The density plots illustrate the distribution of all/the relevant/the 
significant regions with regard to the number of probes in each region. Only the comparisons of the two cancer cell lines 
(C) and the pair of lymphoblastoid cell lines (D) are depicted as the technical replicates yielded no significant DMRs. 
Identification of regions with sufficient probe density 
A region of interest meets the following criteria: 
1. Neighboring probes lay within dmin bp of each other (default = 200), 
2. The number of probes per region  nmin (default = 4), and 
3. All probes are annotated to the same functional class (please see above). 
Default settings of dmin are based on decreasing correlation between methylation status of adjacent 
loci when evaluated at inter-locus distances between 0 and 1 kb (200 bp is reported to correlate 
well) [11,23]. The default value for nmin is based on the theoretical minimal number of 2x4 
observations required for statistical testing using Mann–Whitney U test. Probes annotated to more 
than one class are included in multiple regions and fully identical regions from different classes are 
merged into one region with a combined class. Figure 2 illustrates the number of regions identified 
for various settings of dmin and nmin and the fraction of all probes included in the regions. A 
function is available in DMRforPairs to generate these benchmarking results for specific data sets 
and tune the settings of nmin and dmin. 
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Quantification and testing of methylation status 
As recommended, the methylation percentage Ǆ and the M-values (logit2(Ǆ)) were used for 
visualization and statistical computations respectively [24]. Descriptive statistics are computed by 
DMRforPairs for all regions and samples (optional parallelization). These consist of median 
methylation levels (M and Ǆ values) and pairwise differences in median methylation level between 
all samples. If the median difference in M value between any pair of samples is sufficiently large in 
a specific region (> |©M|), the difference is formally tested using the Mann Whitney U or Kruskal-
Wallis test. Pairwise testing is performed for more than two samples if indicated (pKruskal-Wallis  0.05). 
An į of 0.05 after adjustment for multiple testing (Bejamini & Hochberg (FDR) [25]) is used to 
select significant regions (default settings). į and the method to correct for multiple testing can be 
specified by the user. 
Several issues need to be kept in mind when choosing the algorithm’s parameters and (test) 
results. In general, setting the algorithm’s parameter more stringently (|©M|द,nminद,dminन)) reduces 
the amount of regions to be tested, but also discards potential DMRs that are less optimally 
covered by the probes on the array. Concerning the |©M| threshold it is important to be aware that 
the default setting (1.4) lies at the upper bound of the range (0.4-1.4) recommended by Du et al. A 
less stringent setting might result in a higher detection rate but reduces the true positive rate and 
increases the amount of multiple testing performed by DMRforPairs [24]. Also, correlation of 
methylation levels of CpG sites located closely together on the genome should be kept in mind. 
The potential presence of correlation warrants careful evaluation of statistical test results related to 
the independency assumption even though methylation levels at specific sites are technically 
(different probes) and biologically (different genomic positions) independent. Finally, comparisons 
with a higher number of probes per region have a higher power and are more likely to survive 
multiple testing. Therefore, the list of significant DMRs is theoretically biased towards regions with 
more probes (i.e. larger sample size). This bias was limited in a comparison of samples which are 
derived from a strongly biologically different origin (Figure 1B, C). When comparing the more 
similar samples (28 DMRs) there was some overrepresentation of regions with a high number of 
probes (Figure 1B, D). 
Visualization, export and exploration 
HTML tables listing all, only relevant (median difference  ©M) and only significant regions are 
generated with links to genome browsers (Figure 3A, application of the R2HTMLf package [26]). 
Links are also provided to images depicting observed methylation profiles and a text file with 
additional descriptive statistics (Figure 3). Pairwise plots are generated in case of more than two 
biological samples. For relevant and significant DMRs an extended output can be generated 
including thumbnails in the HTML tables and visualizations that also depict transcripts annotated 
                                                 
f http://cran.r-project.org/web/packages/R2HTML/index.html  
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(close) to the region (Figure 3C, application of the Gvizg & GenomicRangesh packages [27,28]). In 
addition, DMRforPairs includes a number of functions to further inquire the data. Methylation 
status of genes of interest, regions identified by DMRforPairs and custom genomic intervals can be 
visualized, annotated and quantified/tested. 
 
Figure 2. Tuning of the of dmin and nmin parameters. (A) Number of regions identified and (B) fraction of all probes 
included in these regions using different settings of dmin and nmin. dmin denotes the maximal distance in bp allowed 
between two adjacent probes to be accepted in the same region. nmin denotes the minimal number of probes in a region 
(per sample). All runs of the algorithm were done using the 415,712 probes annotated to at least one Illumina class 
grouped according to gene/transcription start site/CpG island (recode parameter = 1). These benchmark statistics can be 
generated using the tune_parameters function in the algorithm (optional parallelization). 
 
Figure 3. DMRforPairs output. (A) One row of the HTML table describing one DMR. Thumbnail, genomic annotation and 
descriptive statistics regarding (the difference between) the samples are presented as well as links to figures/tables 
illustrating the methylation patterns in the samples in detail. Direct links to the genomic region in two genome browsers 
are also provided (Ensembl & UCSC). Region IDs are generated on the fly by the regionfinder function and are specific to 
a dataset and to a set of DMRforPairs parameters. They are therefore not interchangeable between datasets/experiments 
and serve mainly as identifiers during exploration of the dataset. (B) Methylation level per probe (M and Ǆ values) plotted 
against its genomic position. These plots are generated for all relevant and significant regions. (C) Annotated 
visualization of DMRs (Ǆ values) ±10 kb. Black box indicates the DMR. Transcripts overlapping/near the region are 
retrieved from Ensembl. These plots are optionally generated for all relevant and significant regions. (D) Additional 
statistics (STATS link in table) as provided for each region. 
                                                 
g http://www.bioconductor.org/packages/release/bioc/html/Gviz.html  
h http://www.bioconductor.org/packages/release/bioc/html/GenomicRanges.html  
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Results and discussion 
Dataset 
As a proof of concept, DMRforPairs is applied to a public dataset including two commercially 
available EBV transfected lymphoblastoid cell lines from healthy individuals (NA17105 (African 
American male) and NA17018 (Chinese female), Coriell Institute for Medical Researchi (NJ, USA)). 
The dataset also includes the breast cancer cell line MCF7 [29] and HPV negative squamous-cell 
vulva carcinoma cell line A431 [30,31]. Data is available at Illumina’s websitej [12,13] and was 
processed in GenomeStudio V2011.1 and R 3.0.1 (Windows 7 x64) and 2.15.2 (Redhat Linux x64) 
using Illumina’s annotation manifest (v. 1.1k) . Import and pre-processing was carried out using the 
LUMIl package [19] following the optimized “lumi: QN + BMIQ” pipeline [11]. This includes 
exclusion of poorly performing probes (p < 0.01, n = 713), color adjustment, quantile 
normalization and correction for probe type bias (Infinium I vs II) using the BMIQ algorithm [20]. 
Differentially methylated regions were identified by applying the DMRforPairs algorithm using the 
default settings (Figure 1, dmin = 200, nmin = 4, ©M = 1.4, recode = 1, į = 0.05, correction for 
multiple testing = Benjamini Hochberg (FDR)). The networks/enrichment analyses were performed 
in IPA (Ingenuity® Systems, www.ingenuity.com, Core analysis; default settings). 
Results 
In the Illumina manifest, 12% of the probes were not assigned to any of the 11 categories 
(discarded in this analysis with recode parameter set to 1). 35% of the remaining probes was 
included in one or more regions, leading to 29,404 potential regions of interest. Samples were 
compared pairwise in descending order of biological similarity: technical duplicates, 
lymphoblastoid cell lines and cancer cell lines (average of duplicates) (Figure 1, Additional file 2). 
As expected, no DMRs were identified when comparing the pairs of technical replicates (Figure 1B). 
In the two lymphoblastoid cell lines, 28 DMRs were identified (Figure 1B,D). Fitting with the Chinese 
and African American origin of the cell lines, top DMRs were associated with regions encoding 
human leucocyte antigens involved in immune response and known to be differently methylated 
between populations [32] (e.g. HLA-DRB1 (rank 2), HCG27 (rank 4), HLA-K / HCG4B (rank 7)). 
Enrichment / network analysis in IPA showed significant overrepresentation of genes associated 
with immunological diseases. This concerned various auto-immune diseases and lymphoma (9 
genes, p = 0.000271-0.0293 depending on the subcategory; ACTA1, CHST8, GABR1, HCG27, HLA-
DRB1, IGF2-AS, POU5F1, ZNF165, VTRNA2-1). 
                                                 
i http://ccr.coriell.org/  
j http://support.illumina.com/downloads/genomestudio_software_20111.ilmn  
k http://support.illumina.com/downloads/humanmethylation450_15017482_v12.ilmn  
l http://www.bioconductor.org/packages/release/bioc/html/lumi.html  
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Between A431 and MCF7 2,626 DMRs were identified (Figure 1B,C). On top of the list was 
FAM195A a gene with known low expression [33] and complete methylation in MCF7. In A431, the 
region showed complete demethylation, but no public expression data was available for this cell 
line. The rest of the top-5 consisted of homeobox genes which are frequently methylated in breast 
cancer and active in squamous cell carcinoma [34,35]. Cancer was by far the strongest 
overrepresented disease category in the enrichment / network analysis (989 genes, p = 1.31E-19 - 
2.71E-4). Enriched subcategories included breast cancer (n = 234, p = 2.06E-10), head and neck 
(squamous cell) carcinoma (n = 131, p = 1.30E-7) and genital tumor (n = 192, p = 1.94E-7). 
Conclusions 
DMRforPairs defines genomic regions using local probe density and optionally functional 
homogeneity. It quantifies, tests, annotates and visualizes (differential) methylation patterns 
between unique samples including pairwise comparison of samples if n > 2. Here, it is shown that 
in two lymphoblastoid cell lines from healthy individuals and cancer cell lines A431 and MCF7 
(including 2 technical replicates each), DMRforPairs was able to identify an increasing number of 
DMRs related to the sample phenotype when biological similarity of the samples decreased. DMRs 
identified by DMRforPairs were related to the biological origin of the cell lines. In addition, 
DMRforPairs has been applied successfully in the analysis of integrated genome-wide epigenetic 
and expression profiles of germ cell cancer cell lines [36]. 
Availability & Requirements 
Project home page: bioconductor.orgm or martinrijlaarsdam.nln  
Operating system(s) & programming language: R, platform independent 
Other requirements: R 2.15.2 or higher. Bioconductor packages: Gviz (> = 1.2.1) [27], R2HTML (> = 2.2.1) [26], 
GenomicRanges (> = 1.10.7) [28] and parallel. The lumi [19] package is suitable to import and pre-process 450 K data 
for use with DMRforPairs. 
License: GPLv3, no restrictions to use by non-academics 
  
                                                 
m http://bioconductor.org/packages/release/bioc/html/DMRforPairs.html  
n http://www.martinrijlaarsdam.nl/DMRforPairs/  
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CHAPTER 8 
Abstract 
Background: Originating from Primordial Germ Cells/gonocytes and developing via a precursor 
lesion called Carcinoma In Situ (CIS), Germ Cell Cancers (GCC) are the most common cancer in 
young men, subdivided in seminoma (SE) and non-seminoma (NS). During physiological germ cell 
formation/maturation, epigenetic processes guard homeostasis by regulating the accessibility of 
the DNA to facilitate transcription. Epigenetic deregulation through genetic and environmental 
parameters (i.e. genvironment) could disrupt embryonic germ cell development, resulting in 
delayed or blocked maturation. This potentially facilitates the formation of CIS and progression to 
invasive GCC. Therefore, determining the epigenetic and functional genomic landscape in GCC cell 
lines could provide insight into the pathophysiology and etiology of GCC and provide guidance for 
targeted functional experiments. 
Results: This study aims at identifying epigenetic footprints in SE and EC cell lines in genome-wide 
profiles by studying the interaction between gene expression, DNA CpG methylation and histone 
modifications, and their function in the pathophysiology and etiology of GCC. Two well 
characterized GCC-derived cell lines were compared, one representative for SE (TCam-2) and the 
other for EC (NCCIT). Data were acquired using the Illumina HumanHT-12-v4 (gene expression) 
and HumanMethylation450 BeadChip (methylation) microarrays as well as ChIP-sequencing 
(activating histone modifications (H3K4me3, H3K27ac)). Results indicate known germ cell markers 
not only to be differentiating between SE and NS at the expression level, but also in the epigenetic 
landscape.  
Conclusion: The overall similarity between TCam-2 / NCCIT support an erased embryonic germ 
cell arrested in early gonadal development as common cell of origin although the exact 
developmental stage from which the tumor cells are derived might differ. Indeed, subtle difference 
in the (integrated) epigenetic and expression profiles indicate TCam-2 to exhibit a more germ cell-
like profile, whereas NCCIT shows a more pluripotent phenotype. The results provide insight into 
the functional genome in GCC cell lines. 
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Introduction 
Type II (testicular) germ cell tumors, here referred to as Germ Cell Cancers (GCC), are the most 
common malignancy in Caucasian adolescents and young adults, and their incidence is still rising 
[1-3]. GCC originate from primordial germ cells or gonocytes, and are subdivided into seminomas 
(SE) and non-seminomas (NS), with carcinoma in situ (CIS) of the testis as their common precursor 
lesion[1], also known as Intratubular Germ Cell Neoplasia Unclassified (IGCNU) [3]. In contrast to 
CIS and SE, the stem cell component of NS (i.e., embryonal carcinoma, EC) is characterized by 
pluripotent potential [4]. EC can differentiate into somatic lineages and extra–embryonic tissues 
(teratoma vs yolk sac tumor and choriocarcinoma, respectively), including the germ cell lineage [4]. 
Various clinical, environmental and genetic risk factors for GCC have been identified, although the 
exact role of these factors is not completely clear. Clinical risk factors constitute 
urological/andrological/gonadal aberrations [5-8], while environmental factors focus on endocrine 
disruptors and androgen - estrogen balance [9-11]. Genetic risk factors include a number of 
susceptibility Single Nucleotide Polymorphisms, likely related to early gonadal development [12-
15] and an association with familial predisposition [16]. Somatic mutations are rarely found in GCC 
[17]. There are strong indications that the micro-environment of the developing testis is of 
significant importance in the pathogenesis of GCC. Patients with Testicular Dysgenesis Syndrome 
(TDS) and specific forms of Disorders of Sex Development (DSD) are known to have an increased 
risk of developing GCC due to abnormal gonadal development, i.e. hypovirilization [18]. 
Epigenetic processes have a clear role in both the initiation and protection of pluripotency [19]. 
Deregulation of these tightly controlled processes is known to be involved in the formation and 
progression of various cancer types [20-24], including GCC [25]. During physiological germ cell 
formation and maturation, epigenetic processes (e.g. DNA methylation, histone modifications) 
guard homeostasis by regulating the accessibility of the DNA to facilitate transcription [25, 26]. The 
epigenome is highly dynamic, and changes occur depending on cell type and developmental 
stage, influenced by / reflecting the (micro-) environment. In spite of this knowledge, little is known 
about the role of histone modifications and DNA methylation regarding gene expression in GCC in 
general, and the possible similarities and differences between SE and EC [25, 27]. Epigenetic 
deregulation through genetic and environmental parameters (referred to as genvironment) could 
disrupt physiological embryonic germ cell development, resulting in delayed or blocked 
maturation, thereby facilitating the formation of CIS, and potentially progression to an invasive 
GCC [25, 28-30]. Therefore, determining the epigenetic and functional genomic landscape in GCC 
cell lines could provide insight into the pathophysiology and etiology of GCC. The results could 
provide guidance for targeted functional experiments. 
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In this study, epigenetic footprints of SE and EC cell lines were identified by studying the interaction 
between gene expression, DNA methylation and histone modifications. Two well characterized 
GCC-derived cell lines were used, one representative for SE (TCam-2) [31, 32] and the other for EC 
(NCCIT) [33]. Two types of epigenetic modifications were investigated and related to genome wide 
expression analysis: CpG DNA methylation status, and enrichment of activating histone marks 
(H3K4me3, H3K27ac).  
Methods 
Cell culture 
TCam-2 [31, 32, 34] and NCCIT [33] cells were cultured in DMEM medium (#31966-021, Thermo 
Fisher Scientific / Life Technologies, Carlsbad, CA, USA) containing 10% fetal calf serum (FCS, GE 
Healthcare Life Sciences, HyClone Laboratories, Utah, USA) in T75 cm2 flasks to 75-90% 
confluence. For RNA preparation, fresh medium was added 24 hours before harvest. Cells were 
washed once with Hanks balanced Salt Solution (HBSS, #14175-053, Thermo Fisher Scientific / Life 
Technologies, Carlsbad, CA, USA), and lysed with 7ml of ice-cold RNA-Bee (#Cs-105B, TEL-TEST 
Inc, Friendswood, Texas, USA). For methylation, gene expression (biological duplicates) and ChiP-
seq analyses, different cultures of cells from a single source were used (LEPO lab, Department of 
Pathology, Erasmus MC Rotterdam). Biological replicates were started as independent cultures at 
different days and processed similarly. 
Methylation profiling 
DNA was isolated using the DNeasy kit according to manufacturer’s instructions (#69504, QIAGEN, 
Hilden, Germany). Bisulfite conversion (EZ DNA Methylation Gold Kit, Zymo Research, Irvine, CA, 
USA) and methylation detection was performed at ServiceXS (ServiceXS B.V., Leiden, The 
Netherlands). Illumina’s HumanMethylation450 BeadChip was used (Illumina, Inc., San Diego, CA, 
U.S.A, processing and hybridization according to the manufacturer's instructions). Image 
processing took place on the iScan system and the data was extracted using GenomeStudio, using 
default analysis settings (including background correction and normalization based on internal 
controls) and v1.2a of the annotation manifest. Further processing was carried out in R using the 
LUMIb package [35] following the optimized “lumi: QN+BMIQ” pipeline [36] This includes exclusion 
of poorly performing probes (p<0.01), color adjustment, quantile normalization and correction for 
probe type bias (Infinium I vs II) using the BMIQ algorithm [37]. All raw and processed data files are 
                                                 
a http://support.illumina.com/downloads/humanmethylation450_15017482_v12.ilmn 
b http://www.bioconductor.org/packages/release/bioc/html/lumi.html   
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submitted as a GEO SuperSeries and accessible via GSE56454c. Differentially methylated regions 
were identified using the DMRforPairsd algorithm using the default settings [38]. DMRforPairs is 
available via Bioconductor. Briefly, DMRforPairs defines genomic regions using local probe density 
and optionally functional homogeneity (e.g. all probes in a region should be gene associated). It 
quantifies, tests and visualizes (differential) methylation patterns between unique samples. 
Differences were calculated as NCCIT versus TCam-2.  
Gene expression profiling 
Approximately 20 ǌg of RNA was treated with RNase-free DNaseI (#2238, Ambion, Ambion Inc., 
Austin, TX, U.S.A.) for 30 minutes at 37oC and subsequently purified using the RNeasy mini kit 
(#74104, Qiagen, Hilden, Germany) according to the manufacturer’s instructions. Pure RNA was 
eluted in 50μl of water, and quantified using a Nanodrop (Thermo Scientific). Quality control, RNA 
labeling, hybridization and data extraction were performed at ServiceXS B.V. (Leiden, The 
Netherlands) according to their in-house protocol. Biotinylated cRNA was prepared using the 
Illumina TotalPrep RNA Amplification Kit (#AMIL1791, Ambion Inc., Austin, TX, USA) according to 
the manufacturer’s specifications with an input of 200ng total RNA. Per sample, 750 ng of the 
biotinylated cRNA was hybridized onto the Illumina HumanHT-12 v4 (Illumina, Inc., San Diego, CA, 
U.S.A.) according to the Illumina Manual “Direct Hybridization Assay Guide”. Image processing 
took place on the iScan system and the data was extracted using GenomeStudio (default settings). 
Further processing was carried out in R using the LUMIe package  [35]. Following the guidelines 
presented in [39], robust spline normalization was applied to the log2 transformed intensity values. 
Probes with pdetection>0.05 in >50% of the samples were excluded from the analysis (n=27,964 out 
of 47,323). Average log2 intensities of biological replicates and per gene were used to assess 
expression levels (GEO accession number GSE56454f). Log2 ratios (R) of the average intensities in 
the two cell lines (NCCIT/TCam-2) were used to identify significantly differentially expressed genes. 
Genes with expression levels outside the 99% confidence interval (CI) of this log ratio were 
identified as differentially expressed between NCCIT and TCam-2.  
Histone modification profiling (H3K27ac, H3K4me3) 
The ChIP assay was performed according to the low cell number ChIP protocol from Diagenode 
(Liege, Belgium), with minor modifications. In brief, 1x106 cells were cross-linked for eight minutes 
by addition of formaldehyde to a final concentration of 1%, followed by neutralization with 1.25M 
glycine. The cells were then lysed, and chromatin was sheared to ~500 bp fragments using the 
Covaris sonicator under the following conditions; duty cycle 20%, peak incident power 200 watts, 
                                                 
c http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE56454  
d http://www.bioconductor.org/packages/release/bioc/html/DMRforPairs.html 
e http://www.bioconductor.org/packages/release/bioc/html/lumi.html  
f http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE56454  
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cycles/burst 200, time 5min, temperature 4޴C. Protein A-coated Dynabeads (#10002D, Invitrogen, 
Thermo Fisher Scientific / Life Technologies, Carlsbad, CA, USA) were incubated with 7 μg of the 
following antibodies: H3K4me3 (Diagenode pAb-003-050) or H3K27ac (Ab4729, Abcam, 
Cambridge, UK). The beads were combined with chromatin from 1x106 cells overnight on a 
rotating wheel. The immunobeads were washed, and DNA was purified using the iPure DNA 
purification kit (AL-100-0100, Diagenode, Liège, Belgium) according to manufacturer’s instructions. 
DNA fragments were sheared a second time using a Covaris sonicator (duty cycle 10%, peak 
incidence power 175 watts, cycles/burst 200, time 5 minutes, temperature 4޴C). Massively parallel 
sequencing of ChIP DNA (ChIP-Seq) was performed using the 5500xl SOLiD™ sequencing platform 
(Applied Biosystems, Foster City, CA, USA) at the Monash Health Translation Precinct Medical 
Genomics Facility. The sequencing experiments were single-end with 50nt read length (300nt 
average fragment size). Sequencing reads were aligned to the complete hg19 human genome 
(UCSC version, February 2009) using LifeScope™ Genomic Analysis Software v2.5g. ChIP-Seq 
experimental samples were normalized to a total of 107 uniquely mapped sequencing tags. Data 
was processed in HOMERh ([40]) to detect peaks and motif enrichments using the default settings 
(except “fold enrichment over input”; used 2; threshold for p-value 0.01) (GEO: GSE56454). Peak 
heights from HOMER were corrected for background (lowest peak height detectable). Heights 
were then summed per gene (ƷP) as annotated by HOMER and genes without any detectable peak 
were set to 0. The difference in summed peak heights (©ƷP = ƷPTCam-2-ƷPNCCIT) was used to 
quantify differences between the cell lines. Genes with significantly differential histone modification 
patterns were identified for both marks separately (outside 99% CI of ©ƷP). Association of a peak 
with TSS was used as annotated by HOMER (1kb upstream of the TSS - 100bp downstream). 
MLPA-DNaseI analysis 
MLPA probes were designed following previously described criteria [41]. Based on differential 
modification patterns in NCCIT and TCam-2 probes were designed for the following loci: NCCIT: 
chr3:181425532-181425720, chr5:146699813-146699953, chr3:181577755-181577830, 
chr6:15240050-15240160, chr15:93191596-93191696, chr3:178908801-178908966, 
chr5:101550991-101551125, TCam-2: chr11:10613134-10613220, chr1:201278163-201278251, 
chr12:3091402-3091483, chr19:13985162-13985322, chr2:38323813-38323931, chr9:843018-
843110, chr5:140762378-140762475. MLPA-DNaseI was performed as previously described [42], 
with minor modifications. In brief, nuclei from 1x106 cells were isolated, and treated with a range of 
DNaseI concentrations (0; 2 and 5 Units). Digested genomic DNA was purified, and 50-100 ng was 
used in an MLPA reaction. Following PCR amplification of ligated probes, products were separated 
on an ABI3700 DNA sequencer. Data was analyzed as previously described [43], with a reduction 
to 75% of peak height in undigested DNA used as a threshold for defining DNaseI-hypersensitivity. 
                                                 
g http://www.lifetechnologies.com/lifescope  
h http://homer.salk.edu/homer/chipseq/  
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Software 
Analyses were performed in R 3.0.1 (Windows 7 x64) and 2.15.2 (Redhat Linux x64). The 
networks/enrichment analyses were performed in IPA (Ingenuity® Systems, www.ingenuity.com). 
Genomic positions reported in this manuscript are based on the GRch37/hg19 assembly. 
Results 
To investigate epigenetic characteristics of SE and EC and their relationship to gene expression, 
genome-wide histone modification and DNA methylation patterns were investigated in the cell 
lines TCam-2 (SE) and NCCIT (EC), and matched to gene expression profiles. The differences 
between the two cell lines with regard to histone modification and DNA methylation status were 
first investigated separately. Subsequently, the resulting datasets were integrated to identify 
(target) genes with a strong relationship between primed DNA configuration and higher expression 
levels. 
Histone modification  
Histone modification patterns were assessed using chromatin immunoprecipitation combined with 
high throughput sequencing (ChIP-seq). Data analysis was performed as described in the materials 
and methods section. Alterations in H3K4me3 and H3K27ac were investigated, which are markers 
associated with promoter activation (transcription start site (TSS), H3K4me3 and H3K27ac) and 
enhancer activation (primarily H3K27ac) [44, 45]. In addition to the analysis of (differential) 
modification patterns, motif enrichment of the modified regions was investigated and compared 
between the cell lines.  
H3K4me3 and H3K27ac do not show differential enrichment near transcription start sites and their 
peak heights correlated within genes.  
Depending on the cell line, 10.2/11.3% of the H3K27ac enriched loci were located within 1 kb of a 
TSS against a comparable 14.7/16.8% of the H3K4me3 loci (TCam-2/NCCIT). This is in line with 
observations in other cell types showing that, even though H3K4me3 is directly related to 
promoter activation, a large majority of the H3K4me3 loci are located distally of the TSS [46]. 
H3K27ac has no reported preferential localization to TSS [47]. The level of summed peaks per 
gene (ƷP, see Methods) was used to compare histone modification patterns between the two 
histone marks. There was significant correlation in both cell lines between the peak levels at genes 
where both were present (ǐTCam-2=0.62, pTCam-2<0.001, nTCam-2=1837; ǐNCCIT=0.37, pNCCIT<0.001, 
nNCCIT=746; Spearman’s ǐ). This is in line with their overlapping function: open chromatin 
configuration is associated with both marks [19, 22] and allowed us to combine the histone 
modification results in the subsequent analysis.  
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H3K4me3 and H3K27ac enrichment patterns in TCam-2 and NCCIT are in accordance with known 
SE / EC markers specificity. 
We previously showed that active chromatin modification patterns for SOX17 and SOX2 in the cell 
lines TCam-2 and NCCIT match the expected pattern, based on gene and protein expression and 
histological constitution (SOX17 active in TCam-2, SOX2 active in NCCIT) [25]. In line with this, 
SOX17 and SOX2 were differentially enriched for both H3K4me3 and H3K27ac in TCam-2 and 
NCCIT respectively (Figure 1). OCT3/4 showed no enrichment within the coding sequence, 
however there was enrichment of both markers close to the TSS in NCCIT and TCam-2. This is 
consistent with known OCT3/4 mRNA and protein expression in both cell lines [31, 48]. NANOG 
was more enriched for both markers in TCam-2, in line with differences in expression level (see 
below).  
 
Figure 1. Display of H3K4me3 and H3K27ac tracks for both NCCIT and TCam-2. (A) SOX17, (B) SOX2, (C) OCT3/4 
(POU5F1), (D) NANOG. Arrows indicate direction of transcription. Green boxes indicate markers specific for the 
histological subtype represented by the cell line. Black boxes = no difference between the cell lines; red boxes = not a 
marker for that cell type. Note the different ranges on the y-axis for H3K4me3 and H3K27ac. 
On a genome-wide scale, 29,428 H3K4me3 enriched loci were identified in TCam-2 and 19,015 in 
NCCIT. 25-41% more enriched loci were identified for H3K27ac than for H3K4me3 (nTCam-2=41,569, 
nNCCIT=23,763). Genes with significant differences in summed peak height per gene (©ƷP, see 
Methods) were selected for further analysis. For TCam-2, genes showing differential histone 
modifications were higher in number for H3K27ac (nTCam-2=433, NNCCIT=28). For NCCIT, there were 
substantially more genes selected for H3K4me3 compared to H3K27ac (nTCam-2=215, NNCCIT=325). 
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For both marks, 86 / 11 genes overlapped between top differentiating lists in TCam-2 and NCCIT 
respectively. These included the SE marker SOX17 in TCam-2 and the EC marker SOX2 in NCCIT 
(Figure S1, Table S1). Functionally, the gene lists of both cell lines showed significant enrichment 
for (embryonic) stem cell maintenance/pluripotency (Table S2). Enrichment of biological functions 
in TCam-2 indicated similarity to more mature germ cells, which was lacking in the list of NCCIT 
(GO categories TCam-2 included development of normal testis morphology and germ cell 
maintenance). Moreover, two germ cell-specific canonical pathways IGF1 signaling (logp=3.42) and 
germ cell-Sertoli cell Junction Signaling (logp=2.11)) showed enrichment. In TCam-2, two functional 
networks were identified incorporating the AR pathway and lipid metabolism (Table S2). 
Germ cell markers AP-2į and AP-2ǅ are top enriched motifs in TCam-2, while embryonic stem cell 
specific motifs SOX2/OCT4 /TCF/NANOG are enriched in both cell lines. 
Significantly enriched motifs were identified for each cell line and histone mark (HOMER tool, see 
Methods). There was strong overlap between the top-ranked enriched motifs in NCCIT and TCam-
2. This was true for both activating markers. For example, for H3K4me3 the top enriched motif was 
MAZ for both TCam-2 and NCCIT, a transcription factor associated with MYC (binds to two sites in 
its promoter) and known to be involved in transcription initiation as well as termination [49] (Figure 
2A,B; Table S3).  
A limited number of markers showed differences in enrichment between the cell lines (Figure 2C, 
2D, Table S3). For H3K4me3, five motifs were identified which showed sufficient difference. Four 
were higher ranked in TCam-2 and one higher in NCCIT. The top ranked TCam-2 motifs presented 
in this differentiating list were EBF1 (role in developmental processes), AP-2į and AP-2ǅ (known 
germ cell markers) and OCT4/SOX2/TCF/NANOG (pluripotency motif). For NCCIT, E2F1 (cell cycle 
control, action of tumor suppressor proteins, cell proliferation) was ranked higher. For H3K27ac, 
there were four differentiating motifs, of which three were ranked higher in TCam-2 and one 
higher in NCCIT. The OCT4/SOX2/TCF/NANOG motif was the most significantly enriched motif for 
H3K27ac in NCCIT (ranked 20 in TCam-2). This motif is known to be predominantly enriched in 
embryonic stem (ES) cells [50] as well as embryonic germ cells, which is in line with the stem cell-
like origin (EC) of NCCIT and the germ cell-like origin of TCam-2 respectively. Moreover, for 
H3K27ac, AP-2į and AP-2ǅ were ranked as 3rd and 4th most enriched motif in TCam-2 (compared 
to 29th and 31st in NCCIT) reflecting their (embryonic) germ cell origin (Figure 2C,D). For ES cells 
the enrichment rankings for these two motifs were 87th and 105th [50]. These observations fit with 
the proposed more differentiated (germ cell lineage) cell of origin of SE as compared to EC [28], 
and are in line with the findings of related histone peaks (see Discussion section). 
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Figure 2. Motif enrichment in histone modification data. All motifs were significantly enriched in target over background 
sequences (p<0.01). Fold enrichment is indicated relative to background. (A,B) Top ranking motifs in both cell lines 
showed strong overlap (top 10). (C,D) Motifs that differed strongly between the cell lines with regard to their enrichments 
were selected. A motif was assessed favorably if its ranking was high (20) for one cell line and low for the other cell line 
(or was absent in the other list of enriched motifs). Score: The difference in ranking was assessed based on the difference 
in relative position in the list ( |1-(rTCam-2/nTCam-2) – 1-(rNCCIT/nNCCIT)|  15%, n=nr of enriched motifs, r is the rank of a 
specific motif in the list of enriched motifs for either cell line).  
160
GENOME-WIDE EPIGENETIC FOOTPRINTS OF GCC CELL LINES 
 
 
Verification of the H3K4me3 & H3K27ac enrichment-based open chromatin configuration was 
independently confirmed using DNaseI-hypersensitivity. 
As the investigated chromatin marks (H3K4me3 & H3K27ac) are considered to be associated with 
active chromatin, we explored whether their presence was associated with another characteristic of 
active chromatin: DNaseI-hypersensitivity [51]. Using a DNaseI-MLPA approach [43] we targeted 
14 regions which showed the greatest differences in either H3K4me3 and/or H3K27ac enrichment 
between the same two cell lines. Six of seven enriched regions in NCCIT (Figure S2A: 
N1,N2,N3,N4,N6,N7), and five of seven enriched regions in TCam-2 (Figure S2B: S1,S2,S5,S6,S7), 
showed significant DNaseI-hypersensitivity in the respective cell lines. In contrast, only one 
H3K27ac-negative locus in NCCIT (Figure S2A, S1), and no H3K27ac-negative loci in TCam-2 
(Figure S2B), showed DNaseI-hypersensitivity. 
CpG Methylation 
The DMRforPairs algorithm was used to identify differentially methylated regions (DMR) [38]. The 
algorithm was set to detect strong differences, i.e. using stringent settings. Regions containing a 
minimum of four probes within 200 bp distance of each other were considered for further analysis 
(n=30,306). Regions in which median methylation levels (M-values) between the samples differed 
at least |1.4| (n=5,139) were tested for statistical significance (significant: p<0.05; Bonferroni 
adjusted, Wilcoxon-rank-sum test, n=143) (Output DMRforPairs: File S1). 
Methylation patterns at DMRs are in line with marker positivity in SE and EC. 
Because of the activating histone modifications investigated, we focused on hypo- or absence of 
DNA methylation. Global methylation levels were in line with the hyper- and hypomethylated 
global status of NS and SE respectively, and the previously shown intermediate status of TCam-2 
(Figure S3) [52, 53]. After DMR identification using DMRforPairs, a total of 99 DMRs (annotating to 
170 unique gene symbols) were hypomethylated in TCam-2, compared to 44 in NCCIT (annotating 
to 64 unique gene symbols) (Table S1). In line with the histone modifications (see above), the SOX2 
promoter region was found to be strongly hypomethylated in NCCIT (Figure 3A). SOX2 was partly 
methylated in TCam-2, in line with findings illustrating that TCam-2 can differentiate and become 
SOX2 positive after extra-gonadal injection in mice [54]. A 220bp region directly upstream of the 
TSS of SOX2 (chr3:181429712) has previously been shown to be completely hypomethylated in 
TCam-2 [55]. This is in line with our findings as a consistently hypomethylated region 
(chr3:181429233-181430485) is shown directly upstream of the TSS while a 652bp long DMR 
(chr3:181428046-181428697) between NCCIT and TCam-2 is detected by DMRforPairs in a region 
ca. 800bp upstream of the region sequenced by Nettersheim et al. SOX17 did not show a 
significant differential methylation pattern, indicating that it is, in principle, accessible for 
transcription in both cell types (Figure 3B). Indeed, SOX17 expression can be induced in NCCIT 
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(unpublished observation). In line with known gene expression in both cell lines, OCT3/4 showed 
an inconsistent, but non-differential methylation pattern (Figure 3C). The TSS of NANOG was 
hypomethylated in both cell lines (Figure 3D), in line with the expression data and previous reports 
[56]. In the list of top DMRs, the miR-371/2/3 cluster stood out by significant differential 
hypermethylation in NCCIT (Figure 3E). The promoter region of GATA4 was significantly 
hypermethylated in TCam-2 (Figure 3F). In general, 33% (47/143) DMRs were annotated to TSSs 
(File S1, according to Illumina’s manifest) which is similar to the fraction of TSS associated regions 
identified by DMRforPairs (12,652/30,306). Functionally, the DMR list of both cell lines showed 
enrichment for (embryonic) stem cell maintenance/pluripotency. Biological functions indicating 
similarity to more mature germ cells were enriched in TCam-2 (Table S2).  
 
 
 
 
Figure 3. Methylation patterns of known germ cell markers (A-D) and significant DMRs for both cell lines (E, F). Dots 
depict individual CpGs and black boxes denote DMRs identified by DMRforPairs. Percentages below indicate average CG 
density in the plotted regions (calculated using the Repitoolsi R package, gcContentCalc function). (A) SOX2 [44%], (B) 
SOX17 [46%], (C) OCT3/4 (POU5F1), [52%] (D) NANOG, [44%] (E) miR-371/2/3 cluster, [49%] (F) GATA4 [53%].  
                                                 
i http://www.bioconductor.org/packages/devel/bioc/html/Repitools.html  
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DMRs were significantly enriched for imprinted genes, and 59% (51/86) of all imprinted genes 
showed loss of methylation around their TSS in one or both cell lines.  
From the list of verified imprinted human genes (n=88 retrieved from geneimprint.com), 82 were 
also annotated in Illumina’s manifest (total of 21,243 unique gene symbols annotated) and 10 were 
present in the top DMRs between TCam-2 and NCCIT. This overrepresentation of imprinted genes 
in the list of DMRs was significant (p<0.0001, Ǔ2 test). When investigating the region surrounding 
the TSS of the 86 imprinted genes with known genomic localization, 14 showed a differential status 
between the cell lines (8 / 6 hypomethylated in NCCIT and TCam-2 respectively). In total, 37 
imprinted genes displayed a hypomethylated status in both cell lines, compared with 12 
hypermethylated genes (Figure 4). In summary, these results indicate an overall erased status of 
the imprinted regions in both cell lines. Regarding genes with a differential methylation status, 
there is no clear difference in number of hypermethylated genes that would indicate a difference in 
maturation status or environmental disruption. 
Expression 
Expression levels of markers matched histological origin of both cell lines. 
In total, 257 genes were expressed higher in TCam-2, compared to 149 in NCCIT (Table S1). 
Greater than 3.65 fold difference in expression level (99% confidence interval (CI) of log2-ratio of 
intensities) was considered significant. The expression levels were in agreement with the 
classification of the cell lines: SOX17 was higher in TCam-2 compared with NCCIT, with the 
opposite observed for SOX2[57] (Figure 5). OCT3/4, a general marker for the stem cell 
components (SE/EC) of GCC, was expressed at equal levels in both cell lines. NANOG was 
expressed higher in TCam-2, which is in line with the open histone configuration (Figure 1D, 
transcription possible in both cell lines). Functionally, the gene lists of both cell lines showed 
enrichment for (embryonic) stem cell maintenance/pluripotency, and Wnt/Ǆ-catenin signaling. 
Enrichment of biological functions consistent with more mature germ cells was present in TCam-2, 
and absent in NCCIT. In addition, network analysis revealed the androgen pathway in TCam-2, 
represented by both the AR and testosterone, thus showing major overlap between the networks 
found by genes that had differential histone modification patterns (Table S2). 
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Figure 4. Methylation patterns in promoter regions of imprinted genes. Localization of TSS was retrieved from 
ensembl.org and manually corrected for genes with multiple transcripts to select a region with representative coverage 
on the Illumina BeadChip (nprobes varied between the genes: median=10, inter-quartile range 6-21). Promoter region was 
defined as TSS-1000 – TSS+100 (or opposite on reverse strand). Genes with > 0.25 difference in median Ǆ and a 
consistent (stable) methylation pattern were identified as differentially methylated at the TSS between the two cell lines. 
Median methylation <25% for both cell lines was interpreted as a hypomethylated state in both cell line. Median 
methylation >75% was interpreted as hypermethylation. No probes were annotated around the TSS of TCEB3C (M), 
RNU5D (P), SNORD108 (P), SNORD109A (P) and SNORD109B (P). SANG and GNAS-AS1 are known aliases but separate 
entities on geneimprint.com and are depicted separately to preserve consistency. P=paternally imprinted/expressed, 
M=maternally imprinted/expressed, I=isoform-dependent imprinting. 
 
Figure 5. Expression levels of known GCC markers match the histological subtype from which the cell lines originate. 
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Integration of epigenetic and expression data 
Differential gene lists from histone modification, methylation and expression data showed limited 
overlap. 
Differentiating gene lists from the separate analyses discussed above were matched based on 
Gene Symbol to assess the relationship between active histone modifications, the absence of CpG 
methylation and gene expression. Overlap between gene expression and one of the epigenetic 
regulatory mechanisms is of interest as expression of a specific gene does not need to be 
regulated by both mechanisms. Figure 6 shows the overlap of the different variables for the 
differentiating gene lists between TCam-2 and NCCIT. In general, little overlap between relative 
hypomethylation / histone marker enrichment and relatively high expression is observed, but this 
overlap was significant (Figure S4). In TCam-2, one gene, PRAME, was present in all three 
differential lists. H19 and CHCHD5 were differentially hypomethylated in TCam-2 and showed high 
expression compared to NCCIT, but no differential enrichment for H3K27ac or H3K4me3. There 
were 62 genes with overlapping active chromatin marks and expression, including SOX17 and 
NANOG. In NCCIT, three genes showed overlap between the histone marks, hypomethylation and 
expression. Significantly, one of these genes was SOX2. An additional 18 genes showed overlap 
between active chromatin marks and expression. 
 
Figure 6. Overlap between top differentiating genes (methylation/histone modification/gene expression). (Hypo) 
methylation, (high) gene expression and histone marker (enrichment) should be interpreted relative to the other cell line. 
Criteria for selection are described in the main text. Briefly, significant differential methylation of regions with sufficient 
probe density was identified by DMRforPairs (frequently, but not necessarily close to, the TSS). The difference in histone 
modification enrichment was assessed by significant differences in summed peak heights between the cell lines. Finally, a 
fold difference of 3.65 (boundary of 99% CI) was used as cutoff for differential gene expression. Gene lists are presented 
in Table S1, and overlap was determined based on matching gene symbol. 
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Enrichment of both histone marks in general and absence of DNA methylation around the TSS is 
related to higher expression levels. 
Higher expression levels are present when genes are more enriched for either histone mark. 
Quantification of the fraction of genes with higher than median expression at various intervals of 
summed peak heights confirmed the general trend towards higher expression at higher levels of 
enrichment (Figure 7A). DNA methylation levels were only correlated to expression around the 
TSS: a fully methylated TSS is predominantly associated with low gene expression levels while low 
methylation status is not predictive of expression level (Figure 7B). 
 
Figure 7. (A) Relation between histone modification level (summed peak heights per gene) and expression level. Top and 
bottom right images depict the percentage of highly (>p50) expressed genes calculated for an interval of summed 
peaks. For example, 5% of genes with a log2(summed peak height) of ¨5.5-7.5 were highly expressed. (B) Relation 
between CpG methylation (TSS/no TSS) and gene expression. 
NCCIT and TCam-2 show a largely overlapping epigenetically open network with specific elements 
that are differentially regulated based on cell type. 
Histone modification, methylation and gene expression data were analyzed together using 
hierarchical clustering. This unsupervised clustering procedure revealed specific groups of genes 
with a profile poised for transcription. These gene clusters showed active histone marks, combined 
with an activating methylation landscape and are hypothesized to contain genes accessible for 
transcription (e.g. epigenetically ON=transcription possible, Figure 8). Functionally, the ON network 
for both cell lines showed a large degree of overlap (related to the androgen pathway, lipid 
metabolism and pluripotency) (Table S2). There was considerable overlap between the genes 
found in this separate analysis and the differential gene lists (Figure 6, overlap indicated by gene 
symbols in Figure 8).  
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Figure 8. Heat map of epigenetic markers and gene expression profiles. Genes with quantified methylation status around 
their TSS (based on Illumina annotation) and valid (see Materials & Methods) measurement of their expression level were 
included (n=11,620). Log-2 summed peak heights per gene were used as an estimate of histone marker enrichment. 
Variables scaled between 0 and 1. Hierarchical clustering was performed using complete linkage. Clusters of interest 
were identified based on a consistent enriched state for one or more of the active histone markers and a 
hypomethylated state around the TSS. Number of genes in the displayed right panel (zoomed in heat maps, 
topÆbottom): 899/892 (TCam-2) and 1,224/37/308 (NCCIT). Gene expression was allowed to vary within clusters, but 
clusters with almost absent expression levels (completely red) were not selected. Gene symbols indicate genes that 
overlap with the analysis of top differentiating genes between the cell lines (Figure 6). Gene symbols are listed 
alphabetically. An indication of the level for each gene in each column is presented by the color/shade and a blue line 
(for each column: left=0, right=1). 
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Discussion 
Histone and DNA methylation signatures were studied to explore the epigenetic differences 
between representative cell lines for the GCC histological subtypes and their relation to expression. 
TCam-2 and NCCIT cells were used as representatives of SE and EC respectively. Our study 
includes the generation, integration and interpretation of genome-wide profiles for histone marks 
(H3K4me3 and H3K27ac), DNA methylation and gene expression. H3K4me3 and H3K27ac are 
well-characterized markers for active promoter and enhancer sites, respectively. Analysis of the 
histone marks matched the classification of the cell-lines: SOX17 was strongly enriched for 
H3K4me3 and H3K27ac in TCam-2 compared to NCCIT cells, whereas the opposite pattern was 
observed for SOX2. Motifs for germ cell-specific transcription factors AP-2į/ǅ were enriched in 
TCam-2, but not in NCCIT. Methylation profiling showed SOX2 to be in the top DMRs, being more 
methylated in TCam-2 as expected. In addition, SOX2 and SOX17 expression levels confirmed and 
matched the previously described patterns in SE and EC [2]. General SE/EC markers (NANOG and 
OCT3/4) showed expression patterns compatible with their epigenetic configurations [58]. 
Moreover, imprinting patterns confirm the suggested overall erased status of genomic imprinting 
in both cell lines, in line with the situation in early germ cells [59]. 
The cell lines were studied for their differences with regard to epigenetic marks and expression. In 
line with the early germ cell origin of both cell lines (NCCIT more stem cell-like than TCam-2) 
canonical pathways related to stem cell maintenance and regulation were significantly 
overrepresented for all three variables studied (NCCIT more pronounced than TCam-2). In TCam-2 
(differential histone modification) there was strong overrepresentation of genes involved in IGF1 
signaling, a pathway that is implicated in maintenance of spermatogonia [60]. Moreover, genes 
involved in germ cell – Sertoli cell junction signaling were significantly overrepresented in this cell 
line, fitting with a more mature type of germ cell depending on the Sertoli cell niche [2]. In the list 
of top DMRs, the miR-371/2/3 cluster stood out by significant differential hypermethylation in 
NCCIT. These miRs have shown to be specific biomarkers for GCC in serum and tumor tissue [61-
65]. Even though GCCs are reported to express these embryonic miRs [63, 66, 67], NCCIT has 
been shown to exhibit low expression levels due to the absence of a functional TP53 pathway (i.e. 
lacking the need to inactivate this pathway by miR-372/3 expression via LATS2 inhibition) [67]. 
Pathway analysis using IPA revealed a network including the androgen receptor (AR) and 
testosterone targets enriched for open chromatin configuration marks in TCam-2. Such enrichment 
was also identified based on the expression data of TCam-2, and to a lesser extent in NCCIT. 
Despite of this observation, no differential AR expression was present between the cell lines, and 
no enrichment of DMRs in AR targets was identified. Future experiments are needed to validate the 
differential role of the AR pathway between NCCIT and TCam-2 and their in vivo counterparts.  A 
second network was closely related, focused on lipid metabolism (LEP central, late germ cell 
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differentiation and survival [68]). Androgens are well-known environmental and physiological 
factors that influence epigenetic marks and phenotypes. They are related to GCC risk and are 
considered to be crucial for the progression of germ cell development [28] Ammerpohl et al. 
found significant enrichment of hypermethylated AR target genes in androgen insensitivity 
syndrome (AIS) patients versus controls [69]. This is consistent with earlier reports that diminished 
gene activation (due to an AR mutation) results in subsequent increased DNA methylation of 
target genes [70, 71], linking DSD and GCC at the epigenetic level.  
On the other hand, functional analysis for NCCIT predominantly revealed genes involved in 
embryonic stem cell maintenance (less pronounced in TCam-2). More specifically, an interaction 
between SOX2 and DMRT1 was the most important network identified. Both are involved in stem 
cell maintenance in embryonic (mouse) germ cells [28]. It has been reported that Dmrt1 can bind 
the mouse Sox2 promoter, and Dmrt1 controls expression of Sox2 and other pluripotency genes 
(such as Nanog and Oct3/4) in the embryonic testis, in part via transcriptional repression [72]. In 
addition, DMRT1 has a role in sex determination, as it prevents female reprogramming in the 
postnatal mammalian testis [73]. A study by Murphy et al confirmed the influence of DMRT1 on 
SOX2 expression while no change in expression of SOX17 was observed [74]. However, these 
observations in mice are not necessarily representative for the human situation. No consistent 
networks related to progression of germ cell differentiation (as with AR in TCam-2) were identified 
in NCCIT.  
As stated above, motif enrichment based on the histone modification data showed that the AP-2į 
and AP-2ǅ motifs were enriched in TCam-2 only. The ETS family was enriched in both TCam-2 and 
NCCIT. AP-2ǅ is a known germ cell marker, abundantly expressed in CIS and SE, and 
heterogeneously expressed in NS and somatic tumors [75, 76]. AP-2ǅ and KIT are co-expressed in 
gonocytes [76], which could point to a direct regulation loop which supports proliferation, and 
agrees with the observation that TCam-2 is more germ cell-like than NCCIT. AP-2ǅ would then 
serve as a molecule that keeps fetal germ cells in a pluripotent state by suppressing differentiation 
and supporting proliferation [76, 77]. AP-2ǅ expression is induced by estrogens [78] and AP-2į 
and AP-2ǅ are able to induce changes in the chromatin structure known to be associated with ERį 
(ESR1) transcription [79]. The importance of the androgen-estrogen balance is also indicated by 
the strongly androgen/estrogen-centered gene networks identified in this study. Additionally, the 
ETS family was present in the top motif enrichments for both TCam-2 and NCCIT. Recently it was 
shown that overexpression of ETS, combined with loss of PTEN, increases AR binding and restores 
AR transcriptional activity in prostate [80]. Indeed, disruption of the PTEN pathway has been 
suggested to be part of the pathogenesis of GCC [81].  
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Conclusions 
In conclusion, this study provides an integrated analysis of the functional genome in GCC cell lines. 
Our data show that known germ cell markers are not only present and differentiating between SE 
and NS at the expression level, but also in the epigenetic landscape. The overall similarity between 
TCam-2 / NCCIT support an erased embryonic germ cell arrested in early gonadal development as 
common cell of origin although the exact developmental stage from which the tumor cells are 
derived might differ. Indeed, subtle difference in the (integrated) epigenetic and expression profiles 
indicate TCam-2 to exhibit a more germ cell-like profile, whereas NCCIT shows a more pluripotent 
phenotype. Future research has already been initiated to investigate primary cancer samples from 
patients to confirm and further expand the integrated epigenetic EC and SE footprints identified in 
this study. 
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Supplementary information 
Figure S1. Number of top differentially modified regions between TCam-2 and NCCIT, and their overlap between 
H3K27ac and H3K4me3 based on associated genes. Genes with significant differences (outside 99% confidence interval) 
in summed peak height per gene (©ƷP) were identified as top-differentially modified. 
Figure S2. Normalized ratios for each of the 14 loci tested in the MLPA-DNaseI assay. A threshold of < 0.75 was defined 
for DNaseI-hypersensitivity. N=enriched in ChIP-seq analysis in NCCIT (non-seminoma cell model), S=enriched in ChIP-
seq analysis in TCam-2 (seminoma model). (A) Analysis of NCCIT cells. (B) Analysis of TCam-2 cells. (C) Overview of loci 
and interpretation of results. DNaseI hypersensitivity is indicated if present in the cell line in which marker enrichment was 
also found in the ChIP-seq analysis. 
Figure S3. Visualization of global methylation patterns in both cell lines. Depicted is a violin plot of the distribution of 
methylation values (Ǆ) for both cell lines. In general, NS are considered globally hypermethylated in comparison to SE but 
TCam-2 is known to show an intermediate phenotype with regard to global methylation status (see Wermann et al 2010 
and Netto et al 2008 in reference list). Indeed, significantly lower methylation levels were detected in TCam-2 but the 
quantitative difference in methylation distribution was very moderate (p<0.01, Mann Whitney U test, medianɴ (1stͲ3rd
quantileɴ): 51%TCam-2 (46%-84%) versus 63%NCCIT (58%-87%)).  
Figure S4. Venn diagrams analogous to Figure 6 corrected for gene symbols that are not represented by valid 
measurements in the expression or methylation data (histone modification = genome wide assessment). NCCIT: 33 
genes differentially methylated were not annotated in the expression data. 17 overexpressed genes were not annotated 
in the methylation data. 97 genes showing differential histone modifications were not present in the expression or 
methylation data. For TCam-2 these numbers were 101/28/198. Based on an empirical probability distribution we 
assessed random overlap using 10,000 draws from simulated genelists with nexpression (EXPR)=14,525, nhistone-modification 
(HM)=22,000 and nmethylation (MEHTY)=21,243 genes. These numbers correspond with the number of genes with valid 
measurements on the arrays (histone modification: genome wide proxy). Significant overlap indicates more overlapping 
genes identified in these venn diagrams than would we expected based on random subsets of genes. Significant overlap 
is indicated with a * (p<0.05). p-values TCam-2: pEXPR_HM = <0.0001, pEXPR_METHY = 0.0370-0.1604, pHM_METHY = 0.3229-
0.6860, pall3 = 0.0003-0.0167. p-values NCCIT: pEXPR_HM = 0-0, pEXPR_METHY = 0.0001-0.0007, pHM_METHY = 0.3110-1.0000, 
pall3 = <0.0001. (P-values are ranges if in the repeated random draws used to construct the empirical cumulative 
distribution function a specific count of overlapping genes occurred more than once.) 
Table S1. Top differentiating genes in histone modification, CpG methylation and gene expression analyses. 
Table S2. Results of IPA / functional analysis of (differentiating) gene lists. IPA was performed using the default settings 
including “testis” as specific tissue of interest, and only incorporating experimentally observed evidence. Green fill 
indicates overlap between TCam-2 and NCCIT. Reported log(p) values are the result of IPA’s internal enrichment tests. 
Table S3. Detailed results of motif enrichment analysis (HOMER) per cell line and per histone mark. 
File S1. ZIP file containing DMRforPairs output for significant regions. Please start from the html files.  
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CHAPTER 9 
Abstract 
The cell of origin (CoO) of the five subtypes of germ cell tumors (GCT,I-V) are assumed to be germ 
cells from different maturation stages. This is (potentially) reflected in their methylation status as 
fetal maturing primordial germ cells are globally demethylated during migration from the yolk sac 
to the gonad. Imprinted regions are erased in the gonad and later become uniparentally imprinted 
according to fetal sex. Here, 91 GCTs (I-IV) and four cell lines were profiled (Illumina’s 
HumanMethylation450 BeadChip). Data was pre-processed controlling for cross hybridization, 
SNPs, poor detection rate, probe-type bias and batch effects. The annotation was extended, 
covering snRNAs/microRNAs, repeat elements and imprinted regions. A Hidden Markov Model-
based genome segmentation was devised to identify differentially methylated genomic regions. 
Methylation profiles allowed for separation of clusters of non-seminomas (type II, NS), 
seminomas/dysgerminomas (II, SE/DG), spermatocytic seminomas (III, SS) and teratomas/dermoid 
cysts (I, TE/IV, DC). SE/DG/SS were globally hypomethylated, in line with previous reports and the 
demethylated state of their precursor. Differential methylation between subtypes reflected the 
presumed CoO as did imprinting status. Ovarian type I TE and DC: (partial) sex specific uniparental 
maternal imprinting. SS: uniparental paternal imprinting. Testicular TE: partial imprinting erasure. 
Somatic imprinting in type II GCT may indicate an earlier CoO than previously described: after 
global demethylation but before imprinting erasure. This is in line with the totipotent/embryonic 
stem cell like potential of type II GCTs and rare extra-gonadal localization. The results support the 
common origin of the type I TEs  and show strong similarity between ovarian type I TE and DC. In 
conclusion, we identified specific and global methylation differences between GCT subtypes, 
providing insight into the developmental timing and underlying developmental biology of GCTs 
and their CoO, relating them closely to (early) developing embryonic germ cells. Data and 
extended annotation manifest deposited at GEO:GSE58538,GPL18809. 
 
 
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Introduction 
During fetal development primordial germ cells (PGC) migrate from the yolk sac, via the hindgut to 
the genital ridge and enter the gonad where they undergo further maturation into the sex specific 
lineage, i.e. oogonia for females and spermatogonia for males. During migration and maturation 
an epigenetic “reset” takes place. This includes global DNA CpG demethylation during the early 
phases of migration. Specific areas like imprinted regions remain methylated until the PGCs arrive 
in the developing gonads where imprinting is subsequently gradually erased. After these maturing 
gonadal germ cells reach mitotic (male) or meiotic (female) arrest, de novo methylation is initiated 
and uniparental sex specific imprinting is acquired [1-8]. Another informative marker of 
developmental stage is X chromosome reactivation which occurs in female germ cells before the 
initiation of oogenesis. Studies report varying results regarding the exact timing of the various 
steps of the epigenetic reset, i.e. during migration or after arrival in the gonads. However, PGCs 
with an XX chromosomal constitution have been shown to lack X chromosome reactivation if they 
never reach the gonad [9-12]. For ethical reasons, most of these data have been experimentally 
investigated and validated in mice. Even though germ cell development differs between mice and 
men [13], methylation patterns during germ cell development are reported to be highly similar [14, 
15].  
Germ cell tumors (GCT) originate from germ cells at different developmental stages and are 
thought to inherit their methylation profile from their ancestors. The WHO classification supports 
five GCT subtypes. Each subtype has specific molecular, clinical and histopathological properties 
[16-19]. GCT subtypes have been put in context of normal germ cell development (Figure 1A) 
based on gene/microRNA expression, (targeted) epigenetic analysis and genomic constitution as 
described  below and reviewed extensively elsewhere [13, 16, 17, 20-22]. Most of these studies 
were targeted at specific genes/genomic regions or concerned a subset of the GCT subtypes only, 
most prominently type I or II.  
Type I (“infantile”) GCTs manifest clinically as teratoma (TE) and/or yolk sac tumor (YS) along the 
migration route of developing PGCs, i.e. the midline of the body. Extra-gonadal, sacral TEs occur 
most frequently and are mostly benign. Typically these rare tumors (incidence 0.12/100 000) arise 
before the age of 6 and no Carcinoma In Situ (CIS, see below) is found. They show global 
methylation patterns that are reminiscent of their embryonic stem cell progenitor (i.e. bimodal with 
modes at ¨0 and ¨100% methylation). These tumors showed somatic/biparental (¨50%) 
imprinting status in earlier studies. Therefore, type I GCTs have been suggested to originate from 
PGCs at an early stage, prior to global demethylation and imprinting erasure [16-18, 23-25].  
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Å Figure 1. Tumor types/samples and cell lines analyzed and schematic visualization of genomic functional categories of 
interest. This figure presents an overview of (A) GCT subtypes in the hypothesized context of normal germ cell 
development as proposed in earlier studies (grey box) and (B) the samples included in this study. Panel C presents a 
reference to (abbreviations of) the functional genomic regions as mentioned in the rest of the manuscript. (A) 
Developmental schemes are indicated in blue (male), red (female) or when possible in both sexes (white). DG does not 
originate from CIS but is indicated together with SE for reasons of consistency. (B) Compilation of the dataset. 
Abbreviations match Figure 1A and roman numbers indicate the GCT type to which the histological subtypes belongs. n 
indicates the number of tumor samples per group. All samples are from male patients except the DGs, DCs and a subset 
of the type I TEs. Please note that when only TE is denoted, this indicates the group of all type I TEs together. Otherwise 
II.TE (type II pure TE) or the abbreviations for specific localizations are used as indicated in this figure. Four GCT cell lines 
were included; tumor of origin between brackets. (C) Functional genomic categories. Probes were classified according to 
their relation to gene coding regions, micro-RNA (MIR) coding regions, CpG islands and/or transposon elements 
(LINE/SINE). The distance to the transcription start site (TSS) was used in accordance with the Illumina manifest: 200 or 
1500 bp. Of note, the TSSAssociated category contains all probes with a distance < 1500 bp to the TSS in contrast to the 
TSS1500 category from Illumina which is only contains probes 200-1500bp from the TSS. Probes within imprinting 
associated regions were classified as (1) mapped inside a known imprinting control region (ICR) or (2) either mapped 
inside an ICR or mapped close to the TSS of a transcript of an imprinted gene (200/1500bp upstream, not mutually 
exclusive). P/M indicates the expressed allele, i.e. paternal/maternal respectively. Numbers between brackets indicate the 
number of valid probes within each specific category (total number of valid probes: 437,881). *The visualization did not 
permit including the probe count for all categories. The counts for the empty categories are: 5’UTR=59,338; 
ISLAND=136,339; IMPR_P200=638; IMPR_P1500=1,659; IMPR_M200=610; IMPR_M1500=2,265. 
Type II GCTs present most frequently in the gonads and are also called germ cell cancer (GCC). 
The incidence of these tumors peaks between 25-35 years of age depending on the subtype [16, 
17, 19]}. They comprise ¨1% of all solid cancers in Caucasian males and are responsible for 60% of 
all malignancies diagnosed in men between 20 and 40 years with increasing incidence in the last 
decades [26] (Dutch Caner Registration (IKNL)a). Risk factors have been thoroughly investigated 
and are integrated in a genvironmental risk model, in which risk is determined by a combination of 
micro/macro-environmental and (epi)genetic factors [19, 26-32]. A common precursor lesion 
called CIS or intratubular germ cell neoplasia unclassified (IGCNU, WHO definition [18]) is identified 
for type II GCT [16, 17, 33, 34]. Because of the non-epithelial origin these tumors, CIS is technically 
not a proper term but will be used throughout this article in the interest of consistency with existing 
literature. Type II GCT consist of non-seminomatous (NS) and seminomatous (SE) tumors (Figure 
1A), which differ in clinical behavior and molecular profile. SE and embryonal carcinoma (EC) are 
the stem cell components of type II GCT  and EC can further differentiate in the other NS subtypes: 
TE, YS and choriocarcinoma (CH) [16, 17]. Type II GCT originate from maturation arrested, germ 
line committed PGCs or gonocytes and historically have been suggested to exhibit erasure of 
genomic imprinting [13, 16-19, 22, 35]} 
Type III, IV and V GCTs originate from more differentiated germ cell progenitor cells. Type III GCTs 
are also known as spermatocytic seminoma (SS) and occur solely in the testis. They arise after the 
age of 50 and are generally benign and rare (incidence: 0.2/100000). Their presentation in elderly 
males, morphology and immunohistochemical profile separates SS from SE. They originate from 
germ cells around the spermatogonium stage and are paternally imprinted [16, 36-40]. Type IV 
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tumors are historically hypothesized to originate from a maternally imprinted, committed female 
germ cell. Type V GCT were excluded from this study because they show an independent 
pathogenesis. They originate from the fertilization of an empty ovum by two sperm cells, resulting 
in a completely paternally imprinted genomic constitution. This explains their mono-directional 
lineage of differentiation, unrelated to the germ cell origin [16-18]. 
This study aims to identify specific and global differences between the genome-wide methylation 
profiles of GCT subtypes. Type I, II, III and IV GCTs and four cell lines representative of type II GCTs 
are investigated (Figure 1A,B). Differences in methylation profile provides insight into the 
developmental timing and underlying biology of GCTs. The findings ultimately relate GCT subtypes 
to specific stages of (early) developing (embryonic) germ cells. Emphasis was placed on combining 
the results with the available literature and on providing extensive accompanying data to supply an 
integrated, hypothesis generating data source for future research. 
Results 
Methylation differences are investigated, starting from global methylation profiles, followed by 
functional enrichment analysis (functional genomic regions: Figure 1C). Next, specific differentially 
methylated probes are identified (DMPs). Probes represent individual CpG sites. Also, differentially 
methylated regions (DMRs) containing multiple adjacent probes are identified. Finally, imprinting 
status is evaluated. Please note that differential methylation indicates a statistically significant 
difference after correction for multiple testing, unless specifically stated otherwise. For details about 
the statistical procedures, please see the materials and methods section (analysis protocol). 
SS and SE/DG show global hypomethylation when compared to EC/mNS and TE 
Figure 2A shows the methylation distributions for all probes, probes associated with the TSS, 3' 
UTR, LINES, microRNAs and CpG Islands, respectively. The distributions of the remaining functional 
categories are presented in Figure S2A. SS showed global hypomethylation (Figure 2A), i.e. a large  
Figure 2. Methylation patterns in GCT subtypes and cell lines. To illustrate differences in methylation status between 
histological GCT subtypes two (visualization) methods were applied. Firstly, the methylation pattern over the whole 
genome and specific functional categories (Figure 1C) is visualized using the distribution of the methylation percentage Ǆ 
in all samples of a certain GCT subtype. Next, the discriminatory power of the methylation pattern for each individual 
sample is shown using principal component analysis. (A) Distribution of methylation percentage. Violin plots: grey areas 
indicate a kernel density plot of the methylation percentage (Ǆ) of all probes in all samples in a certain category. The 
boxplot indicates the interquartile range (black bars) and median (white squares). X-axis labels indicate histological 
subgroup according to Figure 1A,B. TE indicates type I TE only. (B) Principal Component Analysis. The first two principal 
components (PC) are plotted to evaluate the discriminative power of the methylation pattern between the subtypes. 
Abbreviations of histological subtypes are explained in Figure 1A. CL indicates cell lines. Please note that in legend of the 
PCA the TE group is subdivided based on gender and localization: I=type I; II=type II/formally part of the mNS group, 
s=sacrum, t=testis, o=ovary, m=male, f=female. A more detailed visualization of the TE classes is provided in Figure S2, 
which also includes the full series of 18 functional categories, bootstrap validation of the PCA and an estimation of the 
variance explained by the first two principal components. Æ 
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concentration of probes showing a low percentage of methylation and few probes showing a high 
methylation percentage. Hypermethylated configurations contain a large concentration of probes 
showing a high percentage of methylation and few probes showing a low methylation percentage. 
Hypomethylation was also shown in DG and SE samples albeit to a lesser extent, as can be 
observed from the mode at 50-60% methylation (Figure. 2A). The SE group showed consistent 
hypomethylation (Figure S2B, p.2), in contrast to a study of Nettersheim et al who showed separate 
groups of hypo- and hypermethylated SE in a larger sample series [41]. In contrast to the SE and 
DG samples, the EC, mNS, TE and DC samples consistently showed a bimodal pattern with one 
mode around 10% and one around 90% (Figure 2A). This bimodal pattern is also observed in three 
EC cell lines and a single SE cell line (Fig. 2A, CL_SE & CL_EC). In line with previous reports [14, 42], 
the EC cell lines were more methylated than the SE cell TCam-2 (Figure. 2A). The transcription 
regulatory region upstream of the TSS (TSSAssociated, TSS200) was generally hypomethylated in 
all tumor types as were regions annotated as first exon, 5’UTR and CpG islands. The gene body, 3’-
UTR, micro-RNAs and LINE/SINE elements were generally hypermethylated except in SS, which 
showed a bimodal pattern (Figures 2A, S2A). At these sites, SE/DG showed a median methylation 
level of 50% in line with the maximal methylation of their global profile and previous reports [20, 
43]. Hypermethylation of LINE/SINE elements NS and hypomethylation (Figure 2A) in SE was in line 
with a recent genome wide study [20] but contrasted with a targeted study that showed 
hypomethylation of 3 specific repetitive elements in both SE and NS [44].  
GCT subtypes can be distinguished based on their methylation profile 
Principal component analysis (PCA) showed robust separation of homogeneous clusters of 
EC/mNS, SE/DG, TE/DC and SS samples when all probes were considered (Figure 2B, S2A). In line 
with the larger inter-sample variation (Figure S2B), SE/DG and SS were more scattered in the PCA 
plot. Some mNS, which consist partly of differentiated tissue, showed a tendency towards the 
differentiated TE/DC group. The TE and DC showed an indistinguishable global methylation profile. 
Similar observations were made when subsets of probes were considered that were annotated to 
specific functional genomic regions (Figure 2B, S2A). 
Figure 3. Functional enrichment of DMPs. DMPs were classified according to their functional genomic location (Figure 
1C). Statistical over- and underrepresentation of probes in certain categories provides clues to differences between GCT 
subtypes in regarding function of methylation. Results are shown for four pairwise (A vs B) comparisons of histological 
subtypes: (A) SE/DG versus EC/mNS; (B) SE/DG vs type I TE; (C) EC/MNS vs type I TE and (D) SE/DG vs SS. (LEFT) The 
number (n) of DMPs identified in either the DMP[A-B] (hypermethylated in A, green) or DMP[A-B] (hypermethylated in B, 
red) group. (MIDDLE/RIGHT) Functional enrichment in the DMP[A-B] and DMP[A-B] group respectively. X-axis: positive 
numbers indicate a significant overrepresentation of DMPs in a functional category compared to non-DMPs while 
negative numbers indicate a significant underrepresentation. Depicted is the log2 ratio of (1) the % of either DMP group 
assigned to a category and (2) the % of non-DMPs assigned to that category. Only significant enrichments are depicted 
(2-sided Fisher’s Exact test, see Methods section for Bonferroni corrected į threshold). DMPs[SE/DGvsSS].IMPR_P1500 
showed significant underrepresentation, but could not be plotted on log scale (0 probes in DMP group). Details of 
calculations and raw counts and percentages are presented in Table S2. Y-axis: functional categories as specified in 
Figure 1C. Æ 
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Zooming in: GCT subtype specific methylation patterns  
To further pinpoint differences between pairs of GCT subtypes, DMPs were identified (Table 1, S1), 
tested for functional and chromosomal enrichment (Figure 3, S3; Table 1, S2) and grouped into 
DMRs (Figure 4, S4; Table 1, S3, File S1). SE + DG and EC + mNS subtypes were merged because 
of high similarity of the observed methylation profile (Figure 2A, 2B, S3A), in line with literature 
regarding their similar origin [45]. Recurrent DMRs were identified as genes occurring more than 
once within or between comparisons, which may indicate regions of importance (Table S3, n=149). 
(Differential) methylation of GCT cell lines (4136 DMRs between the cell lines: File S2) showed little 
similarity to their in vivo counterparts (Figure 2,6,S2) but matched with a biologically relevant DMR 
previously validated in these cell lines using bisulfite sequencing in [46] (microRNA-371/2/3 cluster, 
Table 2). 719 gene symbols intersected between tumor and cell line DMRs (Table S3). The major 
differences between the subgroups of GCT will be summarized hereafter. 
Comparing SE/DG, EC/mNS and type I TE 
Regardless of their presumed common origin, EC/mNS and SE/DG show vastly different 
methylation profiles. The relative hypermethylation in EC/mNS versus SE/DG was concentrated in 
regions not involved in transcription regulation (Figure 3A). This points to a global difference in 
methylation status rather than differential methylation of specific regulatory elements. This also 
holds for the hypermethylation of TE when compared to SE/DG (Figure 3B). The 61 DMPs 
hypermethylated in SE/DG relative to TE were concentrated at three specific genes: NCOR2, 
ALOX12 and ECEL1P2 (Table 1, S3, Figure S4A).  
DMPs between TE and EC/mNS indicate a more methylated profile of the EC/mNS group (Figure 
3C). Moreover, the majority of the probes hypermethylated in TE were located on the X 
chromosome and can therefore be traced back to hemi-methylation of chromosome X in females 
(TE=male/female, EC/mNS=male only) (Table 1, Figure S3B). DMRs included many genes involved 
in male gametogenesis like DMRT3 (Figure 4A). The EC marker SOX2 [17, 47] was present as one 
of the only 15 hypermethylated autosomal DMRs in TE (Figure 4B). These DMRs presumably relate 
to the cell of origin as well as to the sex of the patient (Figure S4B, Table 1, S3).  
Type III (SS) versus type II seminomatous GCT (SE/DG)  
The general, hypomethylation in SS (DMP[SE/DG-SS]) is enriched for regions associated with 
paternal expression (Figure 3D). DMRs hypermethylated in SE/DG predominantly included 
recurrent DMRs and DMRs within genes associated with germ cell and testis development (Table 1, 
S3). The promoter of POU5F1 was relatively hypomethylated in SS, while it is a marker for the stem 
cell component of type II GCTs and not expressed in SS [17, 45, 48] (Figure 4C, Table 2). DMRs 
hypermethylated in SS also included genes associated with male germ cell determination, fertility 
and GCTs, enforcing the epigenetic relation between GCT cells and their cell of origin (Table 1, S3).  
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Table 1. Pairwise comparison of GCT subtypes. This table concisely summarizes the results of the search for differentially 
methylated (DM) probes (P) and differentially methylated regions (R) between pairs (A and B) GCT subtypes. Briefly, the 
number of DMPs and DMRs is shown separately for probes hypermethylated in A or B. The subtype in which the probes 
are hypermethylated is indicated in bold and underlined. Also, a brief interpretation of the genomic function of the DMPs 
is provided. For the DMRs the associated genes are discussed in the context of GCTs. (Abbreviations) न significantly 
underrepresented; द significantly overrepresented; % DMPs is calculated relative to the total number of valid probes 
(Materials and Methods section). tr=transcription regulation associated regions (TSS200/TSSAssociated/5’UTR/EXON1); 
non-tr=non transcription regulation associated gene coding regions (GENE.BODY/3’UTR). The other functional 
categories are depicted in Figure 1C. [global] = global methylation difference between subtypes; no distinguishable 
potential subtype specific differentially methylated regulatory elements. (Associated sources) Statistical procedures are 
described in the Materials and methods section. The overall methylation pattern of each histological subtype is visualized 
in Figure 2. Functional enrichment of DMPs is visualized in Figure 3. Details of enrichment calculations and raw counts 
and percentages are presented in Table S2. Enrichment of chromosomes is depicted more detailed in Figure S3B. DMRs, 
recurrent tumor DMR and DMPs are listed in Table S3 and Table S1 respectively. DMRs are visualized in Figures 4 and S4 
and File S1, S2. 
A. Seminomatous (SE/DG) versus non-seminomatous (EC/mNS) GCTs 
DMProbes[SE/DG-EC/MNS] DMProbes[SE/DG-EC/mNS] 
6 110,462 (25%) 
[no enrichment] 
न in tr and द in non-tr, LINE/SINE suggested global 
difference in methylation status rather than differential 
methylation of specific regulatory elements. CpG islands 
were न. miRs regions were weakly द. ICRs were न, 
suggesting no difference in imprinting status. 
DMRegions[SE/DG-EC/MNS] DMRegions[SE/DG-EC/mNS] 
0 [global] 
- [global] 
B. Seminomatous type II (SE/DG) versus type I (TE) 
DMProbes[SE/DG-TE] DMProbes[SE/DG-TE] 
61 56,764 (13%) 
significantly overrepresented on chromosome 12 (13/61) 
and preferentially located in the 5’UTR of genes and CpG 
islands 
नon tr, CpG islands and ICRs and दof non-trs, transposons 
and miRs (¨DMPs[SE/DG-EC/mNS]). 
DMRegions[SE/DG-TE] DMRegions[SE/DG-TE] 
3 [global] 
NCOR2: (SMRT, silencing mediator for retinoic acid and 
thyroid hormone receptors) nuclear receptor co-repressor 
on 12q24.31 involved in mouse spermatogenesis [49] and 
vitamin D metabolism in GCTs [50]. ALOX12: lipoxygenase 
family [51], has not implicated in GC(T) biology. ECEL1P2: 
increased methylation upon aging [52] Æ although not 
implicated in normal/aberrant germ cell development, this 
might explain the hypomethylation in pediatric type I TE as 
compared to adult type II SE/DG. All three genes were also 
DMR hotspots. 
[global] 
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C. Non-seminomatous type II (EC/mNS) versus type I (TE) 
DMProbes[EC/mNS-TE] DMProbes[EC/MNS-TE] 
17,407 1,520 
Enrichments were weak, the strongest being न in 
transposons. 
¨80% on X chromosome Æ differences in sex 
(TE=male+female, EC/mNS=male). द in tr and न in non-tr 
and transposon elements suggests differential methylation 
of specific regulatory elements. द in CpG islands. 
DMProbes[EC/mNS-TE] DMRegions[EC/MNS-TE] 
580 (all autosomal) 128 (15 autosomal) 
e.g. DMRT3: implicated in testis development and male sex 
determination [45, 53] MOV10L1: which has been 
implicated in human male infertility [54] and germ cell 
maturation in mice [55]. DDR2: crucial for spermatogenesis 
in mice [56] ICR_P WT1 was also present. 
e.g. SOX2: EC marker (see: Table 1). IRX5: germ cell 
migration in Xenopus laevis embryos; DMR ¨1kb 
downstream of its 3’UTR [57]. MSX1: progression of germ 
cells into meiosis, leading to germ cell maturation arrest in 
mutant embryos; DMR at its 3’UTR [58]. Hypomethylation 
in type II GCTs [59].  
 
D. Seminomatous type II (SE/DG) versus type III (SS) 
DMProbes[SE/DG-SS] DMProbes[SE/DG-SS] 
15,340 2,830 
द in non-tr and नin the tr. द in ICR_P/IMPR_P200/1500 in 
line with paternal cell of origin of SS.  
 
न at non-tr and CpG islands. 
DMProbes[SE/DG-SS] DMRegions[SE/DG-SS] 
559 30 
e.g. hotspot genes like NCOR2 , ALOX12, ECL1P2, MSX1 
(see above).  IRS2: associated with male germ cell and 
testis development [60]. POU5F1: SE/DG/EC marker (Table 
1). TEX14: associated with known high risk GCT SNP [29]. 
 
SERPINE1 (plasminogen activator inhibitor 1, PAI-1): 
hypomethylated in GCT except in SS. PAI-1 SNPs have 
been associated with poor prognosis in GCTs [61]. The 
plasminogen activator system has been implicated in 
human infertility [62]. MOG: hypermethylated in SS, 
knockdown causes male germ cell differentiation in mog 
deficient C. Elegans [63, 64]. 
 
 
 
Figure 4. Methylation profile at GCT subtype specific differentially methylated regions (DMRs). Visualization of the 
methylation percentage at specific loci is used to zoom in on a predefined region and investigate local methylation 
differences between GCT subtypes. (A) DMRT3, (B) SOX2, (C) POU5F1 (OCT3/4), (D) TEX14. (Visualizations) From top to 
bottom the following is depicted: (1) Four-color heat map indicating methylation % for each individual probe in the 
depicted region. For the sample groups specified on the left the median methylation % is shown. (2) Position of all 
probes in the region of interest (ROI) is annotated as black rectangles. (3) HMM segments are displayed as grey boxes 
spanning the segment’s width and grouped per state. Numbers indicate the state of each (group of) segment(s). (5) GC% 
was obtained from the UCSC genome browser database (gc5Base table). (6) Transcripts overlapping with the ROI are 
plotted at the bottom. Plot generated using the Gviz package. If red rectangles are indicated, they indicate DMPs in the 
visualized DMR. Abbreviations of histological subtypes are explained in Figure 1A and for specific subtypes of TE in the 
lgend of Figure 2. CL indicates cell lines. Æ 
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Specific GCT associated genes 
A number of genes has been associated with (methylation in) GCTs, both regarding pathogenesis 
and diagnosis. Table 2 summarizes the literature for these genes and combines this with the 
methylation data from this study, e.g. overlap with DMRs and methylation profile of these genes 
(see also Figure 5, S5A). A recent meta-analysis of GCT GWAS studies identified 19 SNPs 
associated with 13 genes [29]. For most genes their methylation profile was non discriminative 
between the GCT subtypes, the exceptions being TEX14 which was also independently identified as 
a DMR[SE/DG-SS] (Figure 4D) and BAX1, which also contained a DMR[SE/DG-SS] (all SNP related 
genes: Figure S5B). 
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Å Figure 5. Methylation profile of GCT specific genes and regions of interest (ROIs). Visualization of the methylation 
percentage at specific loci is used to zoom in on a predefined region and investigate local methylation differences 
between GCT subtypes. (A) AR, (B) miR-371-2-3, (C) NANOG, (D) SOX17. The visualization is described in the legend of 
Figure 4 and the genes are reviewed in Table 2. Abbreviations of histological subtypes are explained in Figure 1A and for 
specific subtypes of TE in the legend of Figure 2. CL indicates cell lines. 
Table 2. GCT (methylation) associated genes. Genomic locations and strand were retrieved from genecards.com/UCSC. 
Detailed visualizations of the methylation status of these genes is presented in Figures 5 and S5A. DMRs in the cell lines 
are presented in File S2. ICRs are visualized in Figure 7 and S6. 
Gene & region Description 
APC 
chr5 (+) 
112,043,195 – 
112,181,936 
GCT link: A single study with small sample size (n=10) showed increase methylation in most 
YST as compared to germ cells in normal testis. Expression was high in germ cells and low in 
most YSTs [65]. 
Findings: 2102EP showed mild but significant relative hypermethylation compared to the 
other cell lines, but for all tumor groups APC was consistently hypomethylated. 
AR 
chr X (+) 
66,763,874 –  
66,950,461 
GCT link: Androgen receptor methylation can be used as a readout for X inactivation in non-
germ cells. AR was methylated in differentiated NS, but unmethylated in a proportion of ECs 
and all SE & SS. This supports the hypothesis that methylation does not occur in the germ cell 
lineage [66]. 
Findings: the promoter region of the AR was completely deprived of methylation in all male 
tumors while a certain amount of methylation (ca. 50%) was present in the female samples. 
AR contained a DMR only in the CL where it was relatively methylated in NT2 as compared to 
all other cell lines (Figure 5A). 
CTA genes 
 
GCT link: Cancer Testis Antigens (CTA) are primarily unmethylated in SE. MAGEA1/3 are 
predominantly methylated in NS while SYCP1 is unmethylated in NS [67]. MAGEA1: 
chrX:152,481,522-152,486,116(-), MAGEA3: chrX:151,934,652-151,938,240(-), SYCP1: 
chr1:115,397,424-115,537,991(+) 
Findings: Methylation differences in these genes were not remarkable except for differential 
hypomethylation of TCam-2 and NCCIT compared to the other cell lines. The TSS associated 
regions of MAGEA1 and SYCP1 were consistently hypomethylated in SS. 
GATA4 
chr 8 (+) 
11,534,468 –  
11,617,511 
GCT link: previously identified DMR between TCam-2 and NCCIT, promoter region 
hypermethylated in TCam-2 [68]. 
Findings: The GATA4 promoter was differentially hypomethylated in all CL_EC as compared 
to EC_SE, but this was exactly opposite in the SE and EC tumor samples. Testicular TEs, like 
EC/mNS samples showed relative hypermethylation while sacral/ovarian TEs, DCs and SS 
showed relative hypomethylation like the SE/DG samples. 
HIC1 
chr17 (+) 
1,957,448 – 
1,962,981 
GCT link: 55% of the GCT show methylation of this area which shows frequent loss of 
heterozygosity in somatic adult cancers. 5AZA treatment strongly induced HIC1 expression in 
non-GCT CLs [69]. HIC1 promoter methylation has been implicated in treatment resistance in 
GCTs [70]. 
Findings: HIC1 was showed predominantly hypomethylation in all GCT subtypes even though 
a weak DMR[EC/mNS-TE] was identified. Of the cell lines, only 2102EP showed differential 
hypermethylation.  
KIT & KITL 
KIT: chr4 (+) 
55,524,085 – 
55,606,881 
GCT link: KIT and KITL regulate primordial germ cell development and homing to the gonad 
[71-75]. In the embryonic phase the guidance of KIT+ primordial germ cells from the hind 
gut epithelium to the gonads depends strongly on KITL mediated chemo attraction [74, 76-
78]. In the postnatal testis KIT-KITL signaling takes place via paracrine signaling in the 
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Gene & region Description 
KITL: chr 12 (-) 
88,886,570 – 
88,974,628 
germline stem cell niche and is crucial for spermatogenesis from the spre-matogonial stage 
onwards [72, 74, 79, 80]. More mature mouse spermatids and spermatozoa express a c-
terminal truncated form of KIT transcribed from an intronic promotor [81]. Mechanistically, 
constitutive paracrine / autocrine activation of KIT/KITL signaling is implicated to be a crucial 
initiating event for the malignant transformation of maturation arrested germ cell progenitors 
[17, 19, 22]. In the early stages, KITL positivity is a hallmark of maturation arrested germ cells, 
CIS and intratubular SE [17, 82-84]. Progression into invasive SE is also strongly related to 
KIT/KITL signaling while much less association with the NS phenotype has been shown [79, 
85-88]. Activating KIT mutations are identified in ca 13-60% of the SE (rare in NS) and result 
in constitutive kinase activity because of ligand independent dimerization and 
phosphorylation [89-92]. Recent GWAS studies identified susceptibility loci for GCTs close to, 
within or directly related to GCTs [29, 93-104]. No information about KIT or KITL methylation 
in tumors was presented in literature although KITL promoter methylation was significantly 
lower in blood of these patients [105] and SNPs in KITL combined with aberrations in cAMP 
regulation were suggested to contribute to tumor risk in these patients [104]. 
Findings: KIT (Figure S6A) and KITL (Figure S6B) were not differentially methylated between 
any of the tumor groups or cell lines. 
miR-371/2/3 
chr19 (+) 
(371) 54,290,929 –  
54,290,995 
(372) 54,290,995 –  
54,291,210 
(373) 54,291,959 – 
54,292,027 
GCT link: The micro-371-2-3 cluster is expressed in the stem cell component of GCT [106] 
and is a potential diagnostic serum marker for GCT [107]. Upstream of the TSS of this cluster 
a DMR has been identified between TCam-2 and NCCIT [68]. Differential methylation in GCT 
cell lines has been validated using pyrosequencing and the methylation level showed 
significant and strong inverse correlation with the expression of miR-373 (Spearman’s ǐ -0.90, 
p=0.037) [46]. 
Findings: The miR-371-2-3 cluster was hypomethylated in TCam-2 (CL_SE) and 2102EP and 
hypermethylated in NT2 and NCCIT (Figure 5B). However, with the exception of SS the 
tumors showed hypermethylation of this region, despite known expression in the stem cell 
components of type II tumors [46, 106]. 
NANOG 
chr12 (+) 
7,940,390 – 
7,948,655 
GCT link: Specific marker for the all stem cell components of GCTs [17]. RA treatment of NT2 
cells also increased methylation here [108]. Analogous to this CpG sites in the NANOG 
promoter (0-306 bp upstream of the TSS) were found hypomethylated in spermatogonia and 
hypermethylated in sperm [109]. 
Findings: The NANOG promoter region showed a trend towards relative hypomethylation in 
the undifferentiated stem cell components of the type II tumors as compared to all other 
(more differentiated) GCT subtypes including the type II TE and mNS (intermediate status). 
However, the number of probes+consistency of the difference lacked significance (Figure 5C). 
POU5F1 (OCT3/4) 
chr6 (-) 
31,132,114 – 
31,148,508 
GCT link: Specific marker for the all stem cell components of GCTs [17, 48, 110]. OCT3/4 
transcription is regulated by methylation of conserved regions up to 2.6kb upstream of the 
TSS. Another study also showed that little increase of methylation at specific sites upstream of 
OCT3/4 strongly inhibited expression [108, 111, 112]. Differentiation of NT2 after retinoic acid 
treatment resulted in increased methylation and loss of expression [108]. 
Findings: A promoter DMR[SE/DG-SS] was identified despite the fact the SE/DG express the 
OCT3/4 protein and SS do not [17, 45, 48] (Figure 4C). However, probes located close to its 
transcription start site are generally methylated between 20 and 40% in OCT3/4 positive 
tumors (SE/EC) which results in unmethylated alleles primed for expression. Moreover, the 
promoter region of OCT3/4 showed a non-significant trend towards lower methylation levels 
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Gene & region Description 
in SE/DG and EC/mNS when compared to the differentiated tumors (TE). Most importantly 
however, regulation of OCT3/4 expression is (also) crucially influenced by specific sites more 
upstream (ca. 2.6 kb) and a set of distant enhancer [111, 112]. Also, we previously showed 
that even though high promoter methylation is generally associated with low expression, this 
is not always the case [68].  
PRSS21 
chr16 (+) 
2,867,164 – 
2,876,305 
GCT link: TESTISIN (PRSS21) is a proposed tumor suppressor gene in TGCT regulated by 
methylation of a 385bp long CpG rich island [113] and CpG sites close to the TSS [114]. 
Findings: Al GCT subtypes except SS (DMR[SE/DG-SS]) showed hypermethylation of PRSS21.  
RUNX3 
chr1 (-) 
25,226,002 – 
25,291,612 
GCT link: 90% of the infantile YSTs (type I) showed methylation of RUNX3 while methylation 
was only rarely observed in the adult GCTs [59, 115, 116]. 
Findings: The promoter region of RUNX3 was consistently hypomentylated, progressing to 
hemimethylation on larger distances from the TSS (except SS). RUNX3 only showed 
differential methylation between the cell lines, most consistently showing hypomethylation in 
NCCIT and hypermethylation in 2102EP. 
SOX17 
chr8 (+) 
55,370,495 – 
55,373,456 
GCT link: Discriminative marker between EC (+) and SE (-) [17, 47].  
Findings: SOX17 was consistently hypomethylated in all tumor groups and cell lines (Figure 
5D). 
SOX2 
chr3 (+) 
181,429,712 – 
181,432,224 
GCT link: Discriminative marker between EC (+) and SE (-) [17, 47]. Previously identified DMR 
upstream of TSS between (¨50%) TCam-2 and (¨0%) NCCIT [68] ¨1kb upstream of the 
SOX2 TSS. The region directly upstream of the SOX2 TSS has consistently been found 
hypomethylated in both cell lines [68, 117]. TCam-2 has been shown to differentiate and 
become SOX2 positive after extra-gonadal injection in mice [118]. 
Findings: A region ¨1 kb upstream of the SOX2 TSS was differentially hypomethylated in all 
CL_ECs as compared to TCam-2 (File S2). EC and SE tumor samples showed consistent 
hypomethylation of the region -154 – -2283bp upstream of the SOX2 TSS in contrast to the 
TE samples which showed higher levels of methylation (DMR[EC/MNS-TE], Figure 4B).  
TFAP2C (AP-2ǅ) 
chr20 (+) 
55,204,358 –  
55,214,339 
TFAP2A (AP-2į) 
chr 6 (-) 
10,393,419 – 
10,419,892 
GCT link: AP-2ǅ is crucial for progression of PGCs into the germ line [119]. It is a known germ 
cell marker, abundantly expressed in CIS and SE, and heterogeneously expressed in NS and 
somatic tumors [119, 120]. AP-2y expression is induced by estrogens [121]. Epigenetically, 
ChIP-seq analysis targeting activating histone marks showed strong enrichment of AP-2į and 
AP-2ǅ motifs in the SE-like cell line TCam-2 [68]. 
Findings: TFAP2A showed mostly hypomethylation in all tumor groups and cell lines. Only 
NCCIT was showed significantly increased methylation at the gene coding region compared 
to the other cell lines (File S2). All TE samples showed a non-significant block of 
hemimethylated probes close to the TSS of TFAP2A. TFAP2C was consistently 
hypomethylated in all tumor groups and cell lines. 
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Gene & region Description 
XIST 
chrX (-) 
73,040,486 – 
73,072,588 
GCT link: XIST is completely methylated in male somatic cells, in contrast to female somatic 
cells. Testicular GCTs show hypomethylation of the 5’ end of XIST which, have been 
suggested for TGCT diagnostics [122] but has so far not been validated. SE/NS/SS showed 
XIST expression (X inactivation) [66]. 
Findings: XIST showed no significant differential methylation in the comparison of the tumor 
groups or cell lines. Female gonadal tumors, SE and SS showed a trend towards less 
methylation as compared to the strongly methylated profile of the non-seminomatous 
tumors and male type I TE. 
ICR_P: SNURF/SNRPN 
chr15 
25,199,934 –  
25,200,343 
GCT link: SNURF/SNRPN has been described to show derivation from somatic imprinting in 
type II GCTs (non-quantitative, not necessarily indicating erasure) [123]. Low, but not absent 
methylation in non-allele-specific analysis [124]. Schneider and colleagues showed absence 
of the methylated band in bisulfite restriction analysis in 9 dysgerminomas [125].  
Findings: In this dataset, this SNURF/SNRPN (controlling paternal expression) was only 
covered by a single probe (Figure S6). This very limited evidence suggests somatic imprinting 
in the type II tumors and sacral TE and uniparental status in the other subtypes: loss of 
imprinting in the I.TE.m.t and complete methylation in the ovarian tumors (DC, I.TE.f.o).  
ICR_P: MEST 
chr7 
130,130,740 –  
130,133,111 
GCT link: The MEST ICR regulates paternal expression, is already erased in fetal 
spermatogonia and remains so during male germ cell development [126]. 
Findings: The imprinting during germ cell development is reflected in our findings: (1) 
hypomethylation in the testicular type I TE and SS, (2) somatic imprinting in the type II 
tumors, (3) somatic-high imprinting in the ovarian and sacral TE, (4) high methylation in DC 
(Figure 7A). 
ICR_M: H19-IGF2 
chr11 
2,020,834 –  
2,023,499 
GCT link: H19 (M expressed) and IGF2 (P expressed) are inversely controlled by this ICR 
upstream of H19 [124]. In mice oocytes are erased at H19 before meiosis while bialelic 
methylation occurs before the gonocyte stage in males [127]. In humans H19 is erased in 
fetal spermatogonia, but becomes fully methylated before meisosis (spematogonia) [126]. 
H19 erasure fis unctionally illustrated in [128] and related to pluripotency markers (SOX2 and 
OCT3/4) in germ cell development in [129].  
Previous studies using have suggested low methylation of the H19-IFG2 ICR in a variable, but 
generally high percentage of the type II GCTs. This has generally been interpreted as 
imprinting erasure. Somatic imprinting has been shown in non-gonadal TE and mimicking of 
female germ cells has been seen in ovarian TE. Most studies investigated imprinting indirectly 
using allele specific expression limiting the sample sizes because of the mandatory presence 
of SNPs in this analysis to be informative [125, 130-132]. But a number of studies inquired the 
DNA methylation status directly using bisulfite restriction analysis, identifying consistent 
demethylation of one allele and variable methylation of the other in allele specific analysis 
and low, but not absent methylation in non-specific analysis [124, 133]. Low-somatic 
imprinting in DG was also shown by Amatruda et al. in a high throughput approach [20]. 
Findings: The SS in our series show complete methylation at 1 of the two H19/IFG2 sites 
indicating a paternal committed origin. The sacral TEs exhibit mainly a somatic pattern, 
presumably indicating a pre-erasure origin. The gonadal I TE/DC show the lowest level of 
methylation presumably representing (partial) erasure (I.TE.m.t, TE) or complete maternal 
imprinting (I.TE.f.o, DC). Type II GCTs were found to consistently show somatic imprinting 
(Figure 7B; 2 regions from literature: Table S4). 
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Imprinting status and X chromosome reactivation 
As reviewed in the introduction, gradual and tightly controlled establishment of uniparental 
imprinting and X chromosome reactivation (female only) has been demonstrated in developing 
germ cells which is at least partly mirrored in their malignant counterparts. Regarding imprinting 
controlled regions (Figure 1C, Table S4) in the tumor groups probes covering regions that are 
regulating paternally expressed genes (ICR_P) showed somatic methylation in type I and II GCTs 
with a trend towards hypermethylation in DC (Figure 6A). SS and the cell lines showed 
hypomethylation of ICR_Ps, a distinction also visible in the PCA plots. In IMPR_P200/1500 the 
pattern of the ICR_P probes seems to be pooled with a set of unmethylated probes (type I, II, IV 
GCT) presumably indicating contamination by non-imprinting related regions and hence not 
informative for imprinting status (Figure S2A, p.15,16). A somatic methylation state was shown for 
ICR_M except in the SS (bimodal) and the CL_SE (hypomethylated); a difference corroborated by 
the separation of these groups in the PCA plot (Figure 6B). IMPR_M200/IMPR_P1500 probes 
showed hypomethylation similar to non-imprinted genes in all groups (Figure S2A, p.18,19). No 
reactivation of chromosome X was seen in GCTs from female patients, which is reflected by the 
consistent 50% median methylation of the X chromosome in these cases (Figure 6C). The cell lines 
did not reflect the imprinting status of their in vivo counterpart, warranting caution when using the 
cell lines as a GCT model system in methylation based experiments. 
Methylation status of ICR_Ps and ICR_Ms was similar between individual samples of the same 
histology (Figure S2B) with the exception of type I TE and DC (Figure 6D, S2B). TEs were 
investigated individually, grouped according to sex and anatomical site, in line with sex specific 
imprinting occurring during fetal/germ cell development (Figure 6D). The genome-wide 
methylation pattern was similar for all TEs. No reactivation of chromosome X was seen in the GCTs 
from female patients. Sacral type I TEs showed somatic imprinting patterns both in males and 
females. In line with sex specific imprinting, ICR_P sites in testicular type I TEs were relatively 
hypomethylated compared to sacral TEs. In contrast, ovarian type I TEs showed a tendency 
towards hypermethylation. Of note, testicular type I TE also showed a trend towards 
hypomethylation in ICR_M (only 18 probes). On the other hand, the expected inverse pattern of 
ICR_P was seen in the ovarian TEs at the ICR_M sites. A pattern similar to ovarian TE was observed 
in the individual DC samples: heterogeneity and gradual deviation from biparental imprinting 
towards uniparental maternal imprinting. Two out of three type II TEs showed a somatic imprinting 
pattern of both ICR_P and ICR_M. 
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Å Figure 6. Methylation of imprinting control regions and the X chromosome. Analogous to Figure 2 the differences in 
methylation status between histological GCT subtypes is illustrated by two methods. Firstly, the methylation pattern is 
visualized using the distribution of the methylation percentage Ǆ. Next, the discriminatory power of the methylation 
pattern for each individual sample is shown using principal component analysis. Please see the legend of Figure 2 for a 
more detailed description of the visualizations. (A) All probes associated with paternally expressed genes (ICR_P). (B) All 
probes associated with maternally expressed genes (ICR_M). (C) All probes located on the X chromosome. (D) 
Distribution of methylation in individual TE samples ordered by sex and localization. To compare type I and II TE the n=3 
type II pure TEs from the mNS were included in this visualization. Methylation levels of all probes, and probes associated 
with ICRs (P/M) and probes on the X chromosome are subsequently shown. 
 
Figure 7. Methylation status of imprinting control regions. Visualization of the methylation percentage at specific loci is 
used to zoom in on a predefined region and investigate local imprinting differences between GCT subtypes. Two 
illustrative regions are depicted. (A) ICR_P: MEST. (B) ICR_M: H19-IGF2. The overlapping H19 transcript is an aberrant, 
long alternative transcript (H19-012, ENST00000428066). This ICR regulates H19 and IGF2 expression and lies upstream 
all other transcripts of H19. The other ICRs are visualized in Figure S6 and listed in Table S4. The visualization is described 
in the legend of Figure 4. Abbreviations of histological subtypes are explained in Figure 1A and for specific subtypes of 
TE in the legend of Figure 2. CL indicates cell lines. 
Validated ICRs (Table S4) were also studied individually. After merging overlapping validated ICRs 
from literature, 28 unique ICRs remained of which 21 were covered by the 450K array (4 ICR_M, 16 
ICR_P, 1 unknown). ICRs controlling the expression of H19/IGF2, SNURF/SRPN and MEST have 
been studied in GCTs previously (review & results in Table 2). In the ICR_Ps which constitute the 
majority of the validated ICRs, the dominating pattern is: (1) somatic methylation in the type II 
tumors (2) hypomethylation in the type I testicular TEs and SS and (3) a trend towards 
hypermethylation in DC and ovarian TE. (Figure 7AB,S6).  
In summary, ovarian type I TE and DC showed partial sex specific uniparental maternal imprinting, 
inverse of the uniparental paternal imprinting of SS. Testicular type I TE shows a trend towards 
erasure and type II GCTS (SE/DG/EC/mNS) showed somatic imprinting status. 
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Discussion 
This study provides a detailed overview of the differences in global and local methylation status 
between type I-IV GCTs (Figure 1) and relates it to their cell of origin during normal germ cell 
development. Normal germ cell maturation includes complete de- and subsequent remethylation. 
Establishment of sex specific uniparental imprinting is physiological as is reactivation of 
chromosome X in female gametes. The largest methylation differences were detected between the 
hypermethylated EC/mNS + TE and hypomethylated SS + SE/DG groups, in line with previous 
reports [14, 42, 116, 134] (Figure 2A). However, the methylation profiles also allowed for a more 
detailed separation of EC/mNS, SE/DG, TE/DC and SS clusters, which is in line with the 
differentiation status of the tumors and their cell of origin. This distinction was also apparent when 
specific functional genomic regions were evaluated (Figure 2B). Hypermethylation in EC/mNS and 
TE is concentrated at non-transcription related regions when compared to SE/DG, pointing to a 
global difference in methylation status rather than differential methylation of specific regulatory 
elements. Moreover, EC/mNS is somewhat more methylated than TE and shows specific 
differences at transcription regulating genomic regions including genes implicated in male germ 
cell development. Regarding type III tumors, differential hypomethylation in SS relative to SE/DG is 
enriched for paternally expressed imprinting associated regions and DMRs cover male germ cell 
related genes (Figure 3, 4, 5, Table 1, 2). In addition, marked differences in imprinting status were 
observed. Ovarian type I TE and DC showed partial uniparental maternal imprinting, inverse of the 
uniparental paternal imprinting of SS. Testicular type I TE shows a trend towards imprinting erasure 
and type II GCTS (SE/DG/EC/mNS) showed somatic imprinting status (Figure 6, 7). The local and 
global methylation difference observed between GCTs could be matched to physiological germ 
cell development (Figure 8).  
Limited knowledge exists about the progenitor of type I tumors. The absence of CIS and clinically 
different presentation (pediatric, frequently extra-gonadal, fully differentiated histology: TE/YST) 
sets them apart from the type II tumors [16-18]. Their bimodal global methylation status could a 
pattern generally observed in normal differentiated tissues and in very early germ cell progenitors 
(pre-migration. Historically type I and II tumors are also thought to be different with regard to their 
imprinting status. Imprinting status in these tumors was earlier shown to be somatic (biparental) or 
partially erased in case of the type I tumors and erased  in case of the type II GCTs [16]. This 
positions the progenitor cell of type I tumors before imprinting erasure in the gonad. Indeed 
biparental (somatic) imprinting status in extra-gonadal TE was confirmed in this study and by 
Amatruda and colleagues [20]. There is a trend towards imprinting erasure in testicular type I TE. 
Ovarian type I TE show a trend towards completely maternal imprinting, but starting from a 
biparental status (50%), not showing any evidence of prior complete erasure (Figure 6D). This 
(partial) mimicking of female germ cells in ovarian TE is in line with in several studies [20, 125, 
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132]). However, the non-erased imprinting status, inactivated X chromosome and generally 
methylated state fits with the cell of origin at the very early PGC stage, which is then blocked in 
physiological complete demethylation, erasure and X reactivation and, when subjected to a 
gonadal micro-environment, shows partial erasure/uniparental imprinting [16-18] (Figure 8).  
 
Figure 8. GCT methylation status in context of methylation during germ cell development. The top and bottom line 
charts depict normal germ cell development in female and male respectively (stages specified in the middle black bar). 
Methylation status during normal germ cell development is depicted for the global genome, ICRs and chromosome X 
(see Discussion). Putative cells of origin of the various types of GCTs are indicated in the brown boxes. ICR_P/M=ICR 
regulating paternally/maternally expressed genes. Bimodal indicates a methylation pattern peaking 0 and 100% with the 
exception of SE/DG (between 0 and ¨50). The table (bottom) provides a summary of the results, mainly Figures 2 and 6. 
Abbreviations: pf=primordial follicle. Type I tumors are indicated with their type (I), sex (m=male, f=female) and location 
(s=sacral, t=testis, o=ovary). Other GCT subtypes are indicated with their type (I, II, IV) and the abbreviation of each 
histological class, which are explained in the main text. Gradient bars indicate percentages of methylation (0Æ100%, 
green-white-grey-red) analogous to the gradient used in the other figures. 
Most data is available on the epigenetic constitution of the type II tumors, as reviewed before [13, 
21]. A strongly hypomethylated state was recently shown for all CIS, the common precursor of SE 
and EC [135]. Earlier studies have suggested separated NS-CIS and a SE-CIS types [134], but the 
lack of methylation in CIS combined with absence of SOX2 (EC marker) expression [47, 135, 136] 
increases the likelihood of a single precursor  and progression into SE or NS. The CIS-like state is 
evident in the hypomethylated profile of SE/DG as shown in this article and previous research [14, 
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42, 116, 134, 135]. EC and mNS show a (de novo) methylated profile (Figure 2A). This is in line with 
the previously reviewed increased methylation in the transition of CIS into NS [13, 14, 42, 137], 
possibly illustrating reversal to a hypermethylated ES like state [7, 16, 138-141] or a bimodal 
methylation state normally present in differentiated tissues as shown in the differentiated NS. The 
consistent somatic imprinting pattern in general and at specific ICRs (Figure 6, S6, Table S4) was in 
line with an earlier report [20] but contrasted with targeted studies suggesting erased imprinting 
status at specific ICRs in these tumors using mainly indirect methods (allele specific expression 
analysis) and or non-quantitative methylation analysis (bisulfite specific restriction enzymes) (for 
review Table 2). The hypomethylated progenitor and somatic imprinting pattern (Figure 6A,B) 
situates the cell of origin of the type II tumors possibly earlier than previously described [16]: after 
global demethylation but before imprinting erasement, which is also in line with the occurrence of 
extra-gonadal type II GCTs (brain, anterior mediastinum) and their totipotent, embryonic stem cell 
like potential [16, 138-141] (Figure 8). 
The other GCT subtypes are historically hypothesized to originate from more mature germ cell 
progenitors. Their marker profile has placed the type III tumors at the pre-spermatogonium state 
with regard to their cell of origin [36-39, 45]. Earlier epigenetic data showed a heterogeneous 
profile of histone modification and methylation profiles, not corresponding with a pre-
spermatogonial origin [142]. Our limited series of SS show a consistent pattern of distinct 
hypomethylation and loss of imprinting at the paternally expressed ICRs (ICR_M: heterogeneous  
50%, Figure 2B). This matches with a cell of origin between the gonocyte and spermatogonium 
stage, after establishment of uniparental imprinting but before initiation of de novo methylation. 
The type IV tumors (DC) show a pattern comparable to other differentiated tissues (ovarian type I 
TE) and show a general trend towards uniparental maternal imprinting but not starting from a 
completely erased state, potentially placing their cell of origin and pathogenesis parallel to the type 
I ovarian TE and not as a separate entity originating from a completely maternally imprinted an 
differentiated female germ cell as described before [16] (Figure 6,8,2B). 
In conclusion this exploratory study of genome wide methylation profiles of GCT subtypes 
identified specific and global methylation differences, providing novel insight into the 
developmental timing and underlying biology of the various subtypes of GCTs and their 
(embryonic) cells of origin. However interpret the function of differential methylation between GCT 
subtypes, targeted validation the findings using matched expression data or careful evaluation of 
the effects of methylation in cell line models of GCTs is a crucial next step, even though validation 
of a biological relevant and representative DMR in microRNA-371/2/3 (Table 2) showed excellent 
match with the results of bisulfite sequencing. The in-depth review of related literature and 
extensive accompanying online data (supplementary and on GEO) serve as a hypothesis 
generating source for future research.  
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Materials and Methods 
Samples 
Patient samples 
Use of tissue samples remaining after diagnosis for scientific reasons was approved by Medical 
Ethical Committee (MEC) of the Erasmus MC Rotterdam (The Netherlands), permission 02.981. This 
included the permission to use the secondary tissue without further consent. Samples were used 
according to the “Code for Proper Secondary Use of Human Tissue in The Netherlandsb” 
developed by the Dutch Federation of Medical Scientific Societies (FMWVc (Version 2002, update 
2011)). An overview of the samples in this study is presented in Figure 1A,B. 
Cell lines 
Four cell lines were included (Figure 1B), all modelling type II GCTs. Cell lines derived from EC 
(CL_EC) include NT2[143-147], NCCIT [144, 148] and 2102EP[143-147]. TCam-2 closely resembles 
SE (CL_SE) [149-151]. TCam-2 was grown in RPMI1640 (#61870-010, Thermo Fisher Scientific / Life 
Technologies, Carlsbad, CA, USA). 2102EP and NCCIT were grown in DMEM/F12 (#12634-010, 
Thermo Fisher Scientific / Life Technologies). NT2 was grown in DMEM high glucose (#31966-021, 
Thermo Fisher Scientific / Life Technologies). All cell lines were cultured in T75 cm2 flasks to 75-
90% confluence, each with the addition of 10% Fetal Calf Serum (#CH30160.03, FCS, GE 
Healthcare Life Sciences, HyClone Laboratories, Utah, USA) and 1/100 Penicillin/Streptomycin 
(#15140, Thermo Fisher Scientific / Life Technologies). 
Methylation profiling 
DNA was isolated as described in [109]. The GCT material used contained > 75% tumor cells. 
Bisulfite conversion and methylation detection was performed using Illumina’s 
HumanMethylation450 BeadChip (450K array) and exported as described in [68]. This array does 
not distinguish between DNA methylation variants like 5mC and 5hmC [152].  
  
                                                 
b http://www.federa.org/codes-conduct  
c http://www.federa.org/  
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Data analysis 
Data (pre-)processing 
Further processing was carried out in R using the LUMId package [153] according to [154, 155]. In 
the raw data, no structural differences in quality or batch effects were observed. Poorly performing 
probes (detection p<0.01 in > 95% of the samples), cross hybridizing probes and probes with a 
SNP at or within 10 bp of the target CpG (allele frequency >= 0.05) were excluded [155]. As a 
result 44,540 probes were discarded, leaving 437,881 valid, methylation related probes for 
processing and analysis. Finally, color adjustment, quantile normalization and BMIQ-based 
correction for probe type bias (Infinium I vs II) were performed [153, 154, 156]. Data processing 
resulted in two quantifications of a CpG site’s methylation status: the methylation percentage Ǆ and 
an associated M-value which (logit2(Ǆ)). M-values were used for statistical computations because of 
a more favorable tradeoff between true positive rate and detection rate [157]. All data is available 
via GEO (GSE58538e). 
(Additional) annotation 450K array 
The 450K annotation manifestf (v1.2) as supplied by Illumina contains a number of functional 
genomic classes like a probe’s association with CpG islands, gene coding regions, etc. The manifest 
was extended with (additional) functional genomic classes, based on the GRch37/hg19 assembly. 
Briefly, probes close to small nuclear RNAs and microRNAs from snoRNABaseg and miRBaseh were 
identified, as were probes within repeats defined by RepeatMaskeri (source: UCSCj). Probes close 
to the transcription start site (TSS) of imprinted genes were also identified (geneimprint.com / 
igc.otago.ac.nz). Known imprinting control regions (ICR) were retrieved from WAMIDEXk and 
igc.otago.ac.nz. Imprinting is indicated using the expressed allele. Illumina probe classes were 
extended with a number of merged categories. Where applicable, the upstream (-) and 
downstream (+) margins reported in this manuscript are analogous to the Illumina annotation (-
1500+0; -200+0). The eighteen functional categories of primary interest to this manuscript are 
illustrated in Figure 1C. The extended annotation including its documentation is available at GEO 
(GPL18809l).  
  
                                                 
d http://www.bioconductor.org/packages/release/bioc/html/lumi.html  
e http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE58538  
f http://support.illumina.com/downloads/humanmethylation450_15017482_v12.ilmn  
g https://www-snorna.biotoul.fr/  
h http://www.mirbase.org/  
i http://www.repeatmasker.org/  
j http://genome.ucsc.edu/  
k https://atlas.genetics.kcl.ac.uk/  
l http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL18809  
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Analysis protocol 
Below, the subsequent steps of the data analysis are described. More details are presented in 
Figure S1. Depending on the context, “feature” can refer to a probe or a segment. All results are 
based on the GRch37/hg19 assembly. 
Global methylation 
Violin plots were created per histological subtype using all (global) or functional subsets of 450K 
probes. Violin plots (vioplot packagem) integrate the benefits of a boxplot and a kernel density plot. 
Two-dimensional principal component analysis (PCA) was applied and bootstrap-validated to 
assess how well the methylation values of (subsets of) the probes separated the GCC subtypes.  
Defining genomic segments and discriminative methylation states 
To detect regions of interest rather than only selecting individual differentiating probes (CpG sites) 
a HMM was trained on the tumor samples. Without a priori information about tumor type, the 
HMM combines adjacent probes into segments and assigns these segments to k mutually exclusive 
states, each with distinct methylation profiles over all tumor samples. k=20 was used as the 
likelihood of the model saturated around this number of states (Figure S1, p.11). In total, 133,730 
segments were identified. The median methylation value (M or Ǆ) of all probes in a segment or 
state was taken as methylation proxy. As a proof of concept, Figure S1 (p. 17) shows clear 
separation of male and female samples based on state 15 which almost exclusively contains probes 
on the X chromosome. The result of the HMM is included in the GEO submission of the data 
(GSE58538) and its properties/procedures are summarized in Figure S1. 
Differentiating features (probes or segments) 
Features showing low variability over all samples were excluded before formally testing for 
differential methylation (ĲM,probes<0.8, n=77,154/437,881 (17,62%) & ĲM,segments<0.6, 
n=13,229/133,730 (9,89%), Figure S1, p.8). A Mann Whitney U test was applied to each feature, 
comparing the distribution of M values between two histological subtypes. If significant (p<0.05, 
Benjamini-Hochberg corrected [158]), the subtype specificity was validated in 100 stratified 
bootstrap samples. If the feature proved to be significant in 95% of the validation samples and 
showed a difference in median M values > |0.9| between the pair of histological subtypes it was 
considered potentially discriminating. The value of 0.9 was chosen as the mean of the cut-off 
range recommended by Du and coworkers (0.4-1.4) [157]. Although a less stringent setting might 
result in a higher detection rate, it will considerably reduce the true positive rate [157]. The sign of 
the difference in median M value was used to assign a relative methylation status (hyper/hypo) in 
either of the two subtypes under pairwise consideration. 
                                                 
m http://cran.r-project.org/web/packages/vioplot/index.html  
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Differentiating HMM states 
To identify non-adjacent regions that showed similar patterns of methylation a logistic LASSOn 
regression model was fitted on the M values of the HMM states (glmnet packgageo) [159]. 
Coefficients > 0 were selected from the most regularized regression model within 1 standard 
deviation of the model with minimal cross validation error. A 10 fold cross validated ǋ was used. 
Features included in the selected state(s) and showing a difference in median M values > |0.9| (see 
above) between the pair of histological subtypes compared were considered potentially 
discriminating. The sign of the difference in median M value was used to assign a relative 
methylation status (hyper-/hypomethylated) in each of the subtypes. 
Final selection of differentially methylated probes (DMPs) 
Features of interest were identified in the intersection of (1) all probes in discriminating states, (2) 
all probes in discriminating segments and (3) all individually discriminating probes (Figure S1 (p. 
3/5), sections 2.3.3.3 & 2.3.3.4). This was done separately for probes that showed relative 
hypermethylation in either of the subtypes under pairwise comparison. This way, two groups of 
differentially methylated probes (DMPs) were identified, showing relative hypermethylation in one 
subtype and relative hypomethylation in the other. 
Functional enrichment 
The sets of DMPs were subjected to enrichment analysis for 18 functional categories (Figure 1C) 
using a two sided Fisher’s Exact test. Analogously, association with chromosome and state was 
tested. p<0.05/(18+24+20)=0.00080645161 was considered significant, hence retaining a 
Bonferroni corrected Type I error rate of 5% (18 functional categories, 24 chromosomes, 20 states).  
Differentially methylated regions (DMRs) 
Regions with  5 adjacent DMPs and a maximal inter-DMP distance  1 kb were identified as 
DMRs between the tumor groups. Annotations were retrieved for DMRs including flanking regions 
of 20% of the length of each DMR. 
Analysis of the cell lines 
Cell lines were compared to tumor samples in the evaluation of specific regions of interest in the 
tumor samples and with regard to their global methylation profile. Moreover, they were analyzed 
using the DMRforPairsp package to identify specific DMR in these unique samples ([160], using the 
default settings except min_dM=0.9, see above). For the NCCIT and TCam-2 cell lines this analysis 
matches the one performed in [68]. 
                                                 
n http://statweb.stanford.edu/~tibs/lasso.html  
o http://cran.r-project.org/web/packages/glmnet/index.html  
p http://www.bioconductor.org/packages/release/bioc/html/DMRforPairs.html  
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Software 
Analyses were performed in R 3.1.0/Bioconductor 2.14 (Windows 7 x64) and 2.15.2/Bioconductor 
2.11 (Redhat Linux x64). Additional R packages: parallelq & gplotsr. The HMM was trained using 
Matlab R2012a (64 bits) using the MOGHMMs toolbox.  
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Supporting Information 
Figure S1. Supplementary methods. A flowchart / detailed description of the analysis protocol, the motivation for the 
variance filtering, the properties of the Hidden Markov Model (HMM) and HMM state 15 discriminating male and female 
samples are presented subsequently.  
Figure S2. Methylation patterns in GCT subtypes and cell lines. (A) All categories and validation. In addition to the 
selected categories presented in Figure 2 this figure contains all 18 functional categories presented in Figure 1C and 
includes the primary PCA as well as an its validation (i.e. robustness of the result). PCA was performed on the total 
dataset (left) and validated using stratified bootstrapping (middle: training, right: validation). Please see the legend of 
figure 2 for an explanation of the density and PC plots/legends. (B) Global methylation patterns in individual samples. X-
axis indicates arbitrary sample ID. The sex of the patient from which the sample originates is indicated in blue (male) or 
red (female). Density plots are explained in the legend of Figure 2. Distributions are shown for all probes individual per 
sample. The ICR_P and ICR_M categories are presented separately to facilitate the discussion about imprinting. The red 
dashed line indicates somatic imprinting (50%). Please note that details on the TE group are presented in the main text 
(Figure 6D) and that this category is therefore omitted here. This also holds for the n=3 type II pure TE included in the 
mNS group.  
Figure S3. Enrichment of differentially methylated probes (DMPs) for chromosomal position and HMM state. (A) Merged 
GCT subtypes in pairwise comparisons. The SE+DG and EC+mNS categories were merged because of high similarity in 
biological classification and methylation profile. Despite their similarities, the DC and type I TE because they belong to 
different histological classes. (B) Association between DMPs and chromosome / HMM state. Stacked bar charts indicate 
the fraction of probes in a subset (DMP[A-B], DMP[A-B], non-DMP) that is mapped to a specific chromosome or 
assigned to a specific state. Grey indicates the non-DMPs and red and green indicated the DMPs hypermethylated in the 
subtype with the matching color in the figure (alternating green/white=A, alternating red/white=B). *=significant over-
/underrepresentation of DMPs relative to the non-DMP subset (tested per chromosome/state, 2-sided Fisher’s exact test, 
see Methods for Bonferroni corrected į threshold). In the right bottom of each figure the coefficients of the LASSO 
regression model are depicted. These roughly match the strongest over- and underrepresentations identified by the 
Fisher’s Exact tests on the states. The LASSO selected states are marked orange in the table indicating the significant 
associations between each state and either DMP group. 
 
                                                 
q http://stat.ethz.ch/R-manual/R-devel/library/parallel/doc/parallel.pdf  
r http://cran.r-project.org/web/packages/gplots/index.html  
s http://prlab.tudelft.nl/david-tax/othersoftware.html  
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Figure S4. Methylation profile at GCT subtype specific differentially methylated regions (DMRs) - continued. This figure 
depicts the DMRs discussed in the main text in addition to those already visualized in Figure 4. Legend to the 
visualizations is provided in the legend of Figure 4. 
Figure S5. Methylation status of (A) GCT specific genes and (B) genes with SNPs significantly associated with GCTs. This 
figure depicts the genes discussed in the main text and Table 2 in addition to those already visualized in Figure 5. 
Legend to the visualizations is provided in the legend of Figure 4. Genes are annotated 1.5kb upstream of their TSS and 
1.5kb downstream of their transcription termination site. 
Figure S6. Methylation status of known imprinting control regions (ICRs). ICRs identified as described in the materials and 
methods sections were checked for coverage on the 450K array. 21/28 unique ICRs were covered by one or more 
probes. These were visualized here (overview: Table S4). H19_IGF2 regions: the overlapping transcript is an aberrant, 
long alternative transcript (H19-012, ENST00000428066). These ICRs regulates H19 and IGF2 expression and lie 
upstream all other transcripts of H19. Legend to the visualizations is provided in the legend of Figure 4. 
Table S1. List of DMPs resulting from pairwise comparison of GCT subtypes. 
Table S2. Counts, percentages, log scores and statistical test results for enrichment in functional genomic categories. (A) 
SE/DG vs EC/mNS; (B) SE/DG vs type I TE; (C) EC/mNS vs type I TE; (D) SE/DG vs SS. Rows indicate the functional 
categories. Columns indicate the number of probes in the non-DMP and both subtype specific DMP sets. Next, the 
fraction (%) of this count relative to all non-DMPs or either set of DMPs is presented. The log-scores are calculated as 
log2(%DMP/%non-DMPs) and visually presented in Figure 3 for those categories showing significant over-
/underrepresentation. Significance of the enrichment was evaluated using a two-sided Fisher Exact test with a Bonferroni 
corrected į threshold as specified in the Materials & Methods section. 
Table S3. DMRs between tumor groups List of DMRs for each pair of GCT subtypes. (Recurrent tumor DMRs) Gene 
symbols that occurred in more than one DMR; either irrespective of DMR subset (n.total.occurences) or in multiple 
independent DMR subsets (n.dmr.lists) (Overlap tumor and CL DMRs) Gene symbols involved in DMRs identified 
between both the tumor groups and the cell lines. The second column indicates in which tumor comparisons the gene 
symbol was involved in a DMR. 
Table S4. Merged known ICRs from literature with sources. Also see Figure S6 for a visual representation of the 
methylation status at the ICRs if covered by the 450K array (21/28). 
File S1. Differentially methylated regions between tumors classes as discussed in Table 1. All figures. Please investigate 
using the genomic position as search term. (ZIP, included in GEO submission GSE58538) 
File S2. Differentially methylated regions between GCT cell lines. DMRforPairs output. Significant results only.  Please start 
from the html file. (ZIP, included in GEO submission GSE58538) 
Supplementary information will be made available upon publication. 
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CHAPTER 10 
This thesis presents results on functional genomics in germ cell tumors (GCTs) and possible clinical 
applications of the unique onco-fetal properties of these germ cell derived tumors [1-3]. Analyzing 
various types of “omics” datasets comprises an important part of this work. This discussion will 
therefore focus on the onco-fetal properties of GCTs as well as the paradigm shift towards open 
data and the required multidisciplinary approach to the integrated analysis of “omics” data. 
(Embryonic) miRs and OCT3/4: onco-fetal GCC hallmarks 
OCT3/4 
As reviewed in chapter 2, type II GCTs, also called germ cell cancer (GCC) show strong similarities 
to developing (early fetal) germ cells, i.e. primordial germ cells (PGCs) or gonocytes [3]. Moreover, 
one of the stem cell components (embryonal carcinoma EC) closely represents embryonic stem 
cells. A mainstream marker for GCC is OCT3/4 [2, 4-8]. OCT3/4 is an evolutionary conserved core 
regulator of pluripotency [9, 10] and one of the four Yamanaka factors required to create induced 
pluripotent stem cells [11, 12].  
Chapter 3 demonstrates the specificity of the OCT3/4-A isoform for GCC [7]. In our isoform 
specific analysis, the OCT3/4-B and B1 isoforms were less specific for GCC at the mRNA level. 
Isoform specific OCT3/4 mRNA levels showed a discrepancy with protein levels. OCT3/4-B and B1 
have been associated with other functions than pluripotency. In fact, OCT3/4-B is related to stress 
response and OCT3/4-B1 has been associated with pluripotency, induction of apoptosis and cell 
cycle deregulation. Non-isoform specific detection of OCT3/4 mRNA and protein levels might 
account for the reports of OCT3/4 in non-GCC malignancies as reviewed by us [7]. Recently non-
specific OCT3/4 was also detected in bladder cancer [13]. Because OCT3/4 isoforms differ only in 
their N-terminal region, antibodies targeting the C-terminal region [14] will not be isoform specific. 
Overall, our findings and other studies emphasize the role of alterative transcripts and post-
transcriptional/translational regulation in the execution of OT3/4 function, e.g. by pseudogene 
expression [15, 16], miR regulation [17, 18] and phosphorylation [19]. Therefore, the use of isoform 
specific primers and monoclonal antibodies against the N terminus of the OCT3/4 protein is of 
crucial importance to sensitively detect the pluripotency related isoform OCT3/4-A. Moreover, 
OCT3/4 is post-translationally regulated. AKT mediated phosphorylation of OCT3/4 regulates 
OCT3/4 stability, nuclear localization and transcriptional activity. Via a positive feedback loop 
OCT3/4 also stimulates AKT1 expression [19]. AKT levels are in turn crucial for maintaining PGC 
identity [20] and regulate the migration of PGCs during embryogenesis [21]. We are therefore 
currently investigating phospho-OCT3/4 as a potential marker of pluripotency/GCTs, using specific 
antibodies against phosphorylated OCT3/4.  
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(Embryonic) miRs 
Analogous to OCT3/4-A expression, the micro-RNA (miR) profile of GCC reflects their pluripotent 
embryonic origin. The progenitor and stem-cell components of GCC express a specific set of miRs 
that are physiologically only expressed in early embryonic (stem) cells, specifically the miR-371-2-3 
and miR-302abcd/367 clusters. [22-24]}. The role of these and other miRs in maintaining the onco-
fetal phenotype of these tumors is reviewed in chapter 2. In this review, miRs are shown to be core 
players in facilitating the crossover between pluripotency, cell cycle regulation and therapy 
sensitivity [3]. Relevant miRs include the embryonic miRs mentioned above as well as miR-34a and 
miR-145. Recently, a study by Siemens and colleagues also showed a relation between TP35 
mediated miR-34 expression and repression of the dependence receptor KIT and downstream 
functions (chemosensitivity, migration, stemness) [25]. This is of specific interest because KIT 
signaling is crucial during germ cell migration as well as in GCC pathogenesis [3].  
The detection of miR-mRNA interactions like miR-34/KIT is often hampered by the large number of 
predicted targets for each miR. In Chapter 4 a tool (miMsg) is presented to identify promising 
patterns of matched miR and mRNA expression from genome wide profiles. miMsg is 
implemented in Matlab and is freely available onlinea. In data from seminoma (SE), EC and type III 
GCTs  (spermatocytic seminomas), miMsg identified a number of potentially GCT related 
interactions. These showed an enrichment of the miR-23ab/24//27 paralog cluster, which is 
significantly lower expressed in SE as compared to EC [26]. A significant amount of the selected 
miR-mRNA interactions has also been verified in human embryonic stem (ES) cells [26, 27]. The 
miR-23ab/24//27 clusters and their mRNA targets have been implicated in several 
(patho)biological processes, but have not yet been functionally associated with GCTs [26].  
The potential clinical applicability of embryonic miRs in GCC is explored in chapters 5 & 6 [22, 23, 
28-34]. For GCT diagnosis and follow-up, a number of serum markers is available, including į-
fetoprotein (AFP), human chorionic gonadotropin (hCG), and to a lesser extend lactate 
dehydrogenase (LDH) [35-38]. About 80% of all non-seminomas (NS) and 20% of all SE show 
increased levels of these markers. AFP and hCG are mainly related to the presence of a YS or CH 
component respectively. They therefore show little sensitivity for the stem cell components SE and 
EC. False positivity might be caused by liver disease (AFP) and chemotherapy (hCG), hampering 
specificity for GCTs. Finally, positivity for either marker can change during disease progression. 
Therefore, better biomarkers are of interest, particularly markers with a high sensitivity for SE and 
EC. Chapter 5 describes the TSmiR test, applying a para-magnetic bead based approach to isolate 
miRs from serum and then quantify the levels of the embryonic miRs using a stringently quality 
controlled pipeline [30]. This miR panel showed an overall sensitivity of 98% for detecting GCCs, 
clearly outperforming the traditional serum markers AFP/hCG (36%/57%, sensitivityAFP=3%/45%; 
                                                 
a www.martinrijlaarsdam.nl/mimsg 
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sensitivityhCG=62%/66%, SE/NS). In line with the GCC specificity of these markers, serum levels 
returned to baseline after orchidectomy (stage-I disease). Moreover, there was a trend toward 
higher miR levels in patients with metastasis. These results were very recently validated in an 
independent study [34]. Regarding false positivity, embryonic miRs are normally not expressed in 
somatic tissues, but miR-371-2-3 has been shown to be expressed by a subgroup of thyroid 
adenomas with specific chromosomal rearrangements [39]. Chapter 6 builds on the targeted 
observations from chapter 5 and validates miR-371 and 372 as GCC specific in a high throughput 
serum miR profile covering ¨750 miRs. In addition, potential novel serum miR biomarkers are 
identified which show high levels in serum from GCC cases as compared to controls. These most 
prominently included miR-511 and, less outstanding, miR-26b, 769, 23a, 106b, 365, 598, 340 and 
let-7a. miR-511, a presumed tumor suppressor miR in adenocarcinoma with a role in tumor 
immune response [40-42], might be of interest based on its relatively high levels in serum from 
GCC patients. Further studies are required to inquire the function of this miR in GCC pathogenesis. 
Moreover, miR-mRNA interactions involving miR-23a have been shown to be differentiating 
between GCT subtypes [26] (see discussion of miMsg above). Despite the limited difference in miR 
levels between GCC cases and controls, miR-23a might therefore also be an interesting target for 
future exploration. 
Taken together, these results illustrate the relevance of studying the function of miRs in disease 
pathogenesis, specifically in GCC. The data predominantly illustrate the biological importance of 
miRs in maintaining the onco-fetal identity of GCC and the related clinical opportunities. Based on 
the proof of concept presented by TSmiR, our group received a grant from the Dutch Cancer 
Society (grant number: 13-6001) to further investigate and validate the clinical application of serum 
miRs in the biology and diagnostics/follow-up of GCC. In a national and international collaboration 
the results of TSmiR will be validated and extended in a prospective cohort including long term 
follow-up. To sensitively quantify the low miR-levels in serum, optimization of the measurement 
protocols and adequate normalization is crucial here. Along the way, results from high throughput 
studies like chapter 6, should be taken into account as discussed above. 
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Epigenetics in GCTs: an (embryonic) blueprint 
During embryonic development, the progenitors of mature germ cells migrate from the yolk sac, 
via the hindgut to the genital ridge where they further mature. During this migration and at the 
genital ridge these PGCs / gonocytes undergo a characteristic epigenetic “reset” which is reflected 
in their malignant counterparts: GCTs (for review: chapters 2 and 9, core literature: [43-50]). 
Focusing on DNA CpG methylation, genome-wide methylation is erased early during migration 
and re-established after arrival at the gonads. Uniparental genomic imprinting patterns are 
established via total imprinting erasure and in females the inactivated X chromosome is 
(re)activated. 
Tools to compare groups of samples with regard to their methylation status are broadly available 
[51]. In chapter 7 a tool (DMRforPairs) is presented which allows comparison unique samples [52]. 
DMRforPairs is implemented in R and freely available as a Bioconductor packageb. In chapter 8 and 
9, DMRforPairs was successfully applied to GCT cell line data. Chapter 8 illustrates the similarity of 
GCC cell lines to their PGC / gonocyte ancestor by integrating genome-wide histone modification, 
methylation and gene expression data [53]. A seminoma-like (TCam-2) and an extragonadal 
embryonal carcinoma cell line (NCCIT) were compared. Germ cell marker specificity was shown not 
only in the mRNA data, but also at the epigenetic level. The results support the hypothesis that 
both cell types originate from embryonic germ cells arrested in early gonadal development. Subtle 
difference in the (integrated) epigenetic and expression profiles indicated TCam-2 to exhibit a 
more germ cell-like profile, whereas NCCIT showed a more pluripotent phenotype. Chapter 9 
continues by investigating the genome wide methylation profiles of 91 GCTs and four 
representative cell lines,  providing novel insight into the developmental timing and underlying 
biology of the various subtypes of GCTs and their (embryonic) cells of origin. Cell lines showed little 
correlation with the actual tumor samples, warranting care when extrapolating methylation findings 
from cell lines to in vivo tumors. Different GCT subtypes could be clearly distinguished based on 
their global methylation profile. The methylation status of specific functional regions like imprinting 
control regions was also highly informative in identifying specific GCT subtypes. The observed 
methylation profiles matched with specific stages of germ cell development. Some specific issues 
are of particular interest for future studies. The imprinting status in the GCCs was previously 
thought to be erased (review: chapter 9) but was found to be somatic (50%) in our data. Therefore, 
the specific imprinting control regions evaluated in chapter 9 are primary targets for validation 
studies. The non-erased status identified in chapter 9 changes the proposed developmental stage 
of the precursor cell of GCC. These findings do however fit nicely with the totipotent potential of 
GCC, as demonstrated in mice [1]. Moreover, the “location dependent” imprinting pattern of type I 
TE is of particular interest. The general pattern of imprinting erasure in our small series of testicular 
                                                 
b http://bioconductor.org/packages/release/bioc/html/DMRforPairs.html  
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type I TE might indicate a role for the micro-environment in determining the epigenetic landscape 
of these cells. Furthermore, the strong epigenetic likeness of dermoid cysts (type IV GCTs) and 
ovarian type I TE should be investigated further in a larger dataset, potentially warranting re-
evaluation of the current GCT classification. Finally, the methylation status of the X chromosomes in 
the GCTs represented a normal diploid situation (50% methylation in females or 0% in males) while 
specific GCT subclasses are generally considered aneuploid (tri-/tetraploid) [1, 54, 55], showing 
intact X inactivation [56]. These new insights need further evaluation to understand their impact on 
GCT pathogenesis. 
In summary, these studies use novel tools and existing methods were applied to elucidate part of 
the epigenetic blueprint of GCTs and illustrate their close, onco-fetal relation to (fetal) developing 
germ cells. The datasets and results, including regions differentially methylated between different 
GCT subtypes, are publically available online, intending to serve as a hypothesis generating source 
for future targeted experiments.  
From ball to bytes and back again 
Successful exploration of the (integrated) functional genomics underlying disease faces two major 
challenges: the paradigm of open science / data and the required multidisciplinary approach. 
Crowd science 
Despite significant advances, generating omics data is still expensive and analyzing it takes a 
considerable amount of time and manpower. It is therefore logical to expect some return on 
investment before throwing the data to the online wolves. At this moment, most online databases 
like ArrayExpressc or GEOd provide free access to the published data. Data submission to an online 
repopsitory is often mandatory for publication. Researchers will generally not submit unpublished 
data to such a public data warehouse. Indeed, all datasets discussed in this thesis were made 
available online in a standardized format only upon publication. This also goes for miMsge and 
DMRforPairsf, the bioinformatics tools discussed in chapters 4 and 7. However, omics data grows 
old very fast and publication of such data in a static form alongside a publication does not 
necessarily stimulate expansion of the scientific debate. This suggests that scientific and economic 
revenue could be increased by providing early access to datasets and ongoing 
experiments/analysis in an interactive environment in context of the research aims [57]. In this 
context, crowd funding models are an interesting emerging approach to research and 
                                                 
c http://www.ebi.ac.uk/arrayexpress/  
d http://www.ncbi.nlm.nih.gov/geo/  
e http://martinrijlaarsdam.nl/mimsg  
f http://bioconductor.org/packages/release/bioc/html/DMRforPairs.html  
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development [58, 59]. While becoming more mainstream at the edges of technological 
development and the performing arts, specific alternatives aiming at science are still very limited in 
size. For example, experiment.com includes 139 registered projects registered opposed to >65,000 
on a general crowd funding site like kickstarter.com. In the end, crowd funding might just not be 
directly applicable to science. Crowd science might be a better term, suggesting a business model 
that supersedes the financial focus of classical crowd funding. By contributing to projects, people 
gain access to data, analysis and results in context of the research aims as they become available. 
An added advantage of crowd science is that relevance of a project is judged by all contributors 
together, increasing efficiency. Successful application of these novel approaches requires the 
business model of biomedical research to change. A paradigm shift from an “inwards” a posteriori 
disclosure towards “outwards” shared research and development is indicated in addition to legal, 
organizational and infrastructural issues that need to be addressed. These long-term changes will 
require significant investment and diligence of all involved. 
Lost in translation 
In the analysis of omics data the difference between data and information is essential. Purely 
economically speaking data costs money and information generates revenue. A multidisciplinary 
team is crucial to convert (integrated) omics data into biologically or, even better, clinically relevant 
information [60]. This frequently means learning to communicate in new languages and mixing of 
different scientific cultures and work processes [57]. It would be fruitful to emphasize this approach 
in all levels of scientific education. Only when sufficient synthesis is accomplished, a successful 
translation from bytes to bench and eventually to the patient’s bed can occur, contributing to 
personalized medicine by better understanding the etiology and pathogenesis of disease (Figure 
1). First and foremost, all people involved need to understand the general ideas behind the clinical 
targets, biological hypothesis and technical pitfalls. An important issue in this context is superficial 
transfer of knowledge to other disciplines which might lead to unjustified expectations or even 
complete misinterpretation of the aims. An extreme example is that just asking for “relevant” genes 
might be interpreted completely different by each person/discipline involved. With regard to the 
expectations, too much is often expected from omics data. Omics datasets are large and subject to 
technical errors and bias because of the complex way they are generated and processed. They are 
intended to be evaluated globally, zooming in on relevant patterns as you go. Directly focusing on 
subsets of data might subject the analysis to bias (e.g. known genes of interest). Depending on the 
hypothesis, this is not necessarily wrong, but needs to be taken into consideration when evaluating 
the results. Another potential pitfall is a lack of evaluation during design and analysis. All 
participants need to be involved from the start and the team needs to frequently evaluate (1) the 
status of the analysis, (2) the available results and (3) the general course of the research. It is 
important for all participants to continually loop back to the original research aims: from balls to 
bytes and back again. 
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Figure 1. A multidisciplinary approach  is essential for the successful exploration of functional genomics. A high level of 
understanding should be created between team members. Teams are composed of specialized members from specific 
backgrounds in biology (green), medicine (blue), technology (red) or other disciplines (grey) and all contribute their part. 
Only when the position of each piece is correctly identified and all pieces are combined, the full picture emerges. 
Concluding remarks 
To conclude, this thesis illuminates functional genomic, onco-fetal properties of GCTs from a 
developmental point of view, mainly by investigating (integrated) omics datasets using existing and 
newly developed computational tools. Chapters 3, 5 and 6 zoom in on the role of post-
transcriptional maintenance of the early embryonic and pluripotent phenotype of SE and EC and 
provide a potential clinical application of these unique properties of GCTs. These observations 
need to be validated in prospective studies, which are already initiated. Chapters 8 and 9 focus on 
the epigenetic constitution of GCTs and representative cell lines, providing insight into their 
developmental timing and underlying biology. These results provide hypotheses that can be 
validated in future targeted experiments. Chapters 4 and 7 are devoted to novel exploratory 
bioinformatics tools related to miR-mRNA interactions and detection of differentially methylated 
regions. There tools were also applied to GCT data. In all studies, close collaboration with other 
disciplines including biologists, clinicians and engineers from various specific backgrounds has 
contributed greatly to the research process and the results. In conclusion the results presented in 
this thesis provide insight into epigenetic and (post-)transcriptional regulation in GCT 
pathogenesis. The research focuses on clinical applications of the findings and contributes to the 
emergence of new hypothesis that can be experimentally and clinically validated in the future. 
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SUMMARY
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English 
  
 
 
The work discussed in this thesis explains the role of the functional genome in germ cell tumor 
(GCT) pathogenesis by applying newly developed and existing computational methods to 
(genome-wide) functional genomic datasets. Specifically, epigenetic and (post-)transcriptional 
regulation in GCTs was studied to gain a deeper understanding of disease pathogenesis, also 
aiming at clinical application of the findings.  
GCTs are a unique class of neoplasms originating from (fetal) developing germ cells. Five subtypes 
can be distinguished (I-V), which are related to physiological germ cell development. Type I GCTs, 
also called infantile or pediatric GCTs, are rare and generally benign. Type II GCTs, also called germ 
cell cancer (GCC), include a heterogeneous set of histological subtypes with clearly defined 
totipotent stem cell components. GCC accounts for 60% of all cancers in Caucasian males between 
the ages of 20 and 40. Type III, IV and V GCTs are generally benign. They originate from more 
mature germ cells. Generally speaking, the spectrum of GCT subtypes represents a unique class of 
neoplastic entities in relatively young patients. Moreover, GCTs show strong and traceable onco-
fetal roots advantageous for clinical applications.  
The functional genome includes a broad range of interacting regulatory features in a cell that 
determine its identity and behavior. These features are therefore highly relevant in the 
investigation of GCT pathogenesis and underlying biological processes. Functional genomics 
comprises the field of study targeted at integrating multiple (genome-wide) datasets, aiming to 
better understand these interactions. A general introduction into the field of GCTs and functional 
genomics is provided in chapter 1 of this thesis. Part one / chapter 2 gives a review of the onco-
fetal roots of GCC. It illustrates that GCC is a fascinating model for studying onco-fetal processes 
like cell cycle control, pluripotency maintenance and KIT-KITLG signaling.  
In the second part of this thesis onco-fetal proteins and micro-RNAs (miR) are investigated that 
can serve as diagnostic markers and help understand GCT pathogenesis. For example, the OCT3/4 
protein (transcription factor) is both a mainstream pluripotency regulator and a specific marker for 
GCCs. Chapter 3 underlines the specificity of the OCT3/4-A isoform for GCC showing at the same 
time that the other isoforms (B, B1) are not GCC specific. The findings illustrate the importance of 
using isoform specific primers and monoclonal antibodies against the N terminus of the OCT3/4 
protein to specifically detect the pluripotency related isoform OCT3/4-A. Besides proteins like 
OCT3/4, specific miRs are important in GCC development/identity. miRs are short, non-coding 
RNAs that target mRNAs, primarily promoting their degradation and inhibiting translation. The 
detection of potentially functional miR-mRNA interactions is often hampered by the large number 
of predicted targets for each miR. Therefore, a tool (miMsg) is presented in chapter 4 to identify 
promising patterns of matched miR and mRNA expression from genome wide profiles. In this 
chapter, miMsg is also successfully applied to GCT data. Functionally, miRs are core players in GCC, 
facilitating the crossover between pluripotency, cell cycle regulation and therapy sensitivity of as 
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reviewed in chapter 2. Previous studies have shown that the miR expression profile of GCC tissues 
reflects their pluripotent embryonic origin. Chapters 5 & 6 explore the potential clinical applicability 
of (embryonic) miRs as serum biomarkers in GCC. Chapter 5 describes the Targeted Serum miR 
(TSmiR) test, which uses the levels of the embryonic miR-371-2-3 and 302abc/367 clusters in 
serum as biomarkers for GCC. TSmiR achieved 98% sensitivity in detecting GCC in serum of 
patients versus controls, clearly outperforming classical serum markers like AFP and hCG. 
Prospective studies to validate and extend these findings are already initiated. Chapter 6 builds on 
the targeted observations in chapter 5 and validates miR-371 and 372 as GCC specific in a high 
throughput serum miR profile covering ¨750 miRs. In addition, potential novel serum miR 
biomarkers were identified, including miR-511 and, less prominent, miR-26b, 769, 23a, 106b, 365, 
598, 340 and let-7a.  
The work presented in the third part of this thesis investigates components of the epigenetic 
blueprint of GCTs, and subsequently illustrates their close onco-fetal relation to (fetal) developing 
germ cells as reviewed in chapter 2. During embryonic development, the progenitors of mature 
germ cells migrate from the yolk sac, via the hindgut to the genital ridge where they further 
mature. During this migration and at the genital ridge, these PGCs / gonocytes undergo a 
characteristic epigenetic “reset,” including a reorganization of their methylation state. These 
changes are reflected in their malignant counterparts: GCTs. This process is extensively reviewed in 
chapter 9. Tools to compare the methylation status between groups of samples are widely 
available. Chapter 7 presents a new tool (DMRforPairs) which allows comparison of unique samples 
in cases where large groups of samples are not available. DMRforPairs was successfully applied to 
GCT cell line data in chapters 8 and 9. Chapter 8 illustrates the similarity of GCC cell lines to their 
PGC / gonocyte ancestor by integrating genome-wide histone modification, methylation and gene 
expression data. Subtle differences in the (integrated) epigenetic and expression profiles indicated 
the seminoma-like cell line TCam-2 to exhibit a more germ cell-like profile. The mediastinal 
embryonal carcinoma cell line NCCIT showed a more pluripotent phenotype. Chapter 9 
investigates the genome wide methylation profiles of 91 GCTs and four representative cell lines. 
Different GCT subtypes could be clearly distinguished based on their global methylation profile. 
The methylation status of specific functional regions like imprinting control regions was also highly 
informative in identifying specific GCT subtypes. The observed methylation profiles matched with 
specific stages of germ cell development, providing insight into the developmental timing and 
biology of the various GCT subtypes.  
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To conclude, the studies presented in this thesis illuminate onco-fetal properties of GCTs from a 
developmental point of view, mainly by investigating (integrated) functional genomic datasets 
using existing and newly developed computational tools. In all studies, close collaboration with 
other disciplines including biologists, clinicians and engineers from various backgrounds 
contributed greatly to the research process and the results. All data and results are freely available 
online. The results presented provide insight into epigenetic and (post-)transcriptional regulation in 
GCT pathogenesis, focus on clinical application of the findings and contribute to the emergence of 
new hypothesis that can be experimentally and clinically validated in the future. 
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De resultaten in dit proefschift zijn erop gericht om de rol van het functionele genoom in het 
ontstaan van kiemceltumoren (KT) beter te begrijpen. Nieuwe en bestaande analysemethoden 
werden hiervoor toegepast op functional genomic KT datasets. Met name epigenetische en post-
transcriptionele regulatie in KT werden onderzocht om meer inzicht te verkrijgen in de 
pathogenese van KT, zo mogelijk resulterend in klinische toepassingen. 
KT ontstaan uit de (foetale) voorlopers van uitgerijpte kiemcellen (geslachtscellen). Er zijn vijf KT 
subtypes (I-V) die allemaal gerelateerd zijn aan normale kiemcel ontwikkeling. Type I KT zijn 
zeldzaam, meestal goedaardig en worden ook wel infantiele KT genoemd. Type II KT wordt ook 
wel kiemcelkanker (KK) genoemd. KK betreft een heterogene groep van histologische subtypes. 
Van deze tumoren is veel bekend over hun (totipotente) stamcelcomponenten. Zestig procent van 
alle Kaukasische mannen met kanker tussen de 20 en 40 jaar heeft KK. De type III, IV en V KT zijn 
meestal goedaardig en komen voort uit verder ontwikkelde kiemcellen. KT vormen een unieke 
groep maligniteiten in jonge patiënten waarvan relatief veel bekend is over de onco-foetale 
oorspong. Dit biedt mogelijk kansen in de kliniek.  
Het functionele genoom bevat een grote groep van interacterende regulatoire processen die de 
identiteit en het gedrag van een cell bepalen. Deze processen zijn  cruciaal voor het begrijpen van 
de pathologie van KT en de onderliggende biologische processen. "Functional genomics" is het 
vakgebied wat zich bezighoudt met het integreren van datasets die deze processen beschrijven. In 
hoofdstuk 1 worden KT en functional genomics verder geïntroduceerd. Deel één / hoofdstuk 2 
geeft een overzicht van de literatuur die de onco-foetale eigenschappen van KK beschijft. Daaruit 
blijkt dat KK een goed model is voor het onderzoek naar onco-foetale ontwikkelingsprocessen, 
met name cel cyclus controle, plupotentie en KIT-KITL gerelateerde processen. 
Het tweede deel van dit proefschrift gaat over onco-foetale eiwitten en micro-RNAs (miRs) die 
inzicht geven in de ontwikkeling van KT. Deze eiwitten en miRs kunnen ook als markers voor KT 
dienen in de kliniek. OCT3/4 is een voorbeeld van zo'n eiwit (transcriptiefactor) die tegelijkertijd 
een bekende regulator van pluripotentie en een specifieke marker voor KK is. Hoofdstuk 3 
beschrijft de specificiteit van een isoform van OCT3/4 (OCT3/4-A) voor KK en laat zien dat andere 
isovormen (B en B1) niet specifiek zijn voor KK. Isovorm specifieke detectie van OCT3/4 mRNA en 
eiwit is daarom van groot belang als deze marker gebruikt wordt voor onderzoek en in de kliniek. 
Naast de aanwezigheid van zulke eiwitten laten KT ook een karakteristiek onco-foetaal micro-RNA 
(miR) expressieprofiel zien. miRs zijn korte stukjes RNA die de afbraak van mRNAs stimuleren of 
voorkomen dat mRNAs vertaald worden in eiwitten. Het identificeren van relevante miR-mRNA 
interacties is vaak lastig omdat er veel mRNA targets voorspeld worden voor iedere miR. In 
hoofdstuk 4 wordt een tool beschreven (miMsg) die voor specifieke datasets de meest relevante 
interacties selecteert. miMsg wordt in dit hoofdstuk ook succesvol toegepast op KT data. 
Hoofdstuk 2 beschrijft het belang van miRs in KT, met name met betrekking tot het integreren van 
233
 
 
pluripotentie, cell cyclus controle en therapie gevoeligheid. Hoofdstuk 5 en 6 onderzoeken de 
klinische toepassing van (embryonale) miRs als serum biomarkers voor KK. Hoofdstuk 5 beschrijft 
de Targeted Serum miR (TSmiR) test die embryonale miR clusters miR-371-2-3 en miR302abc/367 
detecteert in serum. Deze test identificeerde 98% van de KK correct, wat een veel hogere 
sensitiviteit impliceert dan de traditionele serum markers AFP en hCG. Prospectieve studies om 
deze resultaten te valideren zijn inmiddels gestart. Hoofdstuk 6 gaat verder op de bevindingen van 
hoofdstuk 5 en vergelijkt de niveaus van ¨750 miRs in serum van KK patienten en controles zonder 
KT. miR-371 en 372 blijken in deze studie wederom sensitief voor het maken van het onderscheid 
tussen KK en controles. Ook werd een aantal nieuwe potentiele KT serum markers geïdentificeerd: 
miR-511, miR-26b, 769, 23a, 106b, 365, 598, 340 en let-7a. 
Het derde deel van dit proefschrift geeft inzicht in de epigenetische blauwdruk van KT en illustreert 
de directe relatie tussen KT en (foetale) ontwikkelende kiemcellen zoals eerder besproken in 
hoofdstuk 2. De karakteristieke epigenetische veranderingen die optreden tijdens 
kiemcelontwikkeling tonen mogelijk gelijkenis met de epigenetische status van KT. Dit geeft inzicht 
in het celtype waarvan de verschillende typen KT afstammen. Tijdens normale ontwikkeling 
migreren kiemcellen door het embryo. Vanaf de dooierzak migreren ze naar de "gential ridge" 
waar later de gonade gevormd wordt die zich uiteindelijk tot testis of ovarium ontwikkelt. Daar 
ontwikkelen de kiemcellen zich verder. Het ontwikkelproces van kiemcellen wordt gekenmerkt door 
een epigenetische "reset" die terug te zien is in de epigenetische staat van KT. Deze reset betreft 
ook de methylatiestatus van het DNA. Dit proces wordt uitgebreid besproken in hoofdstuk 9. Voor 
het vergelijken van de methylatie tussen groepen van weefsels zijn veel tools beschikbaar. 
Hoofdstuk 7 beschrijft een nieuwe tool (DMRforPairs) die specifiek ontwikkelt is om unieke samples 
te vergelijken als er geen groepen beschikbaar zijn. DMRforPairs wordt toegepast op KT data in de 
hoofdstukken 8 en 9. Hoofdstuk 8 beschrijft de vergelijking tussen de epigenetische status van KK 
cell lijnen en relateert de resultaten aan hun vroege kiemcel voorlopers. Deze studie integreert 
histone modificatie, methylatie en gen expressie data. Subtiele verschillen tussen de geïntegreerde 
(epigenetische) profielen laten zien dat de seminoom-achtige cellijn (TCam-2) meer op een 
kiemcel lijkt. De embryonaal carcinoom cellijn (NCCIT) heeft relatief meer pluripotente 
eigenschappen. Hoofdstuk 9 beschrijft het methylatieprofiel van verschillende typen KT en 
vergelijkt dit met bekende resultaten van normaal ontwikkelende kiemcellen. KT subtypes konden 
duidelijk onderscheiden worden op basis van hun methylatie status. Ook specifieke regio’s op het 
genoom zoals de imprinting control regio’s waren informatief voor het voorspellen van het type 
KT. De methylatieprofielen konden worden teruggevoerd naar specifieke ontwikkelingsstadia van 
kiemcellen.  
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Concluderend beschrijft dit proefschift de onco-foetale eigenschappen van KT vanuit een 
ontwikkelingsbiologisch perspectief. Grootschalige functional genomic datasets werden 
geanalyseerd met nieuwe en bestaande methoden. Bij alle studies bleek de nauwe samenwerking 
tussen meerdere disciplines zoals biologen, clinici en ingenieurs uit specifieke vakgebieden cruciaal 
voor het onderzoeksproces en de resultaten. De resultaten zoals beschreven in dit proefschrift 
geven inzicht in de epigenetische en (post-)transcriptionele regulatie in KT pathogenese en zijn 
gericht op klinische toepassingen en het ontwikkelen van toetsbare nieuwe hypothesen. 
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misschien even slikken als je op een kamer zit met het ermitus hoofd van de afdeling. Jij was daar 
heel duidelijk over: geen fratsen, doe maar gewoon normaal. En gelukkig houden we van dezelfde 
muziek. Het was voor mij ook een voorrecht om soms mee te mogen kijken bij de diagnostiek, om 
met je te kunnen discussieren over de biologie van kiemceltumoren en natuurlijk om te praten 
over het minimaal invasieve obductie project, samen met Britt en Ivo. Bedankt ook voor je 
interesse in Kirsten en mij, ook naast het werk. Ik had me geen betere kamergenoot kunnen 
wensen. Ik ben alleen benieuwd wanneer die kar met archiefspullen een keer leeg gaat - .  
Hans, samen met Remko, Ad, Ton en Lambert vorm jij de harde kern van LEPO. Jouw 
vaardigheden met immunohistochemie zijn inspirerend. Dank dat ik dit al helemaal in het begin 
van jou heb mogen leren.  
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Lambert, jij neemt nooit een blad voor je mond en dat is waardevol. Op ten minste vijf 
hoofdstukken uit dit proefschrift heb jij je biologische licht laten schijnen. Regelmatig zette je mij 
daarbij met beide benen terug op de grond. In de kern van je boodschap heb je altijd een goed 
punt. Dank voor de discussies.  
Yvonne, voordat jij mijn pad kruiste wist ik niets van epigenetica. Op een gegeven moment had jij 
“wat data” waarbij ik je kon aanvullen op het gebied van de computational biology. Een paar 
weken later hadden we samen twee publicaties. Het was een intensieve samenwerking onder forse 
tijdsdruk maar ik vond het zo leuk dat ik er het tweede deel van mijn proefschrift maar aan gewijd 
heb. Dank voor de samenwerking en de gezelligheid. 
Ton, jou leerde ik vooral beter kennen tijdens de serum micro-RNA projecten. Na toekennen van 
de KWF grant voor dit onderzoek heb jij dit stokje ten dele van Ad en mij overgenomen. Ik wens je 
veel succes en ben enorm benieuwd naar de resultaten.  
Martine en Berdine, bedankt dat ik met jullie mee mocht kijken in de keuken van de KNO. 
Spannende resultaten waar ik graag meer van hoor ook al zit ik straks niet meer naast jullie. Vanuit 
de urologie mocht ik soms even wat proeven van de kliniek via Katja en Lisette: dank. Katja, ook 
veel dank voor je persoonlijke betrokkenheid. Ten slotte heb ik met veel plezier samengewerkt met 
alle studenten en stagaires die de afgelopen jaren op het lab hebben gewerkt.  
Niet alles draait om werk gelukkig. Het koffie-groepje, een noodzakelijke ontsnapping aan de 
verschikkelijke automatenkoffie, zorgde voor regelmatige onderbrekingen. Yvonne, Berdine, 
Martine en Remko, bedankt voor de afleiding. Lunch met als vaste kern Ad, Hans en Remko was 
ook altijd een goed moment om even ergens anders over te praten dan onderzoek. En Wil, 
bedankt dat je soms zomaar met een casus of dia voor de deur stond met de “simpele” vraag: wat 
heeft de patient? Want van jou mocht ik geen moment vergeten dat ik toch in de eerste plaats een 
dokter ben. Ten slotte Ingrid, jij weet alles, ziet alles, je kent iedereen en je hebt altijd een oplossing 
met een glimlach, super! 
De laatste alineas van dit dankwoord zijn natuurlijk voor de achterban, het vangnet, de boksballen. 
(Schoon)familie en vrienden vormen een lijst die te lang is om op te noemen, maar zijn voor mij 
een onmisbare steunpilaar geweest tijdens dit promotietraject. De beschrijvingen in deze en de 
volgende alineas zijn te kort en doen onvoldoende recht aan de betekenis van deze mensen voor 
mij, maar jullie weten wat ik bedoel. Opa Jan en Oma Tan, altijd geïnteresseerd en begripvol. 
Mieneke en Jeroen, nooit aflatend betrokken en ondersteunend waar nodig. Mieneke, veel dank 
voor jou correcties op de tekst van dit proefschrift. Frits, Renske, Eva en Joost: dank voor jullie 
interesse en dank dat ik de afgelopen jaren deel mocht worden van jullie gezin en dat jullie Kirsten 
aan mij toevertrouwd hebben. 
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Tijdens de verdediging heb ik het voorrecht dat mijn tweelingbroer en mijn zus mij bijstaan als 
paranymfen. Vroeger zouden jullie de verdediging van mij moeten overnemen als het nodig 
mocht blijken, maar vandaag staan jullie hier als symbool van het belang wat ik hecht aan ons 
gezin. David, zoals in bijna alles ging jij mij voor met promoveren. Ik was ook jouw paranymf en we 
hebben samen gepubliceerd. Uniek om al deze dingen samen te doen. Ik wil niet de kracht van 
stelling 8 afhalen, maar het is soms best fijn/handig om tweeling te zijn en een beetje op elkaar te 
lijken. Anne Fleur, je bent net als David een onmisbaar deel van mijn leven. Bedankt dat je je grote 
broer laat voorgaan met promoveren. En met goede reden: jullie geweldige zoonje en mijn neefje 
Seb. Seb, bedankt dat ik je moeder voor mijn verdediging mag lenen. Lex en Sonja, bedankt voor 
het lenen van jullie partners en bedankt voor alle gezelligheid en betrokkenheid. 
De laatste alinea reserveer ik voor drie mensen: mijn ouders en mijn vrouw. Jaja, Kirsten, net op tijd 
getrouwd om dat op te kunnen schrijven - . Lieve ouders,  jullie steun aan ons alle drie en aan 
elkaar is altijd onvoorwaardelijk geweest. Dit is niet vanzelfsprekend, een goed voorbeeld en voor 
een belangrijke deel de reden dat ik hier (samen met David en Anne Fleur) sta. Bedankt. Anne, als 
vader en als persoon ben jij altijd enorm bescheiden, volgens mij niet altijd terecht. Nooit heb jij 
geneeskunde als optie voor mij genoemd, zelfs niet toen ik het zat was bij bedrijfseconomie en 
rechten. Maar je ging wel mee naar de cursus biologie (had ik nooit gehad) en liet me na mijn 
definitieve keuze voor geneeskunde het werk van een patholoog zien. Je hebt me altijd 
voorgehouden (als dokter) bescheiden te zijn, je grenzen te kennen en altijd verder te zoeken dan 
je eerste conclusie/diagnose (“don’t jump into a conclusion”). Aan het onderzoek droeg jij ook bij 
door David en mij jaarlijks mee te nemen op een wandelvakantie: hoofdstuk 4 is daar grotendeels 
ontstaan; zonder computer, op kladpapier. Henriëtte, jij bent van de gezelligheid. Altijd een open 
house en altijd een luisterend oor, hoewel Anne dat sinds zijn pensioen ook behoorlijk heeft 
opgepakt. Je verstaat als geen ander de kunst om met honderd dingen tegelijk voor jan en 
alleman bezig te zijn, waarbij de (klein)kinderen en Anne altijd volop in jouw onverdeelde aandacht 
mogen staan. Het knappe en leerzame aan jou is dat je vaak uit die moordende schemas alleen 
maar energie lijkt te putten. Inspirerend. Kirsten, met jou mag ik dit proefschrift afsluiten en daarna 
in Amsterdam een nieuw leven beginnen. Het is niet altijd makkelijk om naast een work-a-holic als 
ik te leven die vergroeid lijkt met zijn telefoon. Maar zoals een goede vriend van me laatst zei: 
sinds je Kirsten kent ben je gelukkig wel wat relaxter geworden. Geef dus niet op, wat je doet heeft 
wel degelijk effect - . Je bent mijn steun en toeverlaat, mijn thuisbasis en soms mijn symbolische 
boksbal bij stress (sorry!). Dit proefschrift is daarom ook van jou. Je helpt me steeds weer 
herinneren wat echt belangrijk is als ik met mijn hoofd in de cijfertjes zit. Dank je wel. Bij het 
formuleren van de stellingen en het ontwerpen van de cover bleek je een enorme hulp. Niet in de 
laatste plaats door aan te geven dat veel suggesties “veel te saai” of juist te druk waren. Ik ben 
benieuwd wat de toekomst ons gaat brengen, maar één ding weet ik zeker: ik heb er zin in! 
Tot ziens. Het ga jullie goed. Martin  
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